HUDSON RESPIRATORY CARE INC - 10-K Annual Report

Back to GetFilings.com

================================================================================

- --------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

FORM 10-K

(Mark One)

[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2001
OR
[_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________ to ________.

Commission file number 333-56097

HUDSON RESPIRATORY CARE INC.
(Exact name of registrant as specified in its charter)

California 95-1867330
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)

27711 Diaz Road, P.O. Box 9020 92589
Temecula, California (Zip Code)
(Address of Principal Executive Offices)

(909) 676-5611
(Registrant's telephone number, including area code)

Securities Registered Pursuant to Section 12(b) of the Act: None

Securities Registered Pursuant to Section 12(g) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes [_] No [X]

Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K ((S) 229.405 of this chapter) is not contained herein, and
will not be contained, to the best of registrant's knowledge, in definitive
proxy or information statements incorporated by reference in Part III of this
Form 10-K or any amendment to this Form 10-K. [_] Not Applicable.

As of May 31, 2002, the number of shares of Common Stock, $.01 par value,
outstanding (the only class of common stock of the registrant outstanding) was
10,654,293. The registrant's Common Stock is not traded in a public market.

Aggregate market value of the registrant's voting and nonvoting Common Stock:
Not Applicable.
Documents Incorporated by Reference: None

================================================================================

HUDSON RESPIRATORY CARE INC. AND SUBSIDIARIES

Fiscal Year Ended December 31, 2001

TABLE OF CONTENTS

Page
----

PART I ........................................................................................................ 1
Item 1. Business ..................................................................................... 1
Item 2. Properties ................................................................................... 7
Item 3. Legal Proceedings ............................................................................ 8
Item 4. Submissions of Matters to a Vote of Security Holders ......................................... 8

PART II ....................................................................................................... 9
Item 5. Market for Registrant's Common Equity and Related Stockholder Matters ........................ 9
Item 6. Selected Financial Data ...................................................................... 9
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operation ......... 11
Item 7A. Quantitative and Qualitative Disclosure About Market Risk .................................... 28
Item 8. Financial Statements ......................................................................... 29
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure ......... 29

PART III ...................................................................................................... 32
Item 10. Directors and Executive Officers of the Registrant ........................................... 32
Item 11. Executive Compensation ....................................................................... 34
Item 12. Security Ownership of Certain Beneficial Owners and Management ............................... 38
Item 13. Certain Relationships and Related Transactions ............................................... 39

PART IV ....................................................................................................... 41
Item 14. Exhibits, Financial Statement Schedules and Reports on Form 8-K .............................. 41

SIGNATURES .................................................................................................... S-1

ii

PART I

Item 1. Business.

This Annual Report on Form 10-K contains "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. These statements
include without limitation the words "believes," "anticipates," "estimates,"
"intends," "expects," and words of similar import. All statements other than
statements of historical fact included under "Item 1. Business," "Item 2.
Properties," "Item 3. Legal Proceedings" and "Item 7. Management's Discussion
and Analysis of Financial Condition and Results of Operations" include
forward-looking information and may reflect certain judgements by management.
Such forward-looking statements involve known and unknown risks, uncertainties
and other factors that may cause the actual results, performance or achievements
of Hudson Respiratory Care Inc. or the respiratory care and anesthesia products
industries to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. These
potential risks, uncertainties and other factors include, but are not limited
to, those identified in the "Risk Factors" section of this Form 10-K located at
the end of "Item 7. Management's Discussion and Analysis of Financial Condition
and Results of Operations." The Company disclaims any obligation to update any
such factors or to publicly announce the results of any revisions to any of the
forward-looking statements contained herein to reflect future events or
developments.

General

Hudson Respiratory Care Inc. ("Hudson RCI" or the "Company") is a leading
manufacturer and marketer of disposable medical products utilized in the
respiratory care and anesthesia segments of the domestic and international
health care markets. The Company offers one of the broadest respiratory care and
anesthesia product lines in the industry, including such products as oxygen
masks, humidification systems, nebulizers, cannulae and tubing. In the United
States, the Company markets its products to a variety of health care providers,
including hospitals and alternate site service providers such as outpatient
surgery centers, long-term care facilities, physician offices and home health
care agencies. Internationally, the Company sells its products to distributors
that market to hospitals and other health care providers. The Company's products
are sold to over 7,000 distributors and alternate site service providers
throughout the United States and in more than 90 countries worldwide. The
Company has supplied the disposable respiratory care market for over 55 years
and enjoys strong brand name recognition and leading market positions.

The Company manufactures and markets approximately 2,000 respiratory care
and anesthesia products. The Company believes that its broad product offering
represents a competitive advantage over suppliers with more limited product
offerings, as health care providers seek to reduce medical supply costs and
concentrate purchases among fewer vendors. The Company also benefits
competitively in the United States from its extensive relationships with leading
group purchasing organizations ("GPOs"), as large purchasing organizations play
an increasingly important role in hospitals' purchasing decisions.

The Company maintains three manufacturing facilities and two distribution
facilities in the United States, assembly operations in Mexico and Malaysia and
sales and marketing offices in the United States, Sweden, the United Kingdom,
France and Germany.

Hudson Oxygen Therapy Sales Company ("Hudson Oxygen"), Hudson RCI's
predecessor, was founded in 1945. In 1988, Hudson Oxygen formed Industrias
Hudson, a subsidiary that oversees the Company's assembly operation in Mexico.
In 1989, Hudson Oxygen merged with Respiratory Care Inc. to form Hudson RCI. In
April 1998, the Company consummated a recapitalization, pursuant to which it
became a majority-owned subsidiary of River Holding Corp. ("Holding"). In the
past four years, the Company has completed a number of strategic acquisitions in
order to expand its product line and geographic penetration, most significantly
with the July 1999 acquisition of Hudson RCI AB (formerly Louis Gibeck AB), a
Swedish company that manufactures and markets medical devices under the Gibeck
brand. Hudson RCI's principal executive offices are located at 27711 Diaz Road,
P.O. Box 9020, Temecula, California 92589, and its telephone number is (909)
676-5611.

1

Industry Overview

The worldwide market for disposable respiratory care and anesthesia
products consists of the domestic hospital market, the alternate site market and
the international market. Respiratory care and anesthesia principally involve
the delivery of oxygen or anesthesia from a gas source, such as a mechanical
ventilator or respirator, to the patient's pulmonary system. The gas is
typically delivered to the patient through specialized tubing connecting to a
cannula, mask or endotracheal tube. In addition, it is often clinically
desirable to humidify or medicate the gas prior to delivery to the patient. The
market for respiratory care and anesthesia products, including disposable
products, is expected to be positively impacted by demographic trends, both
domestically and internationally. In the United States, changes in demographics,
including an aging population, increased incidence and awareness of respiratory
illnesses and heightened focus on cost-efficient treatment, have had a positive
impact on the domestic respiratory care and anesthesia markets. There has been
an increasing incidence of respiratory illnesses (such as asthma and emphysema),
due in part to an increasingly susceptible aging population, environmental
pollution, smoking-related illnesses and communicable diseases with significant
respiratory impact, such as tuberculosis, HIV and influenza. The Company
believes that the international respiratory care and anesthesia markets will
experience many of the trends currently affecting domestic markets. In addition,
many international markets have high incidences of communicable respiratory
diseases and are becoming increasingly aware of the clinical and economic value
of single-use, disposable products.

The market for respiratory care and anesthesia products is also affected by
trends involving the health care market generally. In particular, the overall
trend towards cost containment and infection control has increased the
desirability of disposable products relative to reusable products, and has
influenced pricing, distribution channels, purchasing decisions and health care
delivery methods.

Efforts to contain rising health care costs have increased the preference
for disposable medical products that improve the productivity of health care
professionals and reduce overall provider costs. Health care organizations are
evaluating modes of treatment that are less labor and/or technology intensive as
a means of decreasing the cost of care, which can often result in increased
disposable usage. In particular, increased utilization of disposable products
can decrease labor and other costs associated with sterilizing reusable
products. In addition, the risks of transmission of infectious diseases such as
HIV, hepatitis and tuberculosis, and related concerns about the occupational
safety of health care professionals, have also contributed to an increased
preference for disposable single-use medical products.

Cost containment has caused consolidation throughout the health care
product supply channel, which has favored reliable manufacturers with large,
high quality product offerings and competitive pricing. In an effort to contain
costs, service providers have consolidated to form GPOs, which take advantage of
group buying power to obtain lower supply prices. This, in turn, has led to
consolidation among distributors, who seek to provide "one-stop shopping" for
these large buying groups. Distributors have also sought to concentrate
purchases among fewer vendors in an effort to reduce supply costs. Since
selection as a contracted GPO provider and strong relationships with
distributors are critical to many health care manufacturers, they have responded
to these trends by providing a broad range of integrated products, combined with
reliable delivery and strong after-sales support.

Cost containment has also caused a migration of the decision making
function with respect to supply acquisition from the clinician to the
administrator. As clinicians lose influence and purchasing agents, materials
managers and upper level management become more involved in the purchasing
decision, a greater emphasis is placed on price relative to product features and
clinical benefits.

As a result of cost containment, health care is increasingly provided
outside of traditional hospital settings through alternate health care sites,
such as outpatient surgery centers, long-term care facilities, physician offices
and patients' homes. Growth of the alternate site market is also attributable to
advances in technology that have facilitated the delivery of care outside of the
hospital, an increased number of illnesses and diseases considered to be
treatable outside of the hospital and increased acceptance by the medical
community of, and patient preference for, non-hospital treatment.

2

Products

The Company manufactures and markets products for use in respiratory care
and anesthesia. The products for each market are similar and often overlap, as
do the distribution channels.

The Company groups its products into four clinical categories: (i) oxygen
therapy; (ii) aerosol therapy; (iii) humidification and filtration; and (iv)
airway management. Although the Company's sales efforts differ depending on the
clinical use of its products, management focuses on geographical segments for
strategic decision making.

Category/Products Description
- ---------------------------------------------------- -------------------------------------------------------

Oxygen Therapy: oxygen masks, cannulae, oxygen Used to transport, regulate, deliver and analyze
catheters, oxygen tubing, prefilled and refillable therapeutic, supplemental oxygen to a patient. Cylinder
humidifiers, oxygen regulators, cylinder carts and carts and bases are used to transport and stabilize
bases, oxygen analyzers/monitors, oxygen sensors, oxygen cylinders. Regulators control the pressure and
and adaptors and connectors. Sales for this flow of oxygen from the primary gas source to the
category as a percentage of total Company sales were patient. Oxygen masks and nasal cannulae cover the nose
32.6%, 34.6% and 40.0% for fiscal years 2001, 2000 and mouth or fit inside the nostrils and are connected
and 1999, respectively. to an oxygen source via small diameter tubing through
which oxygen flows. Oxygen analyzers, monitors and
sensors are utilized to measure and monitor the oxygen
concentration being delivered to the patient. Adaptors
and connectors are frequently used in respiratory care
and anesthesia to add accessories, modify
configurations, and/or customize other related products
to meet specific needs.

Aerosol Therapy: aerosol masks, prefilled and Used to create and deliver aerosolized particles of
refillable large volume nebulizers, aerosol tubing, liquid water, sodium chloride or medication solutions
unit dose solutions, small volume nebulizers, peak to the patient's airways to dilute and mobilize
flow meters, spacers/changers. Sales for this secretions and/or dilate constricted breathing
category as a percentage of total Company sales were passages. The peak flow meter is used to monitor the
16.5%, 17.2% and 21.0% for fiscal years 2001, 2000 patient's respiratory status before and after an
and 1999, respectively. aerosolized medication treatment. Spacers/Chambers are
used as an adjunct to metered dose inhaler therapy to
facilitate optimal treatment effectiveness.

Humidification and Filtration: ConchaTherm heated Heated humidification systems actively heat and
humidifiers and accessories, Humid-Heat and humidify oxygen/air mixtures or anesthetic gases
accessories, AquaTherm and ThermaGard nebulizer provided by a mechanical ventilator or anesthesia gas
heaters; Concha water, Concha Pak, Aqua+ and machine or other gas source. Heat Moisture Exchangers
Humid-Vent HME's, and filters for critical care, (HMEs) passively conserve the heat and humidity in the
anesthesia and pulmonary function. Sales for this patient's exhaled breath for use during inspiration.
category as a percentage of total Company sales were Breathing filters are used to protect patients,
21.6%, 27.3% and 21.5% for fiscal years 2001, 2000 caregivers and medical equipment from
and 1999, respectively. cross-contamination with bacteria and viruses.

Airway Management: oral airways, Sheridan(R) Used to secure and maintain an open airway and
endotracheal tubes, incentive breathing exercisers unobstructed breathing passage; convey an oxygen/air
(IBEs), disposable and re-useable resuscitation mixture and/or anesthetic gas from a mechanical
bags, ventilator,

3

Category/Products Description
- --------------------------------------------------- -------------------------------------------------------

hyperinflation bags, breathing bags, air cushion anesthesia gas machine to a patient; and artificially
masks, anesthesia circuits, heated-wire and support ventilation during resuscitative efforts. The
conventional ventilator circuits, gas sampling infant CPAP system provides non-invasive respiratory
lines and filters, catheter mounts and infant CPAP. support to premature infants with under-developed,
Sales for this category as a percentage of total immature lungs.
Company sales were 29.2, 20.9% and 17.5% for fiscal
years 2001, 2000 and 1999, respectively.

Sales, Marketing and Distribution

The Company's main focus for operational management and strategic decisions
is based on geographical segments. These are defined as the Domestic and
European operations, each having their own, distinct management team.

The Company has sales offices in Temecula, Sweden, Germany, France and the
United Kingdom and two distribution facilities in the United States and one in
Europe. The Company also employs sales representatives in Thailand, China and
Australia. While a majority of the Company's domestic hospital sales are made to
distributors, the Company's marketing efforts are focused on the health care
service provider. In the alternate site market, the Company both sells and
markets directly to the service provider. Internationally, the Company sells its
products to distributors that market to hospitals and other health care
providers. See Note 10 to "Item 8. Financial Statements" for information with
respect to international sales. The Company's U.S. sales personnel currently
call on approximately 5,900 hospitals and surgery centers, over 50 hospital
distributors and over 3,000 alternate site customers. Due to consolidation and
cost pressures among the Company's customer base, the Company's target call
point at the health care provider has been moving away from the clinician to
include a purchasing manager or corporate executive.

In the current U.S. hospital market environment, GPO relationships are an
essential part of access to the Company's target markets and the Company has
entered into preferred supplier arrangements with 14 national GPOs. The Company
is typically positioned as either a sole supplier of respiratory care
disposables to the GPO, or as one of two suppliers. While these arrangements set
forth pricing and terms for various levels of purchasing, they do not obligate
either party to purchase or sell a specific amount of product. In addition, GPO
affiliated hospitals often purchase products from other suppliers
notwithstanding the existence of sole or dual source GPO arrangements. Further,
these arrangements are terminable at any time, but in practice usually run for
two to three years. The Company enjoys longer terms with three of its major
GPOs, Novation LLC, Consorta and HealthTrust Corporation. The Company's most
significant GPO relationships are with AmeriNet Inc., Broadlane, Consorta,
Health Services Corporation of America, HealthTrust Corporation and Novation
LLC.

Health care providers have responded to pressures to reduce their costs by
merging with other members of their industry. The acquisition of a customer of
the Company often results in the renegotiation of contracts, the granting of
price concessions or in the loss of the customer. Alternatively, to the extent a
customer of the Company grows through acquisition activity, the Company may
benefit from increased sales to the larger entity.

The Company markets its products primarily through consultative dialogue
with health care providers, targeted print and web site advertising, trade
shows, selective promotional arrangements with distributors and the Company's
heater lease program. To support sales of the entire line of humidification and
ventilation products, the Company leases heaters to domestic customers without
charge. The revenues from the sale of products used in connection with the
operation of the heaters covers the amortization of the heater cost under the
leases. The Company has heaters with a net book value of approximately $2.2
million as of December 31, 2001 placed at service provider locations under this
program.

4

The Company utilizes a network of over 50 hospital distributors, as well as
over 3,000 alternate site distributors and end-users, to reach its markets. A
number of these distributors carry competing product lines, but many are moving
to select single supply sources for particular product groups. The Company has
been selected as the FOCUS preferred vendor of respiratory disposables for Owens
& Minor Inc. Such status gives preference to the shipping of the Company's
products versus competing product lines. Owens & Minor Inc. is the Company's
largest distributor, accounting for approximately $30.4 million or approximately
19.4% of total fiscal 2001 net sales, $32.2 Million or 20.2% of total fiscal
2000 net sales and $24.5 million or 19.0% of total fiscal 1999 net sales. The
Company provides a price list to its distributors which details base acquisition
prices. Distributors receive orders from the service providers and charge the
contract pricing (which is determined by their GPO affiliation or individual
contract price) plus a service margin. As is customary within the industry, the
Company rebates the difference between base acquisition price and the specific
contract price to the distributor. The Company's international distributors
outside of the European Union ("EU"), Middle East and Africa place their orders
directly with dedicated international customer service representatives. Customer
orders are shipped from one of three warehouse locations. Sales strategies and
marketing plans are tailored to each clinical product group with involvement of
the distributor. Region and territory sales managers are responsible for the
launch of products into their regions, including related support and training.
The Company utilizes a network of approximately 120 international distributors,
typically on an exclusive basis within each market. Customers within Europe, the
Middle East and Africa are serviced by the Company's Sweden office.

Manufacturing and Assembly

The Company operates three manufacturing facilities in the United States
and assembly facilities in Ensenada, Mexico and Kuala Lumpur, Malaysia. While
the Company believes that it is operating at a high utilization rate, existing
facilities could support increased capacity with additional machinery and
workers. The Company's manufacturing facility in Temecula, California houses 77
injection molding machines. During the past several years, many of the machines
have been replaced with more efficient models, which have increased capacity.
Tubing is produced on 11 extrusion lines: 6 corrugated, 4 vinyl and 1
repellitizer/regrinder. The Temecula facility uses approximately 19 million
pounds of over 30 different kinds of resin annually; the most prominent are PVC,
polyethylene, polypropylene and polystyrene. Sterile prefilled humidification
and nebulization products are manufactured using 9 blow/fill/seal machines in
the Company's facility in Arlington Heights, Illinois.

The Company's Argyle, New York facility houses 4 extrusion lines, 4 blow
molding machines and 8 assembly lines designed to produce the SHERIDAN(R) brand
of endotracheal tubes. The SHERIDAN(R) product line was acquired in October,
2000 from Tyco Healthcare Group LP ("Tyco"). The Company leases approximately
fifty percent of the Argyle facility from Tyco under a three year lease ending
in October, 2003. During 2001, the Company made the decision to relocate the
Argyle production facility to Tecate, Mexico, beginning in 2002 and anticipates
completing the move by October, 2003.

The Company's facility located in Ensenada, Mexico is primarily used for
the assembly of certain products molded and/or extruded at the Temecula
facility. The facility is a maquiladora, and therefore there are minimal tariffs
associated with the transport of products and components across the United
States-Mexico border. The Company's facility located in Kuala Lumpur, Malaysia
assembles virtually all of the HME and filter products marketed by the Company.
The components assembled by the Malaysian operation are generally molded by
outside vendors in Malaysia.

The Company monitors the quality of its products at its manufacturing
facilities by statistical sampling and visual and dimensional inspection. The
Company also inspects incoming raw materials for inconsistencies, rating its
vendors on quality and delivery time. The Company is routinely audited by the
FDA and has received no significant regulatory actions. The Company is in
substantial compliance with the GMP/QSR regulations of the FDA and the United
States and Mexico operations have qualified for an "advanced notification"
program allowing the Company to be informed of FDA inspections in advance. The
Company utilizes outside facilities for sterilization of products produced in
Temecula, Argyle, Arlington Heights, Kuala Lumpur and Ensenada. Certain
Arlington Heights products are manufactured in a sterile environment and are
certified sterile as a result of the production process. The Ensenada, Kuala
Lumpur, Argyle and Arlington Heights facilities are certified as ISO 9002
compliant and the Temecula and Sweden facilities are certified as ISO 9001
compliant.

5

Suppliers and Raw Materials

The Company's primary raw materials are various resins, which are
formed into the Company's products. The top 10 purchased products in 2001 were
tubing grade PVC, clear PVC, LDPE-EVA, polypropylene, pre-cut elastic, mask
grade PVC, acrylic resin, hose-end grade PVC, manual resuscitator assembly, and
breathing bag assembly. The Company believes that it is able to purchase
materials at a cost no higher than its competitors. The Company believes that
sufficient availability exists for its raw materials, as they consist of mainly
readily available plastic resins.

Research and Development

The Company's research and development department consists of 20
people, including 14 engineers. The Company's engineering efforts are split
between developing new products and process improvements to its manufacturing
operations. The Company develops new products to expand its product line in
anticipation of changes in demand. Significant products introduced in the last
five years include the line of heat-moisture exchangers, the SHERIDAN(R) brand
of endotracheal tubes, CONCHATHERM(R) IV heated humidification system, expansion
of the Company's ventilator circuit and nebulizer line, a demand oxygen
regulator and CONCHATHERM(R) 2000. CONCHATHERM(R) 2000 is a heated
humidification system for the sleep apnea market. The Company constantly works
to reduce costs through continuous process improvements. The Company incurred
research and development expenses of approximately $2.0 million, $2.4 million
and $2.0 million in fiscal 2001, 2000 and 1999, respectively.

Competition

The U.S. medical supply industry is characterized by intense
competition. The Company's primary competitor in the respiratory care sector is
Allegiance Healthcare (a subsidiary of Cardinal Health, Inc.) and its primary
competitors in the anesthesia sector include Tyco, Smiths Industries Medical
Systems, Inc. ("SIMS"), and Vital Signs, Inc. Many of the products manufactured
by the Company are available from several sources, and many of the Company's
customers tend to have relationships with several manufacturers. The Company
competes on the basis of brand name, product design and quality, breadth of
product line, service and price.

Patents and Trademarks

The Company has historically relied primarily on its technological and
engineering abilities and on its design and production capabilities to gain
competitive business advantages, rather than on patents or other intellectual
property rights. However, the Company does file patent applications on concepts
and processes developed by the Company's personnel. The Company has 27 patents
in the United States. Many of the U.S. patents have corresponding patents issued
in Canada, Europe and various other countries.

Government Regulation and Environmental Matters

The Company and its customers and suppliers are subject to extensive
Federal and state regulation in the United States, as well as regulation by
foreign governments, and the Company cannot predict the extent to which future
legislative and regulatory developments concerning its practices and products
for the health care industry may affect the Company. Most of the Company's
products are subject to government regulation in the United States and other
countries. In the United States, the FD&C Act and other statutes and regulations
govern or influence the testing, manufacture, safety, labeling, storage, record
keeping, marketing, advertising and promotion of such products. Failure to
comply with applicable requirements can result in fines, recall or seizure of
products, total or partial suspension of production, withdrawal of existing
product approvals or clearances, refusal to approve or clear new applications or
notices and criminal prosecution. Under the FD&C Act and similar foreign laws,
the Company, as a marketer, distributor and manufacturer of health care
products, is required to obtain the clearance or approval of Federal and foreign
governmental agencies, including the FDA, prior to marketing, distributing and
manufacturing certain of those products. The Company may also need to obtain FDA
clearance before modifying marketed products or making new promotional claims.
Delays in receipt of or failure to receive required approvals or

6

clearances, the loss of previously received approvals or clearances, or failures
to comply with existing or future regulatory requirements in the United States
or in foreign countries could have a material adverse effect on the Company's
business. Foreign sales are subject to similar requirements.

The Company is required to comply with pertinent sections of the Code
of Federal Regulations, 21CFR GMP/QSR, which set forth requirements for, among
other things, the Company's manufacturing process, design control and associated
record keeping, including testing and sterility. Further, the Company's plants
and operations are subject to review and inspection by state, Federal and
foreign governmental entities. The distribution of the Company's products may
also be subject to state regulation. The impact of FDA regulation on the Company
has increased in recent years as the Company has increased its manufacturing
operations. The Company's suppliers, including contract sterilization
facilities, are also subject to similar governmental requirements. There can be
no assurance that changes to current regulations or additional regulations
imposed by the FDA will not have an adverse impact on the Company's business and
financial condition in the future. The FDA also has the authority to issue
special controls for devices manufactured by the Company. In the event that such
special controls were issued, the Company's products would be required to
conform, which could result in significant additional expenditures for the
Company.

The Company is also subject to numerous federal, state and local laws
and regulations relating to such matters as safe working conditions,
manufacturing practices, fire hazard control and the handling and disposal of
hazardous or infectious materials or substances and emissions of air pollutants.
The Company owns and leases properties which are subject to environmental laws
and regulations. There can be no assurance that the Company will not be required
to incur significant costs to comply with such laws and regulations in the
future or that such laws or regulations will not have a material adverse effect
upon the Company's business, financial condition or results of operations. In
addition, the Company cannot predict the extent to which future legislative and
regulatory developments concerning its practices and products for the health
care industry may affect the Company.

Employees

As of May 31, 2002, the Company employed approximately 2,342 employees,
substantially all of whom were full-time employees. None of the Company's
employees are represented by unions and the Company considers its employee
relations to be good.

Item 2. Properties.

The Company owns approximately 30 acres of land in Temecula, California
on which its headquarters, one of three principal manufacturing centers and
three other buildings totaling approximately 245,000 square feet are located.
Plastic and vinyl components and corrugated tubing are manufactured in Temecula
and assembled into finished goods at a 77,000 square foot facility in Ensenada,
Mexico. The Company owns the Ensenada facility and the underlying land is held
in a 30-year trust that expires in 2019. The Company leases an 86,000 square
foot manufacturing facility in Arlington Heights, Illinois under a lease that
expires in 2005 with an option to extend an additional 5 years. Prefilled
sterile solutions and electronics are manufactured in Arlington Heights. The
Company leases a 73,000 square foot distribution warehouse in Elk Grove,
Illinois under a lease that expires in May, 2010, and a 25,375 square foot
distribution facility in Atlanta, Georgia under a lease that expires in February
2006. In August 2001, the Company made a decision to close the Atlanta
distribution center. The company leases a 99,100 square foot distribution
facility in Temecula, California under a lease that expires in September 2005.
The Company leases sales and marketing offices in Stockholm, Sweden; Ashby de la
Zouch, U.K.; Lyon, France; and Lohmar, Germany under leases that expire in
September 30, 2002, April 25, 2006 and April, 2005, respectively. The Company
leases a 33,260 square foot facility in Kuala Lumpur, Malaysia, under a lease
that expires in July 2002. This facility primarily assembles finished products
for the HME and filter product lines. The Company is currently in discussions
with the owners of the Swedish and Malaysia properties and expects the leases to
be renewed on a favorable basis. The Company also leases approximately fifty
percent of an 80,218 square foot facility in Argyle, New York under a lease that
expires in October, 2003. This facility manufacturers the SHERIDAN(R) line of
endotracheal tubes. During 2001, the Company made a decision to relocate the
endotracheal product line from its manufacturing plant in Argyle, New York to
Tecate, Mexico. The Company has acquired an approximately 99,000 square foot
facility in Tecate, under a lease that expires in March 2005.

7

The Company believes that its current facilities are adequate for its
present level of operations.

Item 3. Legal Proceedings.

The Company is not a party to any material lawsuits or other
proceedings, including suits relating to product liability and patent
infringement. While the results of the Company's existing lawsuits and other
proceedings cannot be predicted with certainty, management does not expect that
the ultimate liabilities, if any, will have a material adverse effect on the
financial position or results of operations of the Company.

Item 4. Submissions of Matters to a Vote of Security Holders.

None.

8

PART II

Item 5. Market for Registrant's Common Equity and Related Stockholder Matters.

There is no established public trading market for the Company's Common
Stock. All of the Common Stock of the Company is held by Holding and the
shareholder of the Company prior to the recapitalization.

The Company has not paid cash dividends to Holding in the past two
years, and does not intend to pay cash dividends to Holding in the foreseeable
future. See "Item 7. Management's Discussion and Analysis of Financial Condition
and Results of Operations--Liquidity and Capital Resources" for a discussion of
restrictions on the Company's ability to pay cash dividends.

Item 6. Selected Financial Data.

The selected fiscal year end historical financial data has been derived
from the audited financial statements of the Company. The information contained
in this table as of December 31, 2000 and 2001, and for each of the three years
in the period ended December 31, 2001 should be read in conjunction with the
Company's audited consolidated financial statements and notes thereto included
elsewhere in this Report.

Fiscal Year
------------------------------------------------------------------
2001 2000 1999(a) 1998 1997
-------- -------- --------- ------- ------

Operating Data:
Net sales ............................................. $ 157,112 $159,278 $128,803 $100,498 $99,509
Cost of sales ......................................... 108,054 84,923 75,418 56,802 54,575
-------- ------- ------- -------- -------
Gross profit .......................................... 49,058 74,355 53,385 43,696 44,934
Operating expenses:
Selling expenses ...................................... 19,496 18,262 13,122 10,350 9,643
Distribution expenses ................................. 11,429 10,109 4,647 3,336 3,170
General and administrative expenses ................... 30,205 (e) 27,343 14,732 10,284 11,456
Impairment of goodwill ................................ 33,128 (f) -- -- -- --
Impairment of fixed assets ............................ 4,469 (g) -- -- -- --
Research and development expenses ..................... 2,043 2,387 2,031 976 1,072
Provision for equity participation plan ............... -- -- -- 63,939 (b) 6,954
Provision for retention payments ...................... -- -- -- 4,754 (c) --
-------- ------- ------- -------- -------
Operating income (loss) ............................... (51,712) 16,254 18,853 (49,943) 12,639
-------- ------- ------- -------- -------
Other (income) and expenses: .......................... -- -- --
Interest expense ...................................... 20,542 21,089 17,263 11,327 1,834
Other (income) expense ................................ 1,563 1,159 1,232 406 (638)
-------- ------- ------- -------- -------
Total other expense ................................... 22,105 22,248 18,495 11,733 1,196
-------- ------- ------- -------- -------
Income (loss) before provision for income taxes ....... (73,817) (5,994) 358 (61,676) 11,443
Provision for income taxes ............................ 69,854 (h) 3,203 1,586 8,405 150
-------- ------- ------- -------- -------
Income (loss) before extraordinary item ............... (143,671) (9,197) (1,228) (70,081) 11,293
Extraordinary item (loss on extinguishment of debt) ... -- -- -- 104 (d) --
-------- ------- ------- -------- -------
Net income (loss) ..................................... $(143,671) $ (9,197) $ (1,228) $(70,185) $11,293
======== ======= ======= ======== =======

continued on following page

9

Fiscal Year
----------------------------------------------------------------
2001 2000 1999(a) 1998 1997
--------- --------- --------- --------- --------
Balance Sheet Data: (dollar amounts in thousands)

Total assets .......................................... $ 137,055 $ 275,234 $ 251,819 $ 165,321 $ 77,554
Total debt ............................................ 226,147 221,914 211,694 159,000 20,250
Mandatorily-redeemable preferred stock 44,989 40,061 35,421 31,513 --
Shareholders' equity (deficit) ........................ (167,821) (22,775) (14,649) (37,735) 22,515
Working capital ....................................... (160) 29,559 35,971 29,533 6,430
Other Financial Data:
Net cash provided by (used in) operating
activities ......................................... $ 5,564 $ 10,379 $ 7,097 $ (83,024) $ 19,269
Net cash used in investing activities ................. (9,017) (26,941) (75,818) (6,444) (3,673)
Net cash provided by (used in) financing
activities ......................................... 7,330 17,464 71,529 89,624 (16,398)
Operating margin before EPP and Retention
Payments (l) ....................................... (32.9)% 10.2% 14.6% 18.7% 19.7%
Depreciation and amortization ......................... $ 12,224 $ 11,719 $ 8,315 $ 6,101 $ 5,847
Capital expenditures .................................. 9,029 11,329 10,973 3,111 4,659
Ratio of earnings to fixed charges (j) ................ --x 0.7x 1.0x --x 6.0x
Deficiency of earnings to cover fixed charges ......... $ (73,817) $ -- $ -- $ (61,676) $ --
Ratio of earnings to fixed charges and
preferred stock dividends (k) ...................... --x 0.8x --x --x 6.0x
Deficiency of earnings to cover fixed charges
and preferred stock dividends ...................... $ (73,817) $ -- $ (6,160) $ (65,863) $ --

- ----------------------
(a) Includes results of operations for (i) Hudson RCI AB, since it was acquired
in July 1999, (ii) Medimex, since certain of its assets were acquired in
October 1999 and (iii) VOLDYNE(R), since certain of its assets were
acquired in November 1999.
(b) Reflects payments made under the equity participation plan ("EPP"), which
was terminated upon consummation of the recapitalization in April 1998.
(c) Reflects retention payments made to substantially every employee of the
Company in connection with the recapitalization. These payments were
intended to ensure the continued employment of all employees after the
recapitalization and no future payments are anticipated.
(d) Reflects the write-off of deferred financing fees related to the payoff of
outstanding debt under the Company's previous credit agreement.
(e) Consist of (i) general and administrative expense of $23,889, (ii)
amortization of goodwill of $3,490 and (iii) provision for bad debts of
$2,826.
(f) Reflects impairment of goodwill based on management's analysis described in
the "Fourth Quarter Charges" section in "Item 7 - Results of Operations."
(g) Reflects the write-off of certain assets management has determined have no
value as described in the Fourth Quarter Charges section of the Results of
Operations.
(h) Includes the write-off of deferred taxes of $68,881 as described in the
Fourth Quarter Charges section of the Results of Operations.

10

(i) Represents ratio of operating income before EPP and retention payments to
net sales.
(j) For the purpose of determining the ratio of earnings to fixed charges,
earnings consist of earnings before income taxes and fixed charges. Fixed
charges consist of interest on indebtedness, the amortization of debt issue
costs and that portion of operating rental expense representative of the
interest factor.
(k) For the purpose of determining the ratio of earnings to fixed charges and
preferred stock dividends, earnings consist of earnings before income taxes
and fixed charges. Fixed charges consist of interest on indebtedness, the
amortization of debt issue costs and that portion of operating rental
expense representative of the interest factor. Preferred stock dividends
have been "grossed up" to a pre-income tax basis to provide comparability
to other components of the ratio.

Item 7. Management's Discussion and Analysis of Financial Condition and Results
of Operations.

The following discussion of the Company's consolidated historical
results of operations and financial condition should be read in conjunction with
the consolidated financial statements of the Company and the notes thereto
included elsewhere in this Form 10-K.

General

The Company's results of operations may fluctuate significantly from
quarter to quarter as a result of a number of factors, including, among others,
the buying patterns of the Company's distributors, GPOs and other purchasers of
the Company's products, forecasts regarding the severity of the annual cold and
flu season, announcements of new product introductions by the Company or its
competitors, changes in the Company's pricing of its products and the prices
offered by the Company's competitors, rate of overhead absorption due to
variability in production levels and variability in the number of shipping days
in a given quarter.

Recent Developments

During 2001, management implemented several initiatives designed to
improve the Company's proficiency with its new management information system, to
decrease the Company's ongoing operating expenses, improve collections and
administration of accounts receivables, and to reduce inventory levels. While
the Company continues to experience some of the issues associated with the
implementation of the new system, management believes customer service levels
and relationships have improved since the business disruption resulting from
difficulties in the implementation of the system in 2000.

In the fourth quarter of 2001, the Company incurred charges of $115.1
million, as described more completely in the "Fourth Quarter Charges" section of
this item.

As of December 31, 2001, based on the Company's financial results, the
Company was not in compliance with certain financial covenants under its Credit
Facility. As a result of this non-compliance and resulting defaults, on March
30, 2002, the Company did not make a scheduled term loan payment to the lenders
as required under the Credit Facility and, as a result, the Company was
prevented from making a scheduled interest payment to its Subordinated Note
holders on April 15, 2002.

11

As of December 31, 2001, the Company's wholly-owned Swedish
subsidiary, Hudson RCI AB, was not in compliance with certain financial
covenants of the Hudson RCI AB bank facility. The Company and Hudson RCI AB are
currently in discussions with the lender and expect to receive a waiver curing
all defaults (see the "Liquidity and Capital Resources" section of this Item).
Due to the uncertainty of receiving this waiver from the lenders, the Company
has classified the entire Hudson RCI AB bank facility as a current liability on
the consolidated balance sheet. The Credit Facility and Senior Subordinated
notes are not cross-defaulted to the Hudson RCI AB bank facility.

On May 14, 2002, the Company amended and restated the Credit Facility
to (i) waive all existing events of default; (ii) extend the final maturity of
the term and revolving facilities under the Credit Facility to June 30, 2004;
(iii) amend existing term loan and acquisition facility amortization to $3.8
million in 2002, $9.3 million in 2003 and $37.0 million in 2004; and (iv) amend
financial covenants. to include only a limitation on capital expenditures and a
minimum EBITDA test. In connection with this amendment, the Company and HRC
Holding, its wholly-owned subsidiary, issued a total of $20.0 million in senior
unsecured notes to affiliates of Holding's majority stockholder. These notes
bear interest at 12%, with interest and principal due upon maturity on December
31, 2004.

During 2001, the Company made the decision to close the Argyle, New
York facility and move its operations to a new facility located in Tecate,
Mexico, beginning in 2002. It is anticipated that this move will cost
approximately $4.6 million, of which $0.9 million relating to severance costs
was recorded in 2001.

Critical Accounting Policies

Accounts Receivable: Management performs various analyses to evaluate
accounts receivable balances to ensure that recorded amounts reflect estimated
net realizable value. Management applies specified percentages to the accounts
receivable aging to estimate the amount that will ultimately be uncollectible
and, therefore, should be reserved. The percentages are increased as the
accounts age.

Management establishes and monitors these percentages through
extensive analyses of historical realization data, accounts receivable aging
trends, other operating trends and the extent of contracted business and
business combinations. Also considered are relevant business conditions,
including general economic factors as they relate to the company's international
customers. If indicated by such analyses, management may periodically adjust the
uncollectible estimate and corresponding percentages. Further, focused reviews
of certain large and/or problematic payors are performed to determine if
additional reserves are required.

In the fourth quarter of fiscal year 2001, management decided to not
pursue certain aged accounts receivable for collection and to allocate resources
to other customer receivables and collection activities. As a result, the
Company provided for such identified accounts receivables totaling $2.2 million.

Inventory: Inventories are stated at the lower of cost (first-in,
first-out ("FIFO") method) or market. Management utilizes various analyses based
on forecasts, historical sales and inventory levels to ensure that the current
carrying value of inventory accurately reflects the current and expected
requirements of the Company within a reasonable timeframe. During the fourth
quarter of 2001, management embarked upon a new strategic initiative to
eliminate certain products that were either unprofitable or marginally
profitable. In addition, management initiated a similar strategic initiative to
eliminate inventory on hand which exceeded more than a reasonable level of
projected future demand. As a result of the above actions, the Company recorded
a charge of $4.6 million in the fourth quarter related to the write-off and
disposal of obsolete and excess inventory.

Revenue Recognition: The Company recognizes revenue when product is
shipped and title passes to customer, as the earnings process is substantially
complete. The Company establishes reserves for sales returns and other
allowances based on historical experience. The Company sells its products to its
distributors without right of return based on a listed price. Distributors
charge the service providers, or the Company's end customers, a contract price
(which is determined by their GPO affiliation or individual contract price) plus
a service margin. As is customary within the industry, the Company rebates the
difference between the list price and the specific contract price to the
distributor.
12

The Company records revenue and receivables net of rebatable amounts. In the
event no rebate is payable, the amount is reversed and recognized as revenue.

Deferred Taxes: The Company applies the asset and liability method in
recording income taxes, under which deferred income tax assets and liabilities
are determined based on the differences between the financial reporting and tax
bases of assets and liabilities and are measured using currently enacted tax
rates and laws. Additionally, deferred tax assets are evaluated and a valuation
allowance is established if it is more likely than not that all or a portion of
the deferred tax asset will not be realized. As a result of significant losses
in the fourth quarter and cumulative losses in recent years, management
reevaluated its ability to realize the future benefit of its deferred tax assets
in light of the historical operating results. Accordingly, the Company recorded
a full valuation allowance against its deferred tax assets of approximately
$68.9 million.

Impairment of Goodwill and Other Intangibles: The Company periodically
reviews the recoverability of the carrying value of goodwill, intangibles and
other long-lived assets for impairment whenever events or changes in
circumstances indicate that the carrying amount of the asset may not be
recoverable. Recoverability of these assets is determined by analysis of the
asset's fair value by comparing the forecasted future net cash flows from the
operations to which the assets relate, based on management's best estimates
using the appropriate assumptions and projections at the time, to the carrying
amount of the assets. If the carrying value is determined not to be recoverable
from future operating cash flows, the asset is deemed impaired and an impairment
loss is recognized equal to the amount by which the carrying amount exceeds the
estimated fair value of the assets. In addition, goodwill is assessed for
recoverability at an entity level, based on fair value determined by estimated
future cash flows discounted at a rate commensurate with the risk involved. In
the fourth quarter of 2001, as a result of significant losses from operations,
the Company recorded a goodwill impairment charge of approximately $33.1
million.

Recent Accounting Pronouncements

Effective January 1, 2001, the Company adopted Statement of Financial
Accounting Standards No.133, "Accounting for Derivative Instruments and Hedging
Activities," as amended by SFAS No. 137 and SFAS No. 138. SFAS No. 133, as
amended, establishes accounting and reporting standards for derivative
instruments. The statement requires that every derivative instrument be recorded
in the balance sheet as either an asset or liability measured at its fair value,
and that changes in the derivative's fair value be recognized currently in
earnings, unless specific hedge accounting criteria are met. The adoption of
this new standard did not have a material impact on the Company's consolidated
financial statements.

In June 2001, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standards No. 141, "Business Combinations"
("SFAS 141"). This Statement addresses financial accounting and reporting for
business combinations and supersedes APB Opinion No. 16, "Business
Combinations," and FASB Statement No. 38, "Accounting for Preacquisition
Contingencies of Purchased Enterprises." All business combinations in the scope
of this Statement are to be accounted for using one method, the purchase method.
Any acquisitions made by the Company after June 2001 will be accounted for in
accordance with SFAS 141.

Also in June 2001, the FASB issued Statement of Financial Accounting
Standards No. 142, "Goodwill and Other Intangible Assets" ("SFAS 142"). SFAS 142
addresses financial accounting and reporting for acquired goodwill and other
intangible assets and supersedes APB Opinion No. 17, "Intangible Assets." This
pronouncement addresses, among other things, how goodwill and other intangible
assets should be accounted for after they have been initially recognized in the
financial statements. Goodwill would no longer be amortized but would be
assessed at least annually for impairment using a fair value methodology. The
Company stopped amortizing goodwill, effective January 1, 2002 and, as a result,
an equivalent charge for goodwill amortization will not be made in 2002. The
Company is still evaluating the impact of the standard on impairment, which is
expected to be completed by the end of the second quarter of 2002. The
amortization of goodwill for 2001 was $3.5 million.

Also in June 2001, the FASB issued SFAS No. 143, "Accounting for Asset
Retirement Obligations" ("SFAS 143"). SFAS 143 addresses financial accounting
and reporting obligations associated with the retirement of tangible

13

long-lived assets and the associated asset retirement costs. It requires
entities to record the fair value of a liability for an asset retirement
obligation in the period in which it is incurred. When the liability is
initially recorded, the entity capitalizes a cost by increasing the carrying
amount of the related long-lived asset. Over time, the liability is accreted to
its present value each period, and the capitalized cost is depreciated over the
useful live of the related asset. Upon settlement of the liability, an entity
either settles the obligation for its recorded amount or incurs gain or loss
upon settlement. SFAS 143 is effective January 1, 2003. The Company does not
expect the adoption of SFAS 143 to have a material impact on the Company's
consolidated financial statements.

In August 2001, the FASB issued SFAS 144 "Accounting for the Impairment
or Disposal of Long-Lived Assets." This statement addresses financial accounting
and reporting for the impairment or disposal of long-lived assets. This
statement supercedes SFAS No. 121, "Accounting for the Impairment of Long-Lived
Assets and for Long-Lived Assets to be Disposed Of," and the accounting and
reporting provisions of APB Opinion No. 30, "Reporting the Results of Operations
- - Reporting the Effects of a Disposal of a Segment of a Business and
Extraordinary, Unusual and Infrequently Occurring Events and Transactions," for
the disposal of a segment of a business (as previously defined in that Opinion).
SFAS No. 144 was effective January 1, 2002. The adoption of SFAS 144 is not
expected to have a material impact on the Company's consolidated financial
statements.

14

Results of Operations

The following tables set forth, for the periods indicated, certain income
and expense items expressed in dollars and as a percentage of the Company's net
sales.

Fiscal Year
----------------------------------------
2001 2000 1999
---------- ---------- -------
(dollars in thousands)

Net sales ...................................................... $ 157,112 $ 159,278 $ 128,803

Cost of sales .................................................. 108,054 84,923 75,418
---------- --------- -----------

Gross profit ............................................... 49,058 74,355 53,385

Selling expenses ............................................... 19,496 18,262 13,122

Distribution expenses .......................................... 11,429 10,109 4,647

General and administrative expenses ............................ 23,889 20,917 12,829

Amortization of goodwill ....................................... 3,490 3,320 1,463

Impairment of goodwill ......................................... 33,128 -- --

Impairment of fixed assets ..................................... 4,469 -- --

Research and development expenses .............................. 2,043 2,387 2,031

Provision for bad debts ........................................ 2,826 3,106 440
---------- --------- ---------

Total operating expenses ....................................... 100,770 58,101 34,532
---------- --------- ---------

Operating income (loss) ........................................ $ (51,712) $ 16,254 $ 18,853
========== ========= =========

Fiscal Year
----------------------------------------
2001 2000 1999
---------- --------- --------

Net sales ...................................................... 100.0% 100.0% 100.0%

Cost of sales .................................................. 68.8 53.3 58.5
---------- --------- --------

Gross profit ............................................... 31.2 46.7 41.5

Selling expenses ............................................... 12.4 11.5 10.2

Distribution expenses .......................................... 7.3 6.3 3.6

General and administrative expenses ............................ 15.2 13.1 10.0

Amortization of goodwill ....................................... 2.2 2.1 1.1

Impairment of goodwill ......................................... 21.1 -- --

Impairment of fixed assets ..................................... 2.8 -- --

Research and development expenses .............................. 1.3 1.5 1.6

Provision for bad debts ........................................ 1.8 2.0 0.3
---------- --------- ---------

Total operating expenses ....................................... 64.1 36.5 26.8
---------- --------- ---------
Operating income (loss) ........................................ (32.9)% 10.2% 14.7%
========== ========= =========

15

Year Ended December 31, 2001 Compared to Year Ended December 31, 2000

Net sales, reported net of rebates, were $157.1 million in 2001, a
decrease of $2.2 million or 1.4% from 2001. On a consolidated basis, domestic
hospital sales decreased by $5.5 million during 2001, or 5.9% as compared to
2000. The decrease in net sales is attributable to the following: (i) reduced
seasonal demand worldwide for certain products due to mild levels of flu-related
illnesses and unusually warm weather in the fourth quarter of 2001; (ii) lower
than normal demand from U.S. hospitals following the September 11, 2001
terrorist attacks in New York and Washington as a result of reduced hospital
admissions and lower levels of elective surgeries; and (iii) a decision by the
Company in 2001 not to offer purchasing incentives at year end to distributors.
Alternate site sales increased by $2.0 million or 8.8% due to market growth and
lower prior year sales which were the result of shipping difficulties
encountered in 2000 relating to the implementation of the management information
system. Original Equipment Manufacturing ("OEM") sales decreased by $1.0 million
or 16.3% during 2001, primarily due to changes in purchasing patterns from some
of its OEM customers and their reduced demand as a result of the weak influenza
season. European sales increased slightly by $0.3 million or 1.5% as compared to
2000 as a result of incremental sales of the SHERIDAN(R) product line (acquired
in October 2000) as well as increased sales in certain European markets now
served on a direct basis through the Company's European distribution center
located in the Netherlands. Pacific Rim sales increased by $2.0 million or 21.5%
as compared to 2000 as a result of incremental sales of the SHERIDAN(R) product
line and continued growth in the use of the Company's products in this
marketplace.

The Company's gross profit for 2001 was $49.1 million, a decrease of
$25.3 million or 34.0% from 2000. As a percentage of net sales, the Company's
gross profit for 2001 was 31.2% as compared to 46.7% for 2000. This decrease was
primarily due to the following: (i) sale of inventory recorded a higher net
realizable value rather than manufacturing cost as a result of the SHERIDAN(R)
acquisition; (ii) increased shipping costs as a result of shipping difficulties
caused by problems associated with the new management information system; (iii)
an unfavorable mix variance caused by higher sales of products with lower gross
margins; (iv) higher level of unabsorbed manufacturing costs resulting from
lower than expected demand and decreased inventories and (v) charges in the
fourth quarter of 2001 relating to an initiative put in place to discontinue and
dispose of less profitable products.

Selling expenses were $19.5 million for 2001, a $1.2 million or 6.8%
increase over 2000. This increase was primarily driven by additions to the sales
and marketing departments to support recently acquired product lines, as well as
an increase in fees associated with certain GPO's. As a percentage of sales,
selling expenses were 12.4% in 2001 as compared to 11.5% in 2000.

Distribution expenses were $11.4 million in 2001, which represents a
$1.3 million or 13.1% increase over 2000. As a percentage of sales, distribution
expenses were 7.3% in 2001 versus 6.3% in 2000. This increase was a result of
the establishment of the European distribution center in the first quarter of
2001.

General and administrative expenses were $23.9 million for 2001, an
increase of $3.0 million or 14.3% over 2000. This increase resulted primarily
from increased staffing levels required to maintain acceptable customer service
levels and operate the business with the new management information system,
expenses related to the closure of the Atlanta distribution center, higher
depreciation associated with the new management information system and other
professional fees and charges related to implementing the new management
information system.

Amortization of goodwill was $3.5 million in 2001, a $0.2 million or
5.1% increase over 2000. The increase was the result of a full year of
amortization related to the SHERIDAN(R) acquisition made during the fourth
quarter of 2000. As a result of significant losses in the fourth quarter, the
Company reassessed future cash flows and determined that goodwill was not
recoverable. Accordingly, the Company recorded a goodwill impairment charge of
approximately $33.1 million.

Research and development expenses were $2.0 million in 2001 as compared
to $2.4 million in 2000, the result of eliminating several positions in the
Company's facility operated by Hudson RCI AB, the Company's Swedish subsidiary,
during 2001.

16

Interest expense was $20.5 million in 2001, a $0.5 million or 2.6%
decrease from 2000. The decrease was primarily due to a general decrease in
interest rates.

Income tax provision was $69.8 million for 2001 as compared to $3.2
million in 2000. As a result of losses in the fourth quarter of 2001 and
cumulative losses in recent years, the Company recorded a full valuation
allowance of $68.9 million in 2001.

Fourth Quarter Charges

The following is a summary of the charges incurred by the Company in
the fourth quarter of 2001 (amounts in thousands):

Write-off of deferred tax asset ...................... $ 68,881
Goodwill impairment .................................. 33,128
Impairment of fixed assets ........................... 4,469
Destruction of obsolete inventory .................... 4,582
Write-off of uncollectible accounts receivable ....... 2,189
Distribution center closure .......................... 930
Relocation of manufacturing facilities ............... 900
---------

Total fourth quarter charges ......................... $ 115,079
=========

As a result of significant losses in the fourth quarter and cumulative
losses in recent years, the Company has reevaluated its ability to realize the
future benefit of its net deferred tax assets held in light of the historical
operating losses. Accordingly, the Company recorded a full valuation allowance
against its deferred tax assets of approximately $68.9 million.

As a result of significant losses in the fourth quarter, the Company
reassessed future cash flows and determined that goodwill was not recoverable.
Accordingly, the Company recorded a goodwill impairment charge of approximately
$33.1 million.

As a result of the Company's analysis of fixed assets in the fourth
quarter, it was determined that certain machinery and equipment was no longer
needed to support current business operations and had no value. Additionally,
certain software development costs incurred in 2001 related to the management
information system failed to achieve their intended results and, as a result,
were determined to have no future value. As a result, the Company recorded an
impairment charge of approximately $4.5 million.

As a result of an analysis of product lines during the fourth quarter
of 2001, the Company concluded that it would no longer support a certain number
of individual products, resulting in the related inventories of those products
no longer having value. The Company recorded charges of $4.6 million related to
the destruction of obsolete inventory resulting from this strategic decision.

The Company made a decision in the fourth quarter of 2001 to not pursue
certain aged accounts receivable for collection and to allocate resources to
other customer receivables and collection activities. As a result, the Company
increased its provision for write-offs based on analysis of those aged customer
receivables.

The Company recorded a charge of approximately $0.9 million related to
the 4th quarter closure of its Atlanta distribution center. This charge
primarily consisted of future rent commitments.

During fiscal 2001, the Company made a decision to relocate from its
manufacturing operation in Argyle, New York to Tecate, Mexico. In addition, the
Company made a decision to move certain product manufacturing

17

from Temecula, California to Ensenada, Mexico. The Company recorded
approximately $0.9 million in severance costs related to the relocations.

During the fourth quarter of 2000, the Company embarked on a detailed
review of the accounts receivable. Upon completion of such analysis, the Company
recorded an additional $2.3 million of provision for bad debts to recognize
certain accounts receivable, which became uncollectible in the fourth quarter.

Year Ended December 31, 2000 Compared to Year Ended December 31, 1999

Net sales, reported net of rebates, were $159.3 million in 2000, an
increase of $30.5 million or 23.7% over 1999. Of the $30.5 million increase,
$9.2 million related to the VOLDYNE(R) incentive breathing exerciser product
line acquisition made in November 1999, and $3.2 million was the result of the
acquisition of the SHERIDAN(R) endotracheal tube product line in October of
2000. In addition, the Louis Gibeck AB (now Hudson RCI AB) acquisition,
completed in July 1999, accounted for an additional $5.4 million of sales in
2000. For the base Hudson RCI business, alternate site sales increased $1.5
million or 7.1% as a result of the continued focus on this important and growing
marketplace. Domestic hospital sales increased by $9.7 million or 13.0% as the
result of new GPO relationships, as well as increased purchases from existing
GPO relationships. Sales to Europe declined by $2.2 million or 18.0%, driven
primarily by backorders and sales losses created during the implementation of a
new management information computer system. Sales to Latin America increased by
$0.4 million, while sales to the Pacific Rim increased by $2.6 million. OEM
sales increased by $0.8 million or 18.6%, the result of new relationships with
several customers.

The Company's gross profit for 2000 was $74.4 million, an increase of
$21.0 million or 39.3% from 1999. As a percentage of net sales, the Company's
gross profit for 2000 was 46.7% as compared to 41.4% for 1999. This increase was
primarily due to increased sales of higher profit margin products, such as the
acquired Louis Gibeck AB and VOLDYNE(R) incentive breathing exerciser product
lines. This was somewhat offset by increased freight costs required to service
customer needs during a period of shipping difficulties caused by problems
associated with the new computer system installation.

Selling expenses were $18.3 million for 2000, a $5.1 million or 39.2%
increase over 1999. This increase was primarily driven by the inclusion of full
year results in 2000 of Hudson RCI AB, as well as establishment of sales offices
in France and the United Kingdom during 2000. As a percentage of net sales,
selling expenses were 10.2% and 11.5% in 1999 and 2000, respectively.

Distribution expenses were $10.1 million in 2000, which represents a
$5.5 million or 117.5% increase over 1999. This increase was caused by
implementation of a second shift at all domestic distribution centers, increased
overtime and the addition of a new distribution warehouse in Temecula,
California. These increased costs were driven by shipping issues caused by the
new system implementation, as well as higher volumes of products shipped during
2000 as compared to 1999. Additionally, freight for products shipped between
distribution facilities increased significantly in order to meet increased
demand, as well as to better serve customers affected by shipping problems
associated with the new system implementation.

General and administrative expenses were $20.9 million for 2000, an
increase of $8.0 million or 62.0% over 1999. This increase resulted primarily
from increased staffing required to maintain acceptable customer service levels
and operate the business with the new computer system. Additionally, due to
increased aging of receivables resulting from lack of experience and visibility
within the new management information system, the Company increased its reserves
for doubtful accounts. In addition, general and administrative expense increases
also resulted from the establishment of sales offices in France and the United
Kingdom, as well as the full year effect of Hudson RCI AB.

Amortization of goodwill was $3.3 million in 2000, a $1.9 million or
126.9% increase over 1999. This increase was driven primarily by the Hudson RCI
AB and VOLDYNE(R) incentive breathing exerciser acquisitions in 1999, as well as
the SHERIDAN(R) endotracheal tube product line acquisition in 2000.

18

Research and development expenses were $2.4 million in 2000 as compared
to $2.0 million in 1999. This increase is solely due to the inclusion of Hudson
RCI AB results for a full year in 2000.

Interest expense was $21.1 million in 2000, a $3.8 million or 22.2%
increase over 1999. This increase was primarily due to increased borrowings to
fund the Hudson RCI AB, VOLDYNE(R) incentive breathing exerciser and SHERIDAN(R)
acquisitions. In addition, borrowings were higher under the working capital
revolver due to increased working capital requirements that resulted from growth
in the Company, as well as from issues relating to the new computer system
implementation.

The Company experienced significant changes in the composition and
complexity of accounts receivable that were aggravated by the Company's
implementation of its new ERP system. During the fourth quarter of 2000, the
Company embarked on a detailed review of accounts receivable. Upon completion of
such analysis, the Company recorded an additional $2.3 million of provision for
bad debts to recognize certain accounts receivable, which became uncollectible
in the fourth quarter.

During 2000, the Company also experienced a shift in customer product
and product mix to a higher rebate percentage. Similar to the problems
associated with the allowance for doubtful accounts, the shift was obscured by
difficulties associated with the implementation of the Company's new ERP system,
which resulted in the Company's reevaluation of the amount of rebates
recognized.

Seasonality

The Company's results of operations exhibit some measure of
seasonality. Generally, the Company's sales and EBITDA are higher in the first
and fourth quarters and lower in the second and third quarters. This is due
primarily to the higher incidence of breathing ailments, such as colds and flu,
during the winter months, which results in increased hospitalization and
respiratory care, especially among higher-risk individuals, such as infants and
the elderly. Fourth quarter sales are generally the Company's highest, as
distributors increase inventory in anticipation of the cold and flu seasons.
First quarter results are generally affected by the length and severity of flu
seasons.

Liquidity and Capital Resources

The Company's primary sources of liquidity are cash flow from
operations and borrowings under its working capital bank facility and,
historically, investments from its shareholders. Cash provided by operations
totaled $5.6 million, $10.4 million and $7.1 million in 2001, 2000 and 1999,
respectively. The decrease from 2000 to 2001 is attributable to lower
profitability and reduction in trade accounts payable offset in part by
decreases in inventories and accounts receivable. The Company had operating
working capital, excluding cash and short-term debt, of $13.4 million and $38.7
million as of the end of fiscal 2001 and 2000, respectively. Inventories were
$25.2 million and $44.6 million as of the end of fiscal 2001 and 2000,
respectively. In 2000, inventories increased to unplanned levels due to problems
related to the implementation of a new management information system, as well as
higher sales levels. The Company significantly reduced inventory levels in 2001,
to levels more consistent with the current operating requirements of the
Company, but over time, the Company expects its level of inventories to increase
as the Company's sales in the international market increase. Accounts
receivable, net of allowances, were $19.3 million and $28.3 million at the end
of fiscal 2001 and 2000, respectively. In 2001 and 2000, the Company recorded
bad debt expense of $2.8 million and $3.1 million, respectively. The average
days sales in accounts receivable outstanding was approximately 55 days for
2001, compared to 65 days for 2000 and 86 days for 1999. The Company offers 30
day credit terms to its U.S. hospital distributors. Alternate site and
international customers typically receive 60 to 90 day terms and, as a result,
as the Company's alternate site and international sales have increased, the
amount and aging of its accounts receivable have increased. The Company
anticipates that the amount and aging of its accounts receivable will increase
gradually over time as alternate site and international sales become a larger
percentage of the Company's total sales. The Company established a European
distribution center in the first quarter of 2001. While this has had the effect
of increasing inventory, the Company believes that it will also result in
improved service to international customers, as well as in lower international
accounts receivable than would otherwise be the case, because customers will
receive products and, consequently, pay for them more quickly.

19

Net cash used in investing activities was $9.0 million, $26.9 million
and $75.8 million in 2001, 2000 and 1999, respectively. These funds were
primarily used to finance customary purchases of property, plant and equipment
in 2001, the SHERIDAN(R) endotracheal tube product line acquisition in 2000, and
Hudson RCI AB and the VOLDYNE(R) incentive breathing exerciser product line
acquisition in 1999, and for capital expenditures. Capital expenditures,
consisting primarily of new manufacturing equipment purchases, computer systems
purchases, production of heaters, and expansion of the Ensenada facility,
totaled $9.0 million, $11.3 million and $11.0 million in 2001, 2000 and 1999,
respectively. The higher levels of spending in 2000 and 1999 relate to the
acquisition and implementation of a new computer system. The Company currently
estimates that capital expenditures will be approximately $8.0 million in 2002,
consisting primarily of additional and replacement manufacturing equipment and
new heater placements.

Net cash provided by financing was $7.3 million in 2001, reflecting
net borrowings by the Company and the issuance of $3.0 million in Junior
Preferred Stock and $100,000 in common stock. Net cash provided by financing
activities in 2000 of $17.4 million, reflecting net borrowings and the issuance
of $6.0 million in common stock, was used primarily to finance the Tyco
SHERIDAN(R) endotracheal tube product line acquisition. Net cash provided by
financing activities was $71.5 million in 1999, reflecting net borrowings and
equity issuances by the Company, which was used primarily to finance the Hudson
RCI AB, Medimex and VOLDYNE(R) acquisitions.

As of December 31, 2001, the Company had outstanding $226.1 million of
indebtedness, consisting of $115.0 million of Subordinated Notes, borrowings of
$77.0 million under the Company's Credit Facility, $17.2 million in notes
payable to affiliates and $16.9 million in outstanding borrowings under the bank
facility of Hudson RCI AB, its Swedish subsidiary.

The following is a summary of the Company's consolidated contractual
obligations as of December 31, 2001:

(amounts in thousands) Payments Due by Period
--------------------------------------------------------------------
Less Than 1-3 4-5 After 5
Total 1 Year Years Years Years
----------- ----------- ------------ ------------ -----------

Long-term debt ................................ $ 226,147 $ 20,680 $ 88,201 $ 2,266 $ 115,000

Mandatorily redeemable preferred securities ... 44,989 -- -- -- 44,989

Leases and other commitments .................. 12,336 2,247 6,065 1,792 2,232
----------- ----------- ------------ ------------ -----------

Total contractual obligations ............. $ 283,472 $ 22,927 $ 94,266 $ 4,058 $ 162,221
=========== =========== ============ ============ ===========

The Credit Facility currently consists of a $40.0 million Term Loan
Facility and a $55.0 million Revolving Loan Facility of which up to $40.0
million (all of which has been borrowed and is outstanding) may be used for
permitted acquisitions ("Acquisition Facility") and up to $15 million (the
"Working Capital Portion") may be used for general corporate purposes (other
than acquisitions). The Revolving Loan Facility has a letter of credit sub-limit
of $7.5 million. The Term Loan Facility and Acquisition Facility, amended as
discussed below, mature on June 30, 2004 and require quarterly principal
installments totaling $3.8 million in 2002, $9.3 million in 2003 and $37.0
million in 2004. The Revolving Loan Facility matures on June 30, 2004.

Total borrowings as of December 31, 2001 and 2000 were $55.0 million
and $53.0 million under the Revolving Loan Facility and Acquisition Facility and
$22.0 million and $29.5 million under the Term Loan Facility, respectively.

As of December 31, 2001, the Company had utilized all available credit
under the Revolving Credit Facility. No additional borrowing was available under
the Term Loan Facility at December 31, 2001.

20

The interest rate under the Credit Facility is based, at the option of
the Company, upon either a Eurodollar rate or a base rate (as defined) plus a
margin during the period and for the applicable type of loan as follows:

Margin
------------------------
Period and Loan Type Base Rate Eurodollar
-------------------- ------------------------

Through June 2002
Term and Working Capital 3.00% 4.00%
Acquisition 3.25% 4.25%

July 2002 through March 2003
Term and Working Capital 3.50% 4.50%
Acquisition 3.75% 4.75%

Thereafter
Term and Working Capital 4.00% 5.00%
Acquisition 4.25% 5.25%

For periods after June 2002, the margins set forth above are subject
to pricing reductions depending on the Company's then existing leverage ratio.

Borrowings under the Credit Facility are required to be prepaid,
subject to certain exceptions, with (i) 75% (or 50% for years when the Company's
ratio of Debt to EBITDA (as defined) is less than 5:1) of Excess Cash Flow (as
defined); (ii) 50% of the net cash proceeds of an equity issuance by Holding or
the Company in connection with an initial public offering or 100% of the net
cash proceeds of an equity issuance by Holding or the Company other than in
connection with an initial public offering (subject in each case to certain
exceptions); (iii) 100% of the net cash proceeds of the sale or other
disposition of any properties or assets of Holding and its subsidiaries (subject
to certain exceptions); (iv) 100% of the net proceeds of certain issuances of
debt obligations of the Company and its subsidiaries and (v) 100% of the net
proceeds from insurance recoveries and condemnations. The Revolving Loan
Facility must be repaid upon payment in full of the Term Loan Facility.

The Credit Facility is guaranteed by Holding and certain of the
Company's subsidiaries. The Credit Facility is secured by a first priority lien
in substantially all of the properties and assets of the Company and the
guarantors now owned or acquired later, including a pledge of all of the capital
stock of the Company owned by Holding and all of the shares held by the Company
of its existing and future restricted subsidiaries, including its Mexican
subsidiaries; provided, that (except for the Mexican subsidiaries) such pledge
is limited to 65% of the shares of any foreign subsidiary to the extent a pledge
of a greater percentage would result in adverse tax consequences to the Company.

The Credit Facility contains covenants restricting the ability of
Holding, the Company and the Company's subsidiaries to, among others, (i) incur
additional debt; (ii) declare dividends or redeem or repurchase capital stock;
(iii) prepay, redeem or purchase debt; (iv) incur liens; (v) make loans and
investments; (vi) make capital expenditures; (vii) engage in mergers,
acquisitions and asset sales, and (viii) engage in transactions with affiliates.
Hudson RCI is also required to comply with financial covenants with respect to
(a) limits on annual aggregate capital expenditures (as defined) and (b) as
amended a minimum EBITDA test.

The Company was not in compliance with certain financial covenants of
the Credit Facility as of December 31, 2001 and did not make the scheduled March
31, 2002 amortization payment of the Term Loan Facility on its due date. As a
result, in early April, 2002, the lenders under the Credit Facility blocked the
Company from making either the April 15, 2002 interest payment required under
the Senior Subordinated Notes or the April 15, 2002 dividend payment required
under the 11-1/2% Senior Exchangeable PIK Preferred Stock due 2010. On May 14,
2002, the Company and banks amended and restated the Credit Facility to (i)
waive all existing events of default; (ii) extend the final maturity of the term
and revolving facilities under the Credit Facility to June 30, 2004; (iii) amend
existing Term Loan and Acquisition Facility amortization to $3.8 million in
2002, $9.3 million in 2003 and $37.0 million in 2004, and (iv) amend the

21

financial covenants to include only a limitation on capital expenditures and a
minimum EBITDA test. As a result of the amendment, the Company is currently in
compliance with the terms and provisions of the Credit Facility. As of May 31,
2002, there was approximately $3.5 million of availability on the revolving Loan
Facility under the Credit Facility.

The Senior Subordinated Notes bear interest at the rate of 9-1/8%,
payable semiannually on each April 15 and October 15, and will require no
principal repayments until maturity. The Senior Subordinated Notes are general
unsecured obligations of the Company and contain covenants that place
limitations on, among other things, (i) the ability of the Company, any
subsidiary guarantors and other restricted subsidiaries to incur additional
debt, (ii) the making of certain restricted payments including investments,
(iii) the creation of certain liens, (iv) the issuance and sale of capital stock
of restricted subsidiaries, (v) asset sales, (vi) payment restrictions affecting
restricted subsidiaries, (vii) transactions with affiliates, (viii) the ability
of the Company and any subsidiary guarantor to incur layered debt, (ix) the
ability of Holding to engage in any business or activity other than those
relating to ownership of capital stock of the Company and (x) certain mergers,
consolidations and transfers of assets by or involving the Company. As discussed
above, the Company was prevented from making the April 15, 2002 interest payment
to holders of the Senior Subordinated Notes pending the completion of the
amendment to the Credit Facility on May 14, 2002. Because the Company made the
interest payment due under the Senior Subordinated Notes within the 30-day grace
period, no event of default occurred by reason thereof. The Company is currently
in compliance with the terms and provisions of the Senior Subordinated Notes.

In connection with the acquisition of Hudson RCI AB during 1999, one
of the Company's subsidiaries borrowed $22.0 million under an unsecured 12% note
payable to Holding's majority stockholder. The note is due August 1, 2006.
During 1999, the Company paid approximately $14.5 million in principal on the
note. In April 2001 an additional $6.0 million in principal on the note was
repaid. Proceeds from the April 2001 repayment were then reinvested by Holding's
majority stockholder in new notes issues by the Company, as described below.

During 2000, the Company borrowed an additional $2.0 million from
Holding's majority stockholder under an unsecured 14% note payable due on
demand. In August of 2001, this note was exchanged for a new long-term note as
described below.

In August 2001, the Company issued approximately $15.0 million of new
unsecured senior subordinated convertible notes to affiliates for $7.0 million
in cash and an exchange of $8.0 million in existing short-term unsecured notes.
The new notes bear interest at 10% and are due in March 2005. The interest may
be paid or deferred to the due date at the option of the Company and the notes
are convertible to the Company's common stock at the demand of the holder. The
notes are subordinated to borrowings under the Credit Facility and the new
senior unsecured notes discussed below and rank pari-passu with the Senior
Subordinated Notes.

As of December 31, 2001 and May 31, 2002, the Company and its
subsidiaries had a total of $17.2 million and $29.2, million, respectively, in
notes outstanding due to affiliates.

As part of the May 2002 amendment and restatement of the Credit
Facility discussed above, the Company issued $12.0 million of the senior
unsecured notes in exchange for $12.0 million of bank term loans purchased by
affiliates of Holding's majority stockholder. Additionally, HRC Holding issued
$8.0 million of unsecured senior notes to affiliates of Holding's majority
stockholder. HRC Holding used the proceeds of the notes issued by it to acquire
certain intercompany receivables from the Company. These notes bear interest at
12% annually with interest and principal due upon maturity on December 31, 2004.
Proceeds from these transactions were used to pay the April 2002 interest due
under the Subordinated Notes, fund expenses associated with the Amended and
Restated Credit Facility and provide funds for ongoing general corporate
purposes

The Company, through its wholly-owned Swedish Subsidiary, Hudson RCI
AB, has incurred bank debt in Sweden (the "HRCI AB Facility") that totaled $16.9
million as of December 31, 2001. The HRCI AB Facility, which is denominated in
Swedish krona, bears interest at three-month STIBOR (the interest rate at or
about 11:00 a.m. Stockholm time, two banking days before a draw-down date or the
relevant interest period, quoted for deposits in krona) plus 1.25% to 1.85%
(5.14% to 5.74% at December 31, 2001), matures in September 2005, and is
guaranteed by Steamer Holding

22

AB, Hudson RCI AB's parent, and is secured by the common stock of Hudson RCI AB.
As of December 31, 2001, Hudson RCI AB was not in compliance with certain
financial covenants under the HRCI AB Facility. The Company and Hudson RCI AB
are currently in negotiations with the lender concerning an amendment curing
these defaults and expects to receive from the lender a waiver curing all past
covenant violations, but no assurance can be given that an agreement will be
reached. Accordingly, the outstanding balance is classified as a current
liability at December 31, 2001. The Company's Credit Facility and the Senior
Subordinated Notes are not cross-defaulted to the Hudson RCI AB facility. If a
waiver of such default is not obtained, the lender may pursue its remedies under
the facility, including, among other things, immediate acceleration of all
borrowings of the facility. In addition, the default entitles the lender to take
control of all the common stock of Hudson RCI AB and its European parent
companies.

In April 1998, the Company issued to Holding 300,000 shares of its
11-1/2% Senior PIK Preferred Stock due 2010 with an aggregate liquidation
preference of $30.0 million, which has terms and provisions materially similar
to those of the Holding Preferred Stock. Under the terms of the Senior PIK
Preferred Stock, at the election of the Company, dividends may be paid in kind
until April 15, 2003 and thereafter must be paid in cash. In August 2001, the
Company issued 3,000 shares of Junior Convertible cumulative preferred stock
(the "Junior Preferred Stock") to Holding for cash consideration of $3.0
million. The May 2002 Amended and Restated Credit Facility prohibits the Company
from paying cash dividends on its Senior PIK Preferred Stock.

Factors Affecting Liquidity

As the result of a number of factors affecting the Company in fiscal
2000 and 2001 resulting from the implementation of the Company's new information
system, management undertook numerous actions during 2001 to improve the
liquidity and improve the operating performance of the Company. Such actions
included: elimination of a distribution warehouse, the elimination of
non-essential management personnel, a reduction in inventory levels, aggressive
collection and write-off of accounts receivable and other cost reduction
measures as management deemed necessary to fund the operations of the Company,
meet anticipated capital expenditures and make required payments of principal
and interest on its debt. In addition, existing shareholders and key management
personnel contributed a total of $10.1 million in new cash in the form of
convertible subordinated debt and equity in 2001, and as discussed above, in May
2002, affiliates of Holding's majority stockholder partially invested an
additional $20.0 million in senior unsecured notes, $12.0 million of which was
exchanged for bank term loans previously acquired. Proceeds from these notes
were used to pay interest due on the Subordinated Notes, pay for expenses
associated with the amendment of the Credit Facility and provide for ongoing
working capital requirements. Based on these actions, as well as anticipated
improved operating performance, management believes it will have sufficient
sources of liquidity to meet its obligations for the remainder of 2002. If the
Company does not generate sufficient cash flow from operations in line with its
current forecasts, the Company would have to initiate measures to raise cash
through asset sales, additional debt or equity issuances and/or curtail
operations. The Company currently has no commitments for additional debt or
equity and no assurance can be given as to whether or, on what terms, additional
debt or equity investments could be secured if required. Failure to achieve
expected cash flows or, if necessary, to obtain additional debt or equity
investment would have a material adverse affect on the Company.

23

RISK FACTORS

Substantial Leverage; Shareholders' Deficit

As of December 31, 2001, the Company had $226.1 million of outstanding
indebtedness and a shareholders' deficit of approximately $167.8 million. This
level of indebtedness is substantially higher than the Company's historical debt
levels and may reduce the flexibility of the Company to respond to changing
business and economic conditions. In addition, subject to the restrictions in
the Credit Facility and the indenture governing the Subordinated Notes (the
"Indenture"), the Company may incur additional senior or other indebtedness from
time to time to finance acquisitions or capital expenditures or for other
general corporate purposes. See "--Liquidity and Capital Resources." The Credit
Facility and the Indenture restrict, but do not prohibit, the payment of
dividends by the Company to Holding to finance the payment of dividends on the
Holding Preferred Stock.

The Company's high degree of leverage may have significant
consequences for the Company, including: (i) the ability of the Company to
obtain additional financing for working capital, capital expenditures,
acquisitions or other purposes, if necessary, may be impaired; (ii) a
substantial portion of the Company's cash flow will be dedicated to the payment
of interest and principal on its indebtedness and will not be available to the
Company for its operations and future business opportunities; (iii) the
covenants contained in the indenture and the Credit Facility will limit the
Company's ability to, among other things, borrow additional funds, dispose of
assets or make investments and may affect the Company's flexibility in planning
for, and reacting to, changes in business conditions; (iv) indebtedness under
the Credit Facility will be at variable rates of interest, which will cause the
Company to be vulnerable to increases in interest rates; and (v) the Company's
high degree of leverage may make it more vulnerable to a downturn in its
business or the economy generally or limit its ability to withstand competitive
pressures. If the Company is unable to generate sufficient cash flow from
operations in the future to service its indebtedness, it may be required to
refinance all or a portion of its existing debt or to obtain additional
financing. There can be no assurance that any such actions could be effected on
a timely basis or on satisfactory terms or that these actions would enable the
Company to continue to satisfy its capital requirements. The Company's ability
to meet its debt service obligations and to reduce its total indebtedness will
be dependent upon the Company's future performance, which will be subject to
general economic conditions and to financial, business and other factors
affecting the operations of the Company, many of which are beyond its control.
The terms of the Company's indebtedness, including the Credit Facility and the
Indenture, also may prohibit the Company from taking such actions.

Medical Cost Containment

In recent years, widespread efforts have been made in both the public
and private sectors to control health care costs, including the prices of
products such as those sold by the Company, in the United States and abroad.
Cost containment measures have resulted in increased customer purchasing power,
particularly through the increased presence of GPOs in the marketplace and
increased consolidation of distributors. Health care organizations are
evaluating ways in which costs can be reduced by decreasing the frequency with
which a treatment, device or product is used. Cost containment has also caused a
shift in the decision-making function with respect to supply acquisition from
the clinician to the administrator, resulting in a greater emphasis being placed
on price, as opposed to features and clinical benefits. The Company has
encountered significant pricing pressure from customers and believes that it is
likely that efforts by governmental and private payers to contain costs through
managed care and other efforts and to reform health systems will continue and
that such efforts may have an adverse effect on the pricing and demand for the
Company's products. There can be no assurance that current or future reform
initiatives will not have a material adverse effect on the Company's business,
financial conditions or results of operations.

The Company's products are sold principally to a variety of health
care providers, including hospitals and alternate site providers, that receive
reimbursement for the products and services they provide from various public and
private third party payors, including Medicare, Medicaid and private insurance
programs. As a result, while the Company does not receive payments directly from
such third party payors, the demand for the Company's products in any specific
care setting is dependent in part on the reimbursement policies of the various
payors in that setting. In order to be reimbursed, the products generally must
be found to be reasonable and necessary for the treatment of medical

24

conditions and must otherwise fall within the payor's list of covered services.
In light of increased controls on Medicare spending, there can be no assurance
on the outcome of future coverage or payment decisions for any of the Company's
products by governmental or private payors. If providers, suppliers and other
users of the Company's products are unable to obtain sufficient reimbursement, a
material adverse impact on the Company's business, financial condition or
operations may result.

The Company expects that the trend toward cost containment that has
impacted the domestic market will also be experienced in international health
care markets, impacting the Company's growth in foreign countries, particularly
where health care is socialized.

Industry Consolidation; Customer Concentration

Cost containment has resulted in significant consolidation within the
health care industry. A substantial number of the Company's customers, including
group purchasing organizations, hospitals, national nursing home companies and
national home health care agencies, have been affected by this consolidation.
The acquisition of any of the Company's significant customers could result in
the loss of such customers by the Company, thereby negatively impacting its
business, financial condition and results of operations. For example, in 1996,
three GPOs that accounted for aggregate sales of approximately $11.0 million
combined and, as a result of a decision of the combined entity to enter into a
sole distributorship arrangement in 1997 with one of the Company's competitors,
the Company has experienced some decrease in sales and may experience additional
sales decreases in the future. In addition, the consolidation of health care
providers often results in the renegotiation of terms and in the granting of
price concessions. The Company's customer relationships, including exclusive or
preferential provider relationships, are terminable at will by either party
without advance notice or penalty. Because larger purchasers or groups of
purchasers tend to have more leverage in negotiating prices, this trend has
caused the Company to reduce prices and could have a material adverse effect on
the Company's business, financial condition or results of operations. As GPOs
and integrated health care systems increase in size, each relationship
represents a greater concentration of market share and the adverse consequences
of losing a particular relationship increases considerably. For fiscal 2001, the
Company's ten largest group purchasing arrangements accounted for approximately
38.7%. Distributors have also consolidated in response to cost containment. For
fiscal 2001, approximately 29.4% of the Company's net sales were to two
distributors, Owens & Minor Inc. and McKesson, which accounted for 19.4% and
10.0%, respectively, of the Company's net sales. The loss of the Company's
relationship with these distributors would have a material adverse effect on the
Company's business, financial condition and results of operations.

The Company and its customers and suppliers are subject to extensive
federal and state regulation in the United States, as well as regulation by
foreign governments. The Company cannot predict the extent to which future
legislative and regulatory developments concerning practices and products for
the health care industry may affect the Company. Most of the Company's products
are subject to government regulation in the United States and other countries.
In the United States, the Federal Food, Drug, and Cosmetic Act, as amended (the
"FD&C Act"), and other statutes and regulations govern or influence the testing,
manufacture, safety, labeling, storage, record keeping, marketing, advertising
and promotion of such products. Failure to comply with applicable requirements
can result in fines, recall or seizure of products, total or partial suspension
of production, withdrawal of existing product approvals or clearances, refusal
to approve or clear new applications or notices and criminal prosecution. Under
the FD&C Act and similar foreign laws, the Company, as a marketer, distributor
and manufacturer of health care products, is required to obtain the clearance or
approval of Federal and foreign governmental agencies, including the Food and
Drug Administration ("FDA"), prior to marketing, distributing and manufacturing
certain of those products, which can be time consuming and expensive. The
Company may also need to obtain FDA clearance before modifying marketed products
or making new promotional claims. Delays in receipt of or failure to receive
required approvals or clearances, the loss of previously received approvals or
clearances, or failures to comply with existing or future regulatory
requirements in the United States or in foreign countries could have a material
adverse effect on the Company's business. Foreign sales are subject to similar
requirements.

The Company is required to comply with pertinent sections of the Code
of Federal Regulations, 21CFR GMP/QSR, which set forth requirements for, among
other things, the Company's manufacturing process, design control

25

and associated record keeping, including testing and sterility. Further, the
Company's plants and operations are subject to review and inspection by state,
federal and foreign governmental entities. The distribution of the Company's
products may also be subject to state regulation. The impact of FDA regulation
on the Company has increased in recent years as the Company has increased its
manufacturing operations. The Company's suppliers, including contract
sterilization facilities, are also subject to similar governmental requirements.
There can be no assurance that changes to current regulations or additional
regulations imposed by the FDA will not have an adverse impact on the Company's
business and financial condition in the future. If the FDA believes that a
company is not in compliance with applicable regulations, it can institute
proceedings to detain or seize products, issue a recall, impose operating
restrictions, enjoin future violations and assess civil and criminal penalties
against the company, its officers or its employees and can recommend criminal
prosecution to the Department of Justice. Other regulatory agencies may have
similar powers. In addition, product approvals could be withdrawn due to the
failure to comply with regulatory standards or the occurrence of unforeseen
problems following initial marketing. The FDA also has the authority to issue
special controls for devices manufactured by the Company. In the event that such
additional special controls were issued, the Company's products would be
required to conform, which could result in significant additional expenditures
for the Company.

The Company is subject to numerous federal, state and local laws and
regulations relating to such matters as safe working conditions, manufacturing
practices, fire hazard control and the handling and disposal of hazardous or
infectious materials or substances and emissions of air pollutants. The Company
owns and leases properties which are subject to environmental laws and
regulations. There can be no assurance that the Company will not be required to
incur significant costs to comply with such laws and regulations in the future
or that such laws or regulations will not have a material adverse effect upon
the Company's business, financial condition or results of operations. In
addition, the Company cannot predict the extent to which future legislative and
regulatory developments concerning its practices and products for the health
care industry may affect the Company.

Risks Related to International Sales; Foreign Operations

Sales made outside the United States represented approximately 26.0% of
the Company's 2001 net sales and the Company intends to increase international
sales as a percentage of total net sales. Foreign operations are subject to
special risks that can materially affect the sales, profits, cash flows and
financial position of the Company, including increased regulation, extended
payment periods, competition from firms with more local experience, currency
exchange rate fluctuations and import and export controls. The Company has sales
operations in Germany, Sweden, the United Kingdom, France and other countries
where sales are made in local currency. While the Company may choose to hedge
its foreign currency exposures by attempting to purchase goods and services with
the proceeds from sales in local currencies where possible, and purchase forward
contracts to hedge receivables denominated in foreign currency, there can be no
assurance that the Company's hedging strategies will allow the Company to
successfully mitigate its foreign exchange exposures. The Company's foreign
exchange exposure has historically not been significant, and was not considered
to be significant in fiscal 2001.

The Company also maintains a manufacturing and assembly facility in
Ensenada, Mexico and an assembly and distribution facility in Kuala Lumpur,
Malaysia and, as a result, is subject to operational risks such as changing
labor trends and civil unrest in those countries. In the event the Company were
required to transfer its foreign operations to the United States or were
otherwise unable to benefit from its lower cost foreign operations, its
business, financial condition and results of operations would be adversely
affected.

Product Liability

The manufacturing and marketing of medical products entails an inherent
risk of product liability claims. Although the Company has not experienced any
significant losses due to product liability claims and currently maintains
umbrella liability insurance coverage, there can be no assurance that the amount
or scope of the coverage maintained by the Company will be adequate to protect
it in the event a significant product liability claim is successfully asserted
against the Company. In addition, the Company cannot predict the extent to which
future legislative and regulatory developments concerning its practices and
products for the health care industry may affect the Company.

26

Dependence on Key Personnel; Management of Expanding Operations

The Company's success will, to a large extent, depend upon the
continued services of its executive officers. The loss of services of any of
these executive officers could materially and adversely affect the Company.

The Company's plans to expand its business may place a significant
strain on the Company's operational and financial resources and systems. To
manage its expanding operations, the Company may be required to, among other
things, improve its operational, financial and management information systems.
The Company may also be required to attract, train and retain additional highly
qualified management, technical, sales and marketing and customer support
personnel. The process of locating such personnel with the combination of skills
and attributes required to implement the Company's strategy is often lengthy.
The inability to attract and retain additional qualified personnel could
materially and adversely affect the Company.

Competition

The medical supply industry is characterized by intense competition.
Certain of the Company's competitors have greater financial and other resources
than the Company and may succeed in utilizing these resources to obtain an
advantage over the Company. The general trend toward cost containment in the
health care industry has had the effect of increasing competition among
manufacturers, as health care providers and distributors consolidate and as GPOs
increase in size and importance. The Company competes on the basis of brand
name, product quality, breadth of product line, service and price.

Risks Generally Associated with Acquisitions

An element of the Company's business strategy is to pursue strategic
acquisitions that either expand or complement the Company's business.
Acquisitions involve a number of special risks, including the diversion of
management's attention to the assimilation of the operations and the
assimilation and retention of the personnel of the acquired companies, and
potential adverse effects on the Company's operating results. The Company may
require additional debt or equity financing for future acquisitions, which may
not be available on terms favorable to the Company, if at all. In addition, the
Credit Facility and the Indenture contain certain restrictions regarding
acquisitions. The Indenture restricts acquisitions to those companies in the
same line of business as the Company, and requires that all such acquired
companies be designated Restricted Subsidiaries (as defined therein). The Credit
Facility restricts all acquisitions. The inability of the Company to
successfully finance, complete and integrate strategic acquisitions in a timely
manner could have an adverse impact on the Company's ability to effect a portion
of its growth strategy.

Patents and Trademarks

The Company has historically relied primarily on its technological and
engineering abilities and on its design and production capabilities to gain
competitive business advantages, rather than on patents or other intellectual
property rights. However, the Company does file patent applications on concepts
and processes developed by the Company's personnel. The Company has 27 patents
in the U.S. Many of the U.S. patents have corresponding patents issued in
Canada, Europe and various Asian countries. The Company's success will depend in
part on its ability to maintain its patents, add to them where appropriate, and
to develop new products and applications without infringing the patent and other
proprietary rights of third parties and without breaching or otherwise losing
rights in technology licenses obtained by the Company for other products. There
can be no assurance that any patent owned by the Company will not be
circumvented or challenged, that the rights granted thereunder will provide
competitive advantages to the Company or that any of the Company's pending or
future patent applications will be issued with claims of the scope sought by the
Company, if at all. If challenged, there can be no assurance that the Company's
patents (or patents under which it licenses technology) will be held valid or
enforceable. In addition, there can be no assurance that the Company's products
or proprietary rights do not infringe the rights of third parties. If such
infringement were established, the Company could be required to pay damages,
enter into royalty or licensing agreements on onerous terms and/or be enjoined
from making, using or selling the infringing product. Any of the foregoing could
have a material adverse effect upon the Company's business, financial condition
or results of operations.

27

Energy Costs and Availability

Over the past several years, there has been a shortfall of available
electricity in several areas of California. This shortage has resulted in
increased energy costs and temporary interruptions in electrical service in
several geographic areas of California, including the area in which the Company
maintains its headquarters and principal manufacturing center. Furthermore, the
Company participates in a program with the utility that provides electricity to
its California facilities whereby the Company receives discounted service rates
in exchange for its consent to temporary interruptions in electrical service to
the California facilities during peak periods of electricity use. There is a
possibility that, with increased demand for electricity in California the cost
of obtaining electricity for the Company's California facilities could continue
to increase and electrical service could result in decreased productivity at the
Company's California facilities. The Company has implemented at its California
facility a generator capable of operating the administrative offices, including
all computer systems, which are required to effectively conduct business at all
locations in the United States and Mexico.

Item 7A. Quantitative and Qualitative Disclosure About Market Risk.

Quantitative Disclosures. With the continued growth in Europe, the
Company has greater foreign currency exposure with respect to its international
operations. In the past, the Company's only international exposure was its
manufacturing operation in Mexico. All sales were previously denominated in U.S.
dollars. Currently, the Company has operations in Germany, Sweden, France and
the United Kingdom and other countries where sales are made in local currency.
The Company may hedge its foreign currency exposures by attempting to purchase
goods and services with the proceeds from sales in local currencies where
possible. The Company may also purchase forward contracts to hedge receivables
denominated in foreign currency that are expected to be collected and converted
into another currency. However, there can be no assurance that the Company's
hedging strategies will allow the Company to successfully mitigate its foreign
exchange exposures.

The Company is exposed to certain market risks associated with
interest rate fluctuations on its debt. All debt arrangements are entered into
for purposes other than trading. The Company's exposure to interest rate risk
arises from financial instruments entered into in the normal course of business
that, in some cases, relate to the Company's acquisitions of related businesses.
Certain of the Company's financial instruments are fixed rate, short-term
investments which are held to maturity. The Company's fixed rate debt consists
primarily of outstanding balances on the Subordinated Notes and its variable
rate debt relates to borrowings under the Credit Facility (see "Item 7.
Management's Discussion and Analysis of Financial Condition and Results of
Operations--Liquidity and Capital Resources"). With respect to the Company's
fixed rate debt, changes in interest rates generally affect the fair value of
such debt, but do not have an impact on earnings or cash flows. Because the
Company generally cannot prepay its fixed rate debt prior to maturity, interest
rate risk and changes in fair value should not have a significant impact on this
debt until the Company is required to refinance. With respect to variable rate
debt, changes in interest rates affect earnings and cash flows, but do not
impact fair value. The impact on the Company's interest expense in the upcoming
year of a one-point interest rate change on the outstanding balance of the
Company's variable rate debt would be approximately $0.9 million.

28

The following table presents the future principal cash flows and
weighted-average interest rates expected on the Company's existing long-term
debt instruments. The fair value of the Company's fixed rate debt is estimated
based on quoted market prices.

Expected Maturity Date
(amended and restated as of December 31, 2001)

Fiscal Fiscal Fiscal Fiscal Fiscal There- Fair
2002 2003 2004 2005 2006 after Total Value
------ ---- ------- ------- -------- ------- --------- -------
(Dollars in thousands)

Fixed Rate Debt ................. $ -- $ -- $ 12,000 $ 14,951 $ 2,266 $115,000 $ 144,217 $ 106,317
Average Interest Rate --% --% --% --% 9.0% 9.1%
Variable Rate Debt .............. $20,680 $24,250 $ 37,000 $ -- $ -- $ -- $ 81,930 $ 81,930
Average Interest Rate 5.8% 5.4% 5.7% --% --% --%

Qualitative Disclosures. The Company's primary exposure relates to (1)
interest rate risk on long-term and short-term borrowings, (2) the Company's
ability to pay or refinance long-term borrowings at maturity at market rates,
(3) the impact of interest rate movements on the Company's ability to meet
interest expense requirements and exceed financial covenants and (4) the impact
of interest rate movements on the Company's ability to obtain adequate financing
to fund future acquisitions. The Company manages interest rate risk on its
outstanding long-term and short-term debt through the use of fixed and variable
rate debt. While the Company can not predict or manage its ability to refinance
existing debt or the impact interest rate movements will have on its existing
debt, management evaluates the Company's financial position on an ongoing basis.

Item 8. Financial Statements.

See the Index included at "Item 14. Exhibits, Financial Statement
Schedules and Reports on Form 8-K."

Item 9. Changes in and Disagreements With Accountants on Accounting and
Financial Disclosure.

On January 25, 2002, the Company dismissed Arthur Andersen LLP
("Andersen") as its independent accountant. Andersen provided both accounting
and audit services to the Company, and was the primary consultant for the
implementation of the Company's SAP software platform.

The reports of Andersen on the Company's financial statements for the
past two fiscal years contained no adverse opinion or disclaimer of opinion and
were not qualified or modified as to uncertainty, audit scope or accounting
principles.

The Company's Board of Directors approved the decision to change
accountants on January 17, 2002, and the Audit Committee of the Board of
Directors approved the decision to change accountants on January 25, 2002. The
Board of Directors believes that it is in the best interests of the Company to
make a change in the Company's certifying accountants to meet the growing
requirements of the future.

In connection with its audits for the two most recent fiscal years and
through January 25, 2002, there have been no disagreements with Andersen on any
matter of accounting principles or practices, financial statement disclosure, or
auditing scope or procedure, which disagreements, if not resolved to the
satisfaction of Andersen, would have caused Andersen to make reference thereto
in its report on the financial statements of the Company for such time periods,
except as follows:

During the audit of its financial statements for the year ended
December 31, 2000, the Company had a disagreement with Andersen regarding the
reserves for accounts receivable (doubtful accounts and rebates) as of December
31, 2000. Andersen informed the Company of its concerns as to the methodology
utilized to establish the level

29

of these reserves as well as that inadequate support had been provided for these
reserves. Upon further review and analysis by the Company, and continuing
discussions with Andersen, these reserves were adjusted, and backup
substantiation developed, to the satisfaction of Andersen, which issued its
report on the Company's financial statements for the year ended December 31,
2000.

Members of the Audit Committee of the Board of Directors of the
Company met with Andersen to discuss these matters. The Company believes that
the concerns expressed by Andersen with respect to the foregoing issue have been
addressed, as evidenced by the fact that Andersen has issued an unqualified
report covering the Company's 2000 financial statements, and that the Company
now has policies and procedures in place to properly establish reserve balances,
and substantiation, in respect of its accounts receivable in accordance with
GAAP. The Company has authorized Andersen to respond fully to the inquiries of
the successor accountant concerning this matter.

During the two most recent fiscal years and through January 25, 2002,
except as described below, there have been no reportable events as defined in
Item 304(a)(1)(v) of Regulation S-K. Andersen informed the Company in a letter
dated July 30, 2001 that the following material weaknesses in internal control
existed during fiscal year ended December 31, 2000:

The Company did not prepare on a timely basis reconciliations for
substantially all of the Company's balance sheet accounts, and the Company's
internal process for review and approval of reconciliations was informal and
inconsistent.

The Company's support for the required reserves for accounts
receivable (doubtful accounts and rebates) was initially inadequate; upon
further review, adjustments required to properly state such reserves as of
December 31, 2000 were material to the Company's consolidated financial
statements.

The Company's consolidated financial statements were not prepared on a
timely basis and eliminating entries were not initially well-supported.

The Company had a shortage of accounting and finance personnel, and
had retained accounting and finance personnel who lacked the appropriate
expertise; as a result, the Company's former Chief Financial Officer was
responsible for a disproportionate amount of the Company's financial reporting
process, and the efficiency, timeliness and accuracy of the Company's financial
reporting was adversely impacted.

Members of the Audit Committee of the Board of Directors of the
Company discussed these matters with Andersen. Except as described above, these
conditions did not result in any disagreements or differences in opinion between
the Company and Andersen. Andersen advised the Company in the July 30, 2001
letter that it understood that the Company had taken certain steps subsequent to
December 31, 2000 to mitigate these material weakness conditions.

The Company provided Andersen with a copy of the disclosures made by
the Company in this report and requested that Andersen furnish the Company with
a letter addressed to the SEC stating whether or not Andersen agrees with the
above statements, and if not, stating the respects in which it does not agree. A
copy of such letter was filed as an exhibit to the 8-K report filed by the
Company on February 1, 2002, in which the Company initially reported this change
in auditors.

New Independent Auditor

On January 31, 2002, the Company engaged Deloitte & Touche LLP
("Deloitte") as the Company's new principal independent auditor to audit the
Company's financial statements, to replace Andersen. During the two most recent
fiscal years and through January 31, 2002, the Company has not consulted with
Deloitte regarding either (i) the application of accounting principles to a
specified transaction, either completed or proposed; or the type of audit
opinion that might be rendered on the Company's financial statements; or (ii)
any matter that was either the subject of a

30

disagreement (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K
and the related instructions to Item 304 of Regulation S-K), or a reportable
event (as described in Item 304(a)(1)(v) of Regulation S-K).

31

PART III

Item 10. Directors and Executive Officers of the Registrant.

The following individuals are the executive officers and directors of
Holding and Hudson RCI as of May 31, 2002:

Name Age Position
- ------------------------------ --- --------------------------------------
Charles A. French ............ 59 President, Chief Executive Officer and
Director
Lougene Williams ............. 57 Senior Vice President
Patrick G. Yount ............. 42 Chief Financial Officer
Ola G. Magnusson ............. 53 Senior Vice President
Jeffery D. Brown ............. 44 Vice President, Marketing and Sales
Helen Hudson Lovaas .......... 63 Director
Jon D. Ralph ................. 37 Director
Charles P. Rullman ........... 54 Director
Ronald P. Spogli ............. 54 Director
Sten Gibeck .................. 58 Director

Charles A. French is President, Chief Executive Officer and a Director
of the Company. Mr. French assumed these positions with both the Company and
Holding in August 2001, and was a consultant to the Company since January 2001.
Prior to joining the Company, he had been a private investor focused on
healthcare and technology companies. Previously, he held senior management
positions at Spectramed, Inc., Caremark, Inc. and Bentley Laboratories, Inc.

Lougene Williams is a Senior Vice President of the Company responsible
for its product development, quality assurance and manufacturing operations,
having served in this capacity since 1996, and assumed the same position with
Holding after consummation of the recapitalization. Prior to 1996, he was the
Company's Vice President, Manufacturing, having held a similar position with
Respiratory Care Inc. From 1976 to 1987, he held manufacturing management
positions of increasing responsibility at various manufacturing plants of The
Kendall Company.

Patrick G. Yount became the Company's Chief Financial Officer in
March, 2001. Prior to joining the company, he held the positions of Chief
Financial Officer and Chief Operating Officer of Good Source Solutions - a
nationwide distributor of specialty food items. Prior to joining Good Source
Solutions in 1998, he held positions as a senior member of the Merchant Banking
Group for Banque Paribas where we was employed in the San Francisco office from
1995 to 1998.

Ola G. Magnusson is a Senior Vice President and serves as President of
Hudson RCI AB in Sweden. Mr. Magnusson joined the company in 1999 in connection
with the acquisition of Louis Gibeck AB where he was the President and Chief
Executive Officer since 1996. Prior to joining Louis Gibeck AB, Mr. Magnusson
held several different positions, primarily in marketing with Pharmacia, a
Swedish pharmaceutical company.

Jeffery D. Brown, Vice President of Marketing and Sales, assumed this
position in January, 2000. From 1997 to 2000 Mr. Brown served as the Company's
Director of Sales. From 1993 to 1997, Mr. Brown served as National Sales Manager
and from 1991 to 1993, as Regional Sales Manager . Mr. Brown has also held
positions of National Account Manager from 1982 to 1991, and Territorial Sales
Manager from 1980 to 1982.

Helen Hudson Lovaas is a director of the Company and became a director
of Holding after consummation of the recapitalization in April 1998. Mrs. Lovaas
began her career at the Company in 1961. She has been Chairman since 1987, when
she inherited ownership of the Company and served as Chief Executive Officer
from 1987 until May 1997. Mrs. Lovaas had served previously as the Vice
President of Administration of Hudson Oxygen for 15 years.

32

Jon D. Ralph became a director of the Company and of Holding in
connection with the recapitalization in April 1998. Mr. Ralph joined Freeman
Spogli in 1989 and became a Principal in January 1998. Prior to joining Freeman
Spogli, Mr. Ralph spent three years at Morgan Stanley & Co. Incorporated where
he served as an analyst in the Investment Banking Division. Mr. Ralph is also a
director of Century Maintenance Supply, Inc., and The Pantry, Inc.

Charles P. Rullman became a director of the Company and of Holding in
connection with the recapitalization in April 1998. Mr. Rullman joined Freeman
Spogli as a Principal in 1995. From 1992 to 1995, Mr. Rullman was a General
Partner of Westar Capital, a private equity investment firm specializing in
middle-market transactions. Prior to joining Westar, Mr. Rullman spent twenty
years at Bankers Trust Company and its affiliate BT Securities Corporation where
he was a Managing Director and Partner. Mr. Rullman is also a director of The
Pantry, Inc.

Ronald P. Spogli became a director of the Company and of Holding in
connection with the recapitalization in April 1998. He is a founding Principal
of Freeman Spogli, which was founded in 1983. Mr. Spogli is also a director of
AFC Enterprises, Inc., Century Maintenance Supply, Inc., and Gaylan's Trading
Co. Inc.

Sten Gibeck became a director of the Company and of Holding in
connection with the July 1999 acquisition of Hudson RCI AB. Mr. Gibeck has been
employed by Hudson RCI AB since 1965, and since 1997 has served as its Vice
President of Research and Development. From 1971 through 1996, Mr. Gibeck served
as the President of Hudson RCI AB.

Directors of the Company and Holding are elected annually and hold
office until the next annual meeting of stockholders and until their successors
are duly elected and qualified.

33

Item 11. Executive Compensation.

The following table sets forth the compensation for each of the fiscal
years in the three-year period ended December 31, 2001 of the following persons:

. Each individual who served as the chief executive officer or
acted in a similar capacity during 2001;
. The four most highly compensated executive officers other than
the chief executive officer at December 31, 2001; and
. Two former executive officers that would have been among the four
most highly compensated executive officers at December 31, 2001
if they were still serving as officers at December 31, 2001.

Compensation is presented only for the years in which each person was an
executive officer.

Summary Compensation Table

Annual Compensation
-------------------------------------------------
Fiscal Other Annual All Other
Year Salary Bonus Compensation Compensation
(1) (2)
----------------------------------------------------------------------------

Charles A. French. ............. (3) 2001 $ 66,923 $ -- $ -- --
President and Chief Executive Officer

Lougene Williams ............... 2001 $ 221,751 $ -- $ -- $ 10,200
Senior Vice President 2000 186,592 -- -- 10,500
1999 190,862 64,798 73,020 9,600

Jeffery D. Brown ............... (4) 2001 $ 157,701 -- $ -- $ 9,462
Vice President, Marketing & Sales 2000 126,023 -- -- 7,561

Patrick G. Yount ............... (5) 2001 $ 145,385 $ -- $ -- $ --
Chief Financial Officer

Ola Magnusson .................. 2001 $ 105,963 $ -- $ 9,099 $ 53,331
Senior Vice President 2000 121,582 -- 10,087 61,901
1999 62,343 -- 5,564 127,828

Richard W. Johansen ............ (6) 2001 $ 310,918 $ -- $ -- 10,200
Former President and Chief Executive
Officer 2000 290,438 -- -- 10,500
1999 294,945 53,100 177,334 9,600

Jay R. Ogram ................... (7) 2001 $ 234,985 $ -- $ -- $ 9,261
Former Chief Information Officer 2000 153,674 -- -- 9,220
1999 148,314 43,159 -- 8,889

- ---------------------
(1) During 2001, no Named Executive Officer named received perquisites and
other personal benefits, security or property in an aggregate amount in
excess of the lesser of $50,000 or 10% of the total of such officer's
salary and bonus nor did any such officer receive any restricted stock
award or stock appreciation right.
(2) Represents payments by the Company under its defined contribution plan.
(3) Charles A French became the Company's President and Chief Executive Officer
in August 2001. The compensation amount shown is based on a partial year of
employment at an annualized salary rate of $200,000.

34

(4) Prior to 2000, the Named Executive was not an officer of the Company.
(5) Patrick G. Yount became the Company's Chief Financial Officer in March
2001. His compensation shown is based on a partial year of employment at an
annualized salary rate of $210,000.
(6) Richard W. Johansen was terminated as President and Chief Executive Officer
in September 2001. He remained on the Board until January 2002. His
compensation is included because had Mr. Johansen been an executive officer
at December 31, 2001, he would have been one of the four most highly
compensated officers of the Company for the fiscal year ended December 31,
2001.
(7) Jay R. Ogram was Chief Financial Officer until March 2001 at which time he
became the Chief Information Officer. He resigned from the Company in
January 2002.

Executive Employment Agreements

On April 7, 1998, the Company entered into employment agreements with
Richard W. Johansen, Jay R. Ogram, Brian W. Morgan and Lougene Williams. Each
Named Executive Officer receives a base salary in an amount and on substantially
the same terms and conditions as was being paid by the Company on that date and
an annual cash bonus in accordance with the Company's existing incentive
programs. Pursuant to the employment agreements, in the event that employment is
terminated by the Company other than for cause (as such term is defined in the
employment agreements), or if the Named Executive Officer resigns pursuant to a
"qualifying resignation" (as such term is defined in the employment agreements),
the Company will be required to pay such Named Executive Officer's base salary
for a period of between 12 and 24 months. The employment agreements also provide
for nondisclosure of confidential information, that the Named Executive Officer
shall not engage in any prohibited activity (as such term is defined in the
employment agreement) during the term of employment and that the Named Executive
Officer will refrain from interfering with the Company's contractual
relationships or soliciting the Company's employees for 12 months following the
Named Executive Officer's termination.

Compensation of Directors

Directors of the Company receive no compensation as directors.
Directors are reimbursed for their reasonable expenses in attending meetings.

Management Bonus Plans

The Company offers a management bonus plan for its executives and
senior management. The plan is based solely on the financial goals of the
Company. The goals for 2001 required the Company to reach a minimum of 95% of a
budgeted EBITDA target. During 2001, the Company did not meet this objective and
no bonuses were paid. The Company periodically offers additional incentive
compensation to individuals who demonstrate superior performance. This
compensation was not material in 2001. The Company has put a similar plan into
place for 2002.

Retirement Plans

The Company sponsors two programs that assist its employees in planning for
retirement. The Company offers a defined contribution pension plan that is
funded by the Company. Employees must be at least 21 years of age and have
completed two years of service to be eligible to participate in the pension
plan. The Company annually contributes an amount equal to 6% of a participating
employee's base earnings to a participant's account, prorated for any part of a
year that a participant was ineligible for a contribution. The funding also
includes a proportionate share of any increase or decrease in the fair market
value of the assets in the trust fund as of the immediately preceding last day
of the plan year. During 2001, the Company determined that the pension plan for
1999 and 2000 was not fully funded. Accordingly, the Company recorded $350,000
in associated penalties and fully funded the plan through 2000. The Company
anticipates fully funding the 2001contribution in 2002. During 2002, the Company
froze the current pension plan and developed a new plan that provides for
discretionary funding determined annually by the Board of Directors. All other
aspects of the new plan are substantially similar to the old plan. In addition,
employees may contribute to a 401(k) plan that allows matching contributions by
the Company. Employees must have six months of service to be eligible to
participate in the

35

401(k) plan and may contribute up to 10% of their annual compensation, or 6% if
the employee is a highly compensated participant.

36

Compensation Committee Interlocks and Insider Participation

The Board of Directors of the Company determines the compensation of
the executive officers. During fiscal 2001, certain members of the Board of
Directors determined the compensation of the Company's Chief Executive Officer
and certain members of the Board of Directors and Mr. French determined the
compensation of the Company's other executive officers.

Stock Subscription Plans

In April 1998, Holding adopted an Employee Stock Subscription Plan and
an Executive Stock Subscription Plan (collectively, the "Stock Subscription
Plans") pursuant to which executives of the Company purchased 800,000 shares of
common stock of Holding valued at $10.00 per share. The Stock Subscription Plans
provide for a repurchase option in favor of Holding upon termination of
employment at stated repurchase prices. In addition, the Stock Subscription
Plans provide for restrictions on the transferability of shares prior to the
fifth anniversary of the recapitalization or Hudson RCI's initial public
offering. The shares are also subject to a right of first refusal in favor of
Holding as well as obligations to sell at the request of Freeman Spogli and
co-sale rights if Freeman Spogli and Affiliates sells its shares to a third
party. No additional shares of Holding common stock were sold under the Stock
Subscription Plans in fiscal 2001.

In 2001, the Board of Directors of Holding approved the adoption of a
Stock Option Plan for eligible employees, officers and consultants of the
Company. The plan allows for the issuance of up to 2,000,000 shares of Holding
common stock pursuant to the exercise of incentive stock options or
non-qualified options. The exercise price of options granted under the plan
shall be set at fair market value at the time of the grant as determined by the
Board of Directors. As of the date of this filing, no options have been granted
under this plan.

37

Item 12. Security Ownership of Certain Beneficial Owners and Management.

The following table sets forth certain information, as of May 31, 2002,
with respect to the beneficial ownership of capital stock of the Company by (i)
each person who beneficially owns more than 5% of such shares, (ii) each of the
Named Executive Officers, (iii) each director of Hudson RCI and (iv) all Named
Executive Officers and directors of Hudson RCI as a group.

Shares of
Shares of Shares of Junior
Common Percent of Preferred Percent of Preferred Percent of
Name of Beneficial Owner Stock Class Stock Class Stock Class
- ----------------------------------------------- ---------- ---------- --------- ---------- --------- ----------

River Holding Corp.(1) ........................ 9,454,293 30.6% 470,307 100% 3,000 100%
Jon D. Ralph(1) .............................
Charles P. Rullman(1) .......................
Ronald P. Spogli(1) .........................
FS Equity Partners IV, LP (2) ................. 20,000,000 64.6% -- --
Jon D. Ralph (2) ............................
Charles P. Rullman (2) ......................
Ronald P. Spogli (2) ........................
Helen Hudson Lovaas(3) ........................ 1,500,000 4.8% -- --
Sten Gibeck(4) ................................ -- -- --
Richard W. Johansen(4) ........................ -- -- -- --
Lougene Williams(4) ........................... -- -- -- --
Jay R. Ogram(4) ............................... -- -- -- --
Brian W. Morgan(4) ............................ -- -- -- --
Charles A. French(4) .......................... -- -- -- --
Patrick G. Yount(4) ........................... -- -- -- --
Jeffrey D. Brown(4) ........................... -- -- -- --
Ola Magnusson(5) .............................. -- -- -- --
All Named Executive Officers and directors of
the Company as a group (9 individuals) ...... 30,954,293 100.00% 470,307 3,000 100%

- -----------------

(1) As beneficial owner of 85.9% of the common stock of Holding, Freeman Spogli
has the power to vote and dispose of the shares held by Holding. Includes
300,000 shares issuable upon the conversion of 3,000 shares of Junior
Preferred Stock by Holding. 1,441,251 shares, 58,749 shares and 6,364,648
shares of common stock of Holding is held of record by FS Equity Partners
III, L.P. ("FSEP III"), FS Equity Partners International, L.P. ("FSEP
International") and FS Equity Partners IV, L.P. ("FSEP IV"), respectively.
As general partner of FS Capital Partners, L.P. ("FS Capital"), which is
general partner of FSEP III, FS Holdings, Inc. ("FSHI") has the sole power
to vote and dispose of the shares owned by FSEP III. As general partner of
FS&Co. International, L.P. ("FS&Co. International"), which is the general
partner of FSEP International, FS International Holdings Limited ("FS
International Holdings") has the sole power to vote and dispose of the
shares owned by FSEP International. As general partner of FSEP IV, FS
Capital Partners LLC ("FS Capital LLC") has the sole power to vote and
dispose of the shares owned by FSEP IV. Messrs. Spogli and Rullman and
Bradford M. Freeman, William M. Wardlaw, J. Frederick Simmons and John M.
Roth are the sole directors, officers and shareholders of FSHI, FS
International Holdings and Freeman Spogli & Co. Incorporated and such
individuals, in addition to Mr. Ralph and Todd W. Halloran and Mark J.
Doran, are the sole managing members of FS Capital LLC, and as such may be
deemed to be the beneficial owners of the shares of the common stock and
rights to acquire the common stock owned by FSEP III, FSEP International and
FSEP IV. The business address of Freeman Spogli & Co. Incorporated, FSEP
III, FSEP IV, FS Capital, FSHI, FS Capital LLC, and its sole directors,
officers, shareholders and managing members is 11100 Santa Monica Boulevard,
Suite 1900, Los Angeles, California 90025 and the business address of FSEP
International, FS&Co. International and FS International Holdings is c/o
Padget-Brown & Company, Ltd., West Winds Building, Third Floor, Grand
Cayman,

38

Cayman Islands, British West Indies. Holding has pledged all shares of the
Company's capital stock held by it to secure its guarantee of the Company's
obligations under the New Credit Facility.
(2) Includes 20,000,000 shares of common stock issuable upon exercise of an
immediately exercisable warrant (3) Represents 1,073,560 shares held of
record by the Helen Lovaas Separate Property Trust U/D/T dated 7/16/97
("Trust No. 1") and 426,440 shares held of record by the Helen Lovaas Trust
No. 2 U/D/T dated as of January 10, 2000 ("Trust No. 2"). As sole trustee
of Trust No. 1, Mrs. Lovaas has the sole power to vote and dispose of the
shares owned by Trust No. 1. As co-trustee of Trust No. 2, Mrs. Lovaas has
shared power to vote and dispose of the shares owned by Trust No. 2. The
address of each of Trust No. 1 and Trust No. 2 is c/o Hudson Respiratory
Care Inc., 27711 Diaz Road, P.O. Box 9020, Temecula, California 92589.
(4) The business address of these individuals is Hudson Respiratory Care Inc.,
27711 Diaz Road, P.O. Box 9020, Temecula, California 92589.
(5) The business address of this individual is Hudson AB, Central Vagen 1, P.O.
Box 711, SE-194 27, Uplands Vasby, Sweden.

Item 13. Certain Relationships and Related Transactions.

Shareholders' Agreement

Helen Hudson Lovaas (The "Continuing Shareholder") and Holding have
entered into a Shareholders' Agreement, as amended (the "Shareholders'
Agreement"). The Shareholder Agreement provides that i) Holding and the
Continuing Shareholder have the right to purchase their pro rata share of
certain new issuances, ii) in consideration for the contribution of
consideration received from Holding for certain issuances of the common stock of
Holding, the Company will issue an equivalent shares of Company common stock to
Holding, iii) in the event of a sale of Company stock by Holding or Freeman
Spogli, the Continuing Shareholder is obligated to sell all or part of her
shares at the request of Holding and the Continuing Shareholder has the right to
participate in such sale on a pro rata basis, iv) the restriction on the
tranferability of the shares for a two year period following the
recapitalization and provides for a right of first offer on the Continuing
Shareholder's common stock and v) in the event the Company participates in an
IPO, the Company will exchange all of the Company's existing common stock for
newly issued common stock.

Note to Freeman Spogli

In connection with the acquisition of Hudson RCI AB during 1999, one
of the Company's subsidiaries borrowed $22.0 million under an unsecured 12% note
payable to Holding's majority stockholder. The Note is due August 1, 2006.
During 1999, the Company paid approximately $14.5 million in principal on the
note. In April 2001, the Company repaid an additional $6.0 million in principal
on the note. Proceeds from the repayment were then reinvested by Holding's
majority stockholder in new notes issued by the Company, as described below.

During 2000, the Company borrowed an additional $2.0 million from
Freeman Spogli under an unsecured 14% note payable due on demand. In August of
2001, this note was exchanged for a new long term note as described below.

In August 2001, the Company issued approximately $13.2 million of new
unsecured senior subordinated convertible notes consisting of $5.2 million in
new cash and an exchange of $8.0 million in existing short-term unsecured notes
to Freeman Spogli. The notes bear interest at 10% and are due in March 2005. The
interest may be paid or deferred to the due date at the option of the Company
and the notes are convertible to common stock at the demand of the holder. The
notes are subordinated to borrowings under the Credit Facility and rank
pari-passu with the Senior Subordinated Notes.

As of December 31, 2001, the Company had an aggregate of $13.2 million
in long-term notes payable to Freeman Spogli.

In May 2002, the Company issued an additional $20 million in senior
unsecured notes payable to Freeman Spogli. The notes bear interest at 12%
annually with interest and principal due upon maturity at December 31, 2004.

39

In May 2002, the Company issued warrants to purchase 20 million shares
of the Company's common stock.

40

PART IV

Item 14. Exhibits, Financial Statement Schedules and Reports on Form 10-K.

(a) Documents filed as part of this Report:

Page

(1) Financial Statements
Financial Statements are filed as part of this Form 10-K ............... F-1
(2) Financial Statement Schedules
Report of Independent Public Accountants ............................... II-1
Schedule II -- Valuation and Qualifying Accounts ....................... II-2

All other schedules have been omitted because they are not
applicable, not required, or the information is included in
the consolidated financial statements or notes thereto.

(3) Exhibits

2.1(1) Agreement dated May 7, 1999 between Sten Gibeck,
Hudson RCI and Holding.
2.2(1) Agreement dated May 7, 1999 between Euroventures
Nordica I B.V., Hudson RCI and Holding.
2.3(1) Agreement dated May 7, 1999 between Forsakrings AB
Skandia and Livforsakrings AB Skandia, Hudson RCI and
Holding.
2.4(1) Agreement dated May 7, 1999 between Maud Gibeck,
Hudson RCI and Holding.
2.5(1) Stock Subscription Agreement dated August 4, 1999
between Sten Gibeck, Holding, FSEP III, FSEP
International and FSEP IV.
2.6(2) Asset Purchase Agreement dated September 18, 2000
between Hudson RCI and Tyco Healthcare Group L.P.
2.7(3) Amendment to Asset Purchase Agreement dated September
27, 2000 between Hudson RCI and Tyco Healthcare Group
L.P.
2.8(4) Amendment No. 2 to Asset Purchase Agreement dated
October 28, 2000 between Hudson RCI and Tyco
healthcare Group L.P.
3.1(5) Amended and Restated Articles of Incorporation of
Hudson RCI, as amended to date.
3.2(5) Bylaws of Hudson RCI.
4.1(5) Indenture dated as of April 7, 1998 among Hudson RCI,
Holding and United States Trust Company of New York,
as Trustee, with respect to the 9-1/8% Senior
Subordinated Notes due 2008 (including form of 9-1/8%
Senior Note due 2008).
4.2(5) Exchange Indenture dated as of April 7, 1998 among
Hudson RCI, Holding and United States Trust Company
of New York, as Trustee, with respect to the 11-1/2%
Subordinated Exchange Debentures due 2010 (including
form of 11-1.2% Senior Subordinated Exchange
Debenture due 2010).
10.1 Amended and Restated Credit Agreement dated as of May
14, 2002 among Hudson RCI, Holding, the lenders party
thereto, and Deutsche Bank Trust Company Americas
("Deutsche Bank"), as administrative agent and
collateral agent.
10.2 Form of Amended and Restated Security Agreement dated
as of May 14, 2002 between Hudson RCI and Deutsche
Bank.
10.3(5) Pledge Agreement dated as of April 7, 1998 (the
"Pledge Agreement") between Holding and Bankers
Trust.
10.4(5) Deed of Trust, Security Agreement, Fixture Filing and
Assignment of Leases and Rents dated April 7, 1998
between Hudson RCI and Chicago Title Insurance
Company fbo Bankers Trust.
10.5(5) Holding Guarantee Agreement dated as of April 7, 1998
between Holding and Bankers Trust.

41

10.6(5) Indemnity, Subrogation and Contribution Agreement
dated as of April 7, 1998 among Hudson RCI, Holding
and Bankers Trust.
10.7(5) Shareholders Agreement dated April 7, 1998 among
Holding, The Helen Hudson Lovaas Separate Property
Trust U/D/T dated July 17, 1997 (the "Hudson Trust"),
FS Equity Partners III, L.P. ("FSEP III"), FS Equity
Partners International, L.P. ("FSEP International"),
FS Equity Partners IV, L.P. ("FSEP IV"), and Hudson
RCI.
10.8(5) Stock Subscription Agreement dated April 7, 1998
between Holding and River Acquisition Corp.
10.9(5) Employment Agreement dated April 7, 1998 between
Hudson RCI and Richard W. Johansen.
10.10(5) Employment Agreement dated April 7, 1998 between
Hudson RCI and Jay R. Ogram.
10.11(5) Employment Agreement dated April 7, 1998 between
Hudson RCI and Lougene Williams.
10.12(5) Employment Agreement dated April 7, 1998 between
Hudson RCI and Brian W. Morgan.
10.13 Form of Nonrecourse Pledge Agreement dated as of May
14, 2002 among the Pledgor and Deutsche Bank, as
collateral agent for the lenders.
10.14(6) Amendment No. 1 to Shareholders Agreement dated April
8, 1998 among Holding, the Hudson Trust, FSEP III,
FSEP IV and Hudson RCI.
10.15 Tecate Facility Sub-Lease.
10.16 Form of Supplement No. 1 dated as of May 14, 2002, to
the Pledge Agreement.
10.17 Form of Master Assignment and Exchange Agreement
dated as of May 14, 2002 by and among Holding, Hudson
RCI, the financials institutions listed on the
signature pages thereof, Deutsche bank, as
administrative agent for the lenders and FSEP IV.
10.18 Letter agreement dated August 17, 2001 between Hudson
RCI and Charles French.
10.19 Form of Stock Option Plan
10.20 Form of Stock Option Agreement.
10.21 Receivables Purchase Agreement dated May 14, 2002 by
and between Hudson RCI and HRC Holding.
12.1 Statement re Computation of Earnings to Fixed Charges
Ratio. (see page II-3 of this document)
21.1 Subsidiaries of Hudson RCI.
24.1 Power of Attorney (included on the signature pages
hereof).

____________________
(1) Incorporated by reference to the exhibit designated by
the same number in the Form 8-K filed by the Company on
August 6, 1999 (date of earliest event: July 22, 1999)
(File No. 333-56097).
(2) Incorporated by reference to the exhibit designated by
number 2.1 in the Form 8-K filed by the Company on
November 13, 2000 (date of earliest event: October 28,
2000) (File No.: 333-56097).
(3) Incorporated by reference to the exhibit designated by
number 2.2 in the Form 8-K filed by the Company on
November 13, 2000 (date of earliest event: October 28,
2000) (File No.: 333-56097).
(4) Incorporated by reference to the exhibit designated
by number 2.3 in the Form 8-K filed by the Company on
November 13, 2000 (date of earliest event: October 28,
2000) (File No.: 333-56097).
(5) Incorporated by reference to the exhibit designated by
the same number in the Form S-4 filed by the Company on
June 5, 1998 (File No. 333-56097).
(6) Incorporated by reference to the exhibit designated
by the same number in to the Form 10-K filed by the
Company for the fiscal year ended December 25, 1998.

(b) Current Reports on Form 8-K.

None.

42

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.

HUDSON RESPIRATORY CARE INC.

Date: June 19, 2002 By: /s/ Patrick G. Yount
----------------------------------------------
Patrick G. Yount
Chief Financial Officer and Secretary

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears
below constitutes and appoints Patrick G. Yount his true and lawful
attorney-in-fact with full power of substitution and resubstitution, for him or
her and in his or her name, place and stead, in and any all capacities, to sign
any and all amendments to this Report on Form 10-K and to file same, with all
exhibits thereto, and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said attorney-in-fact and
agents, and each of them, full power and authority to do and perform each and
every act and thing requisite and necessary to be done in and about the
premises, as fully to all intents and purposes as he or she might or could do in
person, hereby ratifying and confirming all that said attorney-in-fact and
agent, or his substitute or substitutes, may lawfully do or cause to be done by
virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.

Signature Title Date
--------- ----- ----

/s/ Charles A. French Chief Executive Officer and Director June 19, 2002
------------------------- (Principal Executive Officer)
Charles A. French

/s/ Patrick G. Yount Chief Financial Officer and Secretary June 19, 2002
------------------------- (Principal Financial Officer)
Patrick G. Yount

/s/ Helen Hudson Lovaas June 19, 2002
-------------------------
Helen Hudson Lovaas Director

/s/ Ronald P. Spogli June 19, 2002
-------------------------
Ronald P. Spogli Director

/s/ Charles P. Rullman June 19, 2002
-------------------------
Charles P. Rullman Director

/s/ Jon D. Ralph June 19, 2002
-------------------------
Jon D. Ralph Director

/s/ Sten Gibeck June 19, 2002
-------------------------
Sten Gibeck Director

S-1

Supplemental Information to be Furnished With Reports Filed Pursuant to
Section 15(d) of the Act by Registrants Which Have Not Registered Securities
Pursuant to Section 12 of the Act

No annual report or proxy material has been sent to security holders.

S-2

HUDSON RESPIRATORY CARE INC. AND SUBSIDIARIES

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED DECEMBER 31, 2001 PAGE
- ---------------------------------------------------------------------- ----

Report of Independent Auditors....................................................................................... F-2

Consolidated Balance Sheet as of December 31, 2001................................................................... F-3

Consolidated Statements of Operations and Comprehensive Loss for the year ended December 31, 2001.................... F-4

Consolidated Statement of Stockholders' Deficit for the year ended December 31, 2001................................. F-5

Consolidated Statement of Cash Flows for the year ended December 31, 2001............................................ F-6

Notes to Consolidated Financial Statements........................................................................... F-8

Additional Unaudited Quarterly Financial Information................................................................. F-24

CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED DECEMBER 31, 2000
- ----------------------------------------------------------------------

Report of Independent Public Accountants............................................................................. F-25

Consolidated Balance Sheets as of December 31, 1999 and December 31, 2000............................................ F-26

Consolidated Statements of Operations and Comprehensive Loss for the years ended
December 31, 1998, December 31, 1999 and December 31, 2000.................................................. F-27

Consolidated Statements of Stockholders' Equity (Deficit)............................................................ F-28

Consolidated Statements of Cash Flows for the years ended December 31, 1998,
December 31, 1999 and December 31, 2000..................................................................... F-29

Notes to Consolidated Financial Statements........................................................................... F-31

F-1

REPORT OF INDEPENDENT AUDITORS

To the Board of Directors of
Hudson Respiratory Care Inc.:

We have audited the accompanying consolidated balance sheet of Hudson
Respiratory Care Inc., (a California Corporation) (a majority-owned subsidiary
of River Holding Corp.) and subsidiaries as of December 31, 2001, and the
related consolidated statements of operations and comprehensive loss,
stockholders' deficit and cash flows for the year then ended. Our audit also
included the financial statement schedule for the year ended December 31, 2001
listed in Item 14. These financial statements and the financial statement
schedule are the responsibility of the Company's management. Our responsibility
is to express an opinion on these financial statements and the financial
schedule based on our audit.

We conducted our audit in accordance with auditing standards generally
accepted in the United States of America. Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audit provides a
reasonable basis for our opinion.

In our opinion, such financial statements present fairly, in all
material respects, the financial position of Hudson Respiratory Care Inc. and
subsidiaries as of December 31, 2001, and the results of their operations and
their cash flows for the year then ended in conformity with accounting
principles generally accepted in the United States of America. Also, in our
opinion, such 2001 financial statement schedule, when considered in relation to
the basic 2001 consolidated financial statements taken as a whole, presents
fairly, in all material respects, the information set forth therein.

DELOITTE & TOUCHE LLP

Costa Mesa, California
May 15, 2002

F-2

HUDSON RESPIRATORY CARE INC. AND SUBSIDIARIES
(a majority-owned subsidiary of River Holding Corp.)

CONSOLIDATED BALANCE SHEETS
(In thousands, except per share amounts)

ASSETS

December 31,
2001
------------

CURRENT ASSETS:
Cash .............................................................................................. $ 7,085
Accounts receivable, less allowance for doubtful accounts of $1,801 ............................... 19,287
Inventories ....................................................................................... 25,218
Other current assets .............................................................................. 1,483
---------
Total current assets .......................................................................... 53,073
---------

PROPERTY, PLANT AND EQUIPMENT, net .................................................................. 46,268
---------

INTANGIBLE ASSETS, net .............................................................................. 28,498
DEFERRED FINANCING COSTS, net of accumulated amortization of $5,981 ................................. 8,316
OTHER ASSETS ........................................................................................ 900
---------
Total assets .................................................................................. $ 137,055
=========

LIABILITIES, MANDATORILY-REDEEMABLE PREFERRED STOCK AND
STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES:
Accounts payable .................................................................................. $ 15,251
Accrued liabilities ............................................................................... 17,302
Notes payable to banks - current portion .......................................................... 20,680
---------

Total current liabilities ..................................................................... 53,233

NOTE PAYABLE TO AFFILIATE ........................................................................... 17,217

NOTES PAYABLE TO BANKS, net of current portion ...................................................... 73,250

SENIOR SUBORDINATED NOTES PAYABLE ................................................................... 115,000

OTHER NON-CURRENT LIABILITIES ....................................................................... 1,187
---------

Total liabilities ............................................................................. 259,887
---------
COMMITMENTS AND CONTINGENCIES (Note 7)

MANDATORILY-REDEEMABLE PREFERRED STOCK:
$0.01 par value: 1,800 shares authorized; 445 shares issued and outstanding;
liquidation preference--$44,474 ................................................................... 43,847
Accrued preferred stock dividends, payable in kind .................................................. 1,142
---------
44,989
---------
STOCKHOLDERS' DEFICIT:
Common stock, no par value: 15,000 shares authorized; 10,654 shares issued and outstanding ........ 98,258
Junior preferred stock, $0.01 par value; 6 shares authorized; 3 shares issued and
outstanding ................................................................................... 3,137
Other comprehensive loss-- Cumulative translation adjustment ...................................... (698)
Accumulated deficit ............................................................................... (268,518)
---------
Total stockholders' deficit ................................................................... (167,821)
---------
Total liabilities, mandatorily-redeemable preferred stock and stockholders' deficit .... $ 137,055
=========

See notes to consolidated financial statements.

F-3

HUDSON RESPIRATORY CARE INC. AND SUBSIDIARIES
(a majority-owned subsidiary of River Holding Corp.)

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands)

Fiscal Year
Ended
December 31,
2001
------------

NET SALES ....................................................... $ 157,112
COST OF SALES ................................................... 108,054
------------
Gross profit ............................................... 49,058
------------

OPERATING EXPENSES:
Selling ...................................................... 19,496
Distribution ................................................. 11,429
General and administrative ................................... 23,889
Amortization of goodwill ..................................... 3,490
Impairment of goodwill ....................................... 33,128
Impairment of fixed assets ................................... 4,469
Research and development ..................................... 2,043
Provision for bad debts ...................................... 2,826
------------
Total operating expenses ................................... 100,770
------------

Loss from operations ......................................... (51,712)

OTHER EXPENSES:
Interest expense ............................................. 20,542
Other, net ................................................... 1,563
------------
22,105
------------

Loss before provision for income taxes .......................... (73,817)
PROVISION FOR INCOME TAXES ...................................... 69,854
------------
Net loss ........................................................ (143,671)

OTHER COMPREHENSIVE LOSS:
Foreign currency translation gain ............................... 453
------------
Comprehensive loss ........................................... $ (143,218)
============

See notes to consolidated financial statements.

F-4

HUDSON RESPIRATORY CARE INC. AND SUBSIDIARIES
(a majority-owned subsidiary of River Holding Corp.)

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT
(In thousands)

Other
Comprehensive
Loss--
Cumulative
Common Stock Junior Preferred Stock Translation Accumulated
------------------- ------------------------
Shares Amount Shares Amount Adjustment Deficit Total
-------- --------- ---------- ---------- -------------- ------------ -----------

BALANCE, December 31, 2000 ........... 10,644 $ 98,158 $ (1,151) $ (119,782) $ (22,775)

Issuance of common stock ............. 10 100 100
Issuance of junior preferred stock ... 3 $ 3,000 3,000
Pay-in-kind junior preferred stock
dividends ............................ 137 (137) --
Foreign currency translation gain .... 453 453
Issued or accrued pay-in-kind
preferred stock dividends ............ (4,928) (4,928)
Net loss ............................. (143,671) (143,671)
-------- --------- ---------- ---------- -------------- ------------ -----------

BALANCE, December 31, 2001 ........... 10,654 $ 98,258 3 $ 3,137 $ (698) $ (268,518) $ (167,821)
======== ========= ========== ========== ============== ============ ===========

See notes to consolidated financial statements.

F-5

HUDSON RESPIRATORY CARE INC. AND SUBSIDIARIES
(a majority-owned subsidiary of River Holding Corp.)

CONSOLIDATED STATEMENT OF CASH FLOWS
(In thousands)

Fiscal Year
Ended
December 31,
2001
------------

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss ............................................................. $ (143,671)
Adjustments to reconcile net loss to net cash provided by operating
activities--
Depreciation and amortization .................................... 12,223
Amortization/write-off of deferred financing costs and other ..... 1,676
Loss on disposal of equipment .................................... 681
Change in deferred tax asset ..................................... 68,881
Provision for bad debts .......................................... 2,826
Impairment of goodwill ........................................... 33,128
Impairment of fixed assets ....................................... 4,469
Changes in operating assets and liabilities:
Accounts receivable .............................................. 6,916
Inventories ...................................................... 17,304
Other current assets ............................................. 257
Other assets ..................................................... 503
Accounts payable ................................................. (4,614)
Accrued liabilities .............................................. 3,675
Other non-current liabilities .................................... 1,310
------------
Net cash provided by operating activities .................... 5,564
------------

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment ........................... (9,029)
Proceeds from sale of property, plant and equipment .................. 12
------------
Net cash used in investing activities ......................... (9,017)
------------

CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of notes payable to bank ................................... (21,209)
Proceeds from bank borrowings ........................................ 20,136
Additions to deferred financing costs ................................ (403)
Proceeds from note payable to affiliate .............................. 14,951
Repayment of note payable to affiliate ............................... (8,000)
Bank overdraft ....................................................... (1,245)
Net proceeds from sale of common, mandatorily-redeemable and junior
preferred stock, net of transaction costs ......................... 3,100
------------
Net cash provided by financing activities ..................... 7,330
------------

Effect of exchange rate changes on cash ................................. (322)
------------

NET INCREASE IN CASH .................................................... 3,555

CASH, beginning of year ................................................. 3,530
------------

CASH, end of year ....................................................... $ 7,085
============

See notes to consolidated financial statements.

F-6

December 31,
2001
-------------

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

Cash paid during the year for--
Interest ......................................................... $ 18,856
=============

Income taxes ..................................................... $ 2,315
=============

NON-CASH FINANCING ACTIVITIES:

Payment of preferred dividends through issuance of stock ............ $ 4,703
=============

Capital lease obligation incurred for purchase of equipment ......... 295
=============

See notes to consolidated financial statements.

F-7

HUDSON RESPIRATORY CARE INC. AND SUBSIDIARIES
(a majority-owned subsidiary of River Holding Corp.)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2001

1. General

Hudson Respiratory Care Inc. ("Hudson" or the "Company"), a California
corporation founded in 1945, is a manufacturer and marketer of disposable
medical products utilized in the respiratory care and anesthesia segments of the
domestic and international health care markets. The Company is a majority-owned
subsidiary of River Holding Corp., a Delaware corporation ("River"). River has
no operations of its own, other than its investment in the Company. The
Company's respiratory care and anesthesia product lines include such products as
oxygen masks, humidification systems, nebulizers, cannulae and tubing. In the
United States, the Company markets its products to a variety of health care
providers, including hospitals and alternate site service providers, such as
outpatient surgery centers, long-term care facilities, physician offices and
home health care agencies. Internationally, the Company sells its products to
distributors that market to hospitals and other health care providers. The
Company's products are sold to distributors and alternate site service providers
throughout the United States and internationally. The Company's respiratory
product operations are conducted from its primary facility in Temecula,
California; facilities in Arlington Heights and Elk Grove, Illinois; and a
facility in Ensenada, Mexico.

Management Plans to Improve Financial Condition and Results of
Operations

The accompanying consolidated financial statements have been prepared
on a going concern basis, which contemplates the realization of assets and the
satisfaction of liabilities in the normal course of business. As shown in the
financial statements, during the year ended December 31, 2001, the Company
incurred a net loss of $143.7 million. The Company historically has had
sufficient assets to continue operations despite the losses. As of December 31,
2001, the Company was in violation of certain financial covenants.

Management believes that the Company's continuation as a going concern
is dependent upon its ability to generate sufficient cash flow to meet its
obligations on a timely basis, to comply with the terms and covenants of its
financing agreements, to obtain additional financing as may be required and,
ultimately to attain profitable operations. As further discussed in Note 12, on
May 14, 2002, the Company reached an agreement with its senior lenders to amend
the Credit Facility to bring the Company into compliance with all terms and
provisions of this agreement. As part of this amendment, the Company issued $20
million in new senior term notes with warrants to the Company's majority
shareholder.

In addition, management has taken numerous actions to improve the
operating performance of the Company. Such actions included: the elimination of
a distribution warehouse, elimination of non-essential management personnel,
reductions in inventory levels, aggressive collection of accounts receivable and
elimination of individual products that did not attain acceptable levels of
profitability.

Management believes that the results of its plans and the agreement
reached and funding received on May 14, 2002 discussed above will enable the
Company to meet its ongoing obligations on a timely basis and continue
operations for at least the next twelve months.

F-8

Reporting Requirements

The Company is privately owned and has no class of securities
registered under the Securities Act of 1934 or any publicly traded equity
securities. The Company complies with Securities and Exchange Commission filing
requirements on a voluntary basis, as required in the indenture for its senior
subordinated notes.

2. Summary of Significant Accounting Policies

Fiscal Year-End

The Company reports its operations on a calendar year basis, with the
year ending on December 31.

Principles of Consolidation

The accompanying consolidated financial statements include the
accounts of Hudson and its wholly-owned subsidiaries. Intercompany account
balances and transactions have been eliminated in consolidation. Hudson and its
wholly-owned subsidiaries are collectively referred to herein as the Company.

Accounts Receivable

Accounts receivable are stated net of allowances for doubtful accounts
of approximately $1.8 million at December 31, 2001, for those accounts from
which payment is not expected to be received, although services were provided
and revenue was earned. Management performs periodic analyses to evaluate the
net realizable value of accounts receivable. Specifically, management considers
historical realization data, accounts receivable aging trends, other operating
trends and relevant business conditions.

Inventories

Inventories are stated at the lower of cost (first-in, first-out
(FIFO) method) or market. At December 31, 2001, inventories consisted of the
following (amounts in thousands):

Raw materials ............................. $ 7,377
Work-in-process ........................... 5,392
Finished goods ............................ 14,481
-----------
27,250
Provision for obsolescence ................ (2,032)
-----------
$ 25,218
===========

Raw materials principally consist of bulk resins. Work-in-process and
finished goods include raw materials, labor and overhead costs. Certain finished
goods are purchased for resale and are not manufactured. The Company considers
deterioration, obsolescence and historical trends in evaluating net realizable
value of inventory.

Internal Software Development Costs

The Company capitalizes costs incurred to develop internal-use
computer software in accordance with Statement of Position (SOP) 98-1
"Accounting for the Costs of Computer Software Developed or Obtained for
Internal Use". Such costs are amortized on a straight-line basis over the
economic useful lives of the software, which range from three to five years. The
Company applies the provisions of SOP 98-1 in assessing any potential impairment
of its capitalized software costs.

F-9

Property, Plant and Equipment

Property is stated at cost. Major renewals and betterments are
capitalized while maintenance costs and repairs are expensed in the year
incurred. Depreciation and amortization are computed using the straight-line
method over the estimated useful lives of the assets or term of the related
lease, if shorter. Estimated useful lives range from 3 to 7 years for furniture
and fixtures; 5 to 7 years for machinery, equipment and purchased software; and
31.5 years for buildings. Total depreciation expense related to property was
$8,733,000 for the year ended December 31, 2001.

The Company reviews property for impairment whenever events or changes
in circumstances indicate that an asset's book value exceeds the undiscounted
expected future cash flows to be derived from that asset. Whenever undiscounted
expected future cash flows are less than the book value, the asset will be
reduced to fair value based on the net present value of the expected future cash
flows, and an impairment loss will be recognized.

Goodwill and Other Intangible Assets

Goodwill and other intangible assets are amortized under a
straight-line method over the estimated useful lives. The Company periodically
reviews the recoverability of the carrying value of goodwill, intangibles and
other long-lived assets for impairment whenever events or changes in
circumstances indicate that the carrying amount of the asset may not be
recoverable. Recoverability of these assets is determined by analysis of the
assets' fair value by comparing the forecasted future undiscounted net cash
flows from the operations to which the assets relate, based on management's best
estimates using the appropriate assumptions and projections at the time, to the
carrying amount of the assets. If the carrying value is determined not to be
recoverable from future operating cash flows, the asset is deemed impaired and
an impairment loss is recognized equal to the amount by which the carrying
amount exceeds the estimated fair value of the assets. In addition, goodwill is
assessed for recoverability at an entity level, based on fair value determined
by estimated future cash flows, discounted at a rate commensurate with the risk
involved. In the fourth quarter of 2001, as a result of significant losses from
operations, the Company reassessed future cash flows and operating results and
recorded a goodwill impairment charge of approximately $33,128,000. Amortization
expense related to goodwill and other intangibles was approximately $3,490,000
for the year ended December 31, 2001.

Revenue Recognition

The Company recognizes revenue when product is shipped and title
passes to the customer, as the earnings process is substantially complete. The
Company establishes reserves for sales returns and other allowances based on
historical experience. The Company sells its products to its distributors
without right of return based on a listed price. Distributors charge the service
providers, or the Company's end customers, a contract price (which is determined
by their group purchasing organization affiliation or individual contract price)
plus a service margin. As is customary within the industry, the Company rebates
the difference between the list price and the specific contract price to the
distributor. The Company records this revenue and receivables net of rebatable
amounts. In the event no rebate is payable, the rebate amount is reversed and
recognized as revenue.

Income Taxes

The Company applies the asset and liability method in recording income
taxes, under which deferred income tax assets and liabilities are determined
based on the differences between the financial reporting and tax bases of assets
and liabilities and are measured using currently enacted tax rates and laws.
Additionally, deferred tax assets are evaluated for recoverability and a
valuation allowance is established if it is more likely than not that all or a
portion of the deferred tax asset will not be realized.

Foreign Currency Translation

The Company uses the local currency as the functional currency of its
foreign operating subsidiaries. Accordingly, all assets and liabilities at the
Company's subsidiaries located outside the United States are translated into
U.S. dollars at the rate of exchange in effect at the balance sheet date. Income
and expense items are translated at the weighted-average exchange rate
prevailing during the period. The resulting translation gains and losses are
recorded as other comprehensive income (loss) in stockholders' deficit in the
accompanying consolidated financial statements.

F-10

Concentration of Credit Risk

The Company sells its products primarily to customers in the United
States and Europe. Historically, the Company has not experienced significant
losses related to trade receivables from concentrations of individual customers
or from groups of customers in any geographic area.

Fair Value of Financial Instruments

The fair value of long-term debt is determined based on quoted market
prices for issues listed on exchanges. The carrying amounts of cash, accounts
receivable, accounts payable and accrued liabilities approximate fair value
because of their short maturity.

Use of Estimates

The preparation of financial statements in conformity with accounting
principles generally accepted in the United States requires management to make
certain estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities as of the date
of the consolidated financial statements and the reported amounts of revenues
and expenses during the reporting period. Actual results could differ from those
estimates.

New Accounting Pronouncements

Effective January 1, 2001, the Company adopted Statement of Financial
Accounting Standards No.133, "Accounting for Derivative Instruments and Hedging
Activities," as amended by SFAS No. 137 and SFAS No. 138. SFAS No. 133, as
amended, establishes accounting and reporting standards for derivative
instruments. The statement requires that every derivative instrument be recorded
in the balance sheet as either an asset or liability measured at its fair value,
and that changes in the derivative's fair value be recognized currently in
earnings, unless specific hedge accounting criteria are met. The adoption of
this new standard did not have a material impact on the Company's consolidated
financial statements.

In June 2001, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standards No. 141, "Business Combinations"
("SFAS 141"). This Statement addresses financial accounting and reporting for
business combinations and supersedes Accounting Principals Board ("APB") Opinion
No. 16, "Business Combinations," and FASB Statement No. 38, "Accounting for
Preacquisition Contingencies of Purchased Enterprises." All business
combinations in the scope of this Statement are to be accounted for using one
method, the purchase method. Any acquisitions made by the Company after June
2001 will be accounted for in accordance with SFAS 141.

Also in June 2001, the FASB issued Statement of Financial Accounting
Standards No. 142, "Goodwill and Other Intangible Assets" ("SFAS 142"). SFAS 142
addresses financial accounting and reporting for acquired goodwill and other
intangible assets and supersedes APB Opinion No. 17, "Intangible Assets." This
pronouncement addresses, among other things, how goodwill and other intangible
assets should be accounted for after they have been initially recognized in the
financial statements. Goodwill will no longer be amortized but will be assessed
at least annually for impairment using a fair value methodology. The Company
stopped amortizing goodwill, effective January 1, 2002, and as a result an
equivalent charge for goodwill amortization will not be made in 2002. The
Company is still evaluating the impact of the standard on impairment, which is
expected to be completed by the end of the second quarter of 2002. The
amortization of goodwill for 2001 was $3.5 million.

Also in June 2001, the FASB issued SFAS No. 143, "Accounting for Asset
Retirement Obligations" ("SFAS 143"). SFAS 143 addresses financial accounting
and reporting obligations associated with the retirement of tangible long-lived
assets and the associated asset retirement costs. It requires entities to record
the fair value of a liability for an asset retirement obligation in the period
in which it is incurred. When the liability is initially recorded, the entity
capitalizes a cost by increasing the carrying amount of the related long-lived
asset. Over time, the liability is accreted to its present value each period,
and the

F-11

capitalized cost is depreciated over the useful live of the related asset. Upon
settlement of the liability, an entity either settles the obligation for its
recorded amount or incurs a gain or loss upon settlement. SFAS 143 will become
effective January 1, 2003. The Company does not expect the adoption of SFAS 143
to have a material impact on the Company's consolidated financial statements.

In August 2001, the FASB issued SFAS 144 "Accounting for the
Impairment or Disposal of Long-Lived Assets." This statement addresses financial
accounting and reporting for the impairment or disposal of long-lived assets.
This statement supercedes SFAS No. 121, "Accounting for the Impairment of
Long-Lived Assets and for Long-Lived Assets to be Disposed Of," and the
accounting and reporting provisions of APB Opinion No. 30, "Reporting the
Results of Operations - Reporting the Effects of a Disposal of a Segment of a
Business and Extraordinary, Unusual and Infrequently Occurring Events and
Transactions," for the disposal of a segment of a business (as previously
defined in that Opinion). SFAS No. 144 became effective January 1, 2002. The
adoption of SFAS 144 is not expected to have a material impact on the Company's
consolidated financial statements.

3. Detail of Selected Balance Sheet Accounts

Property, Plant and Equipment

The following is a summary as of December 31, 2001 (amounts in
thousands):

Land.............................................. $ 2,044
Buildings ........................................ 15,965
Leasehold improvements............................ 1,849
Machinery, equipment and purchased software....... 91,078
Furniture and fixtures............................ 2,900
-----------
113,836
Less-- Accumulated depreciation and amortization.. (68,281)
-----------
45,555
Construction in process........................... 713
-----------
Property and equipment, net....................... $ 46,268
===========

Intangible Assets

The following is a summary of the components of intangible assets as of
December 31, 2001 (amounts in thousands):

Goodwill ......................................... $ 37,354
Other identifiable intangibles ................... 4,022
-----------
41,376
Less-- Accumulated amortization .................. (12,878)
-----------
$ 28,498
===========

Deferred Financing Costs, net

The following is a summary of the components of deferred financing
costs as of December 31, 2001 (amounts in thousands):

Deferred financing costs ......................... $ 14,297
Less: Accumulated amortization ................... (5,981)
----------

Deferred financing costs, net ................... $ 8,316
==========

F-12

Accrued Liabilities

Accrued liabilities consisted of the following as of December 31, 2001
(amounts in thousands):

Payroll and related.............................. $ 5,784
Interest......................................... 4,260
Vacation......................................... 1,905
Taxes............................................ 1,630
Pension.......................................... 1,077
Medical self-insurance........................... 876
GPO fees......................................... 821
Closure of distribution facility................. 738
Other............................................ 211
----------
$ 17,302
==========

4. Mandatorily-Redeemable Preferred Stock

In connection with the recapitalization in April 1998, the Company
issued 300,000 shares of mandatorily-redeemable 11-1/2% senior exchangeable
pay-in-kind ("PIK") preferred stock due 2010. Net proceeds from the original
issuance were $29.0 million. The preferred stock is exchangeable for subsequent
offerings of Company preferred stock or subordinated notes. Dividends are
payable semi-annually in arrears on April 15 and October 15 each year. Dividends
will be payable in cash, except on dividend payment dates occurring on or prior
to April 15, 2003, for which the Company has the option to issue additional
shares of preferred stock (including fractional shares) having an aggregate
liquidation preference equal to the amount of such dividends. The stock is
mandatorily redeemable as of 2010. Accordingly, the Company is accreting the
original issuance costs of $1,000,000 over a 10 year period to PIK preferred
stock to current redemption value on the consolidated financial statements
through a charge to accumulated deficit. As of December 31, 2001, the Company
had accreted to PIK preferred stock $373,000 of the issuance costs. The
preferred stock ranks junior in right of payment to all obligations of the
Company and its subsidiaries.

The Company issued PIK preferred stock with a liquidation preference
of approximately $4,703,000 to satisfy the dividend requirements in 2001. As of
December 31, 2001, the Company accrued for PIK preferred stock dividends in the
amount of $1,142,000.

5. Junior Preferred Stock

In August 2001, the Company issued 3,000 shares of 12% Junior
Convertible Cumulative Preferred Stock (the "Junior Preferred Stock") to River
for cash consideration of $3,000,000. Each share of the Junior Preferred Stock
may be redeemed from time to time, in whole or in part, at the option of the
Company at the redemption price of 100% of the Liquidation Preference of the
Junior Preferred Stock or $1,000 per share plus accumulated and unpaid dividends
that would be payable on such shares of Junior Preferred Stock.

F-13

6. Long-Term Debt Obligations

The Company's long-term debt obligations as of December 31, 2001, as
amended and restated (see Note 12) consist of the following (amounts in
thousands):

Borrowings under revolving credit facility........... $ 55,000
Term loan payable to domestic banks.................. 10,000
Term loan payable to domestic banks to be exchanged
for notes payable to affiliates................. 12,000
Term and revolving loan payable to Swedish bank ..... 16,930
Senior subordinated notes............................ 115,000
Note payable to affiliate............................ 17,217
----------
226,147
Less--current portion................................ (20,680)
----------
Long-term debt....................................... $ 205,467
==========

Credit Facility

The Credit Facility as of December 31, 2001 consists of a $40.0 million
Term Loan Facility and a $55.0 million Revolving Loan Facility. The Revolving
Loan Facility permits borrowings of up to $40.0 million (all of which has been
borrowed and is outstanding) which may be used for permitted acquisitions (the
"Acquisition Facility") and up to $15 million (the "Working Capital " portion)
which may be used for general corporate purposes (other than acquisitions). The
Revolving Loan Facility has a letter of credit sublimit of $7.5 million. The
Term Loan Facility matures on June 30, 2003 and requires quarterly principal
installments totaling $3.0 million in 1999, $5.5 million in 2000, $7.5 million
in 2001, $9.5 million in 2002 and $14.5 million in 2003. The Revolving Loan
Facility matures on June 30, 2003.

The interest rate under the Credit Facility is based, at the option of
the Company, upon either a Eurodollar rate or a base rate (as defined) plus a
margin during the period and for the applicable type of loan as follows:

Margin
---------------------
Period and Loan Type Base Rate Eurodollar
-------------------- --------- ----------

Through June 2002
Term and Working Capital............ 3.00% 4.00%
Acquisition......................... 3.25% 4.25%

July 2002 through March 2003
Term and Working Capital............ 3.50% 4.50%
Acquisition......................... 3.75% 4.75%

Thereafter
Term and Working Capital............ 4.00% 5.00%
Acquisition......................... 4.25% 5.25%

For periods after June, 2002, the margins set forth above are subject
to pricing reductions depending on the Company's then existing leverage ratio.

F-14

The following summarizes interest rate data on the Credit Facility as
of December 31, 2001:

Revolving credit facility rate....................... 6.511%

Term and acquisition loan facility rate.............. 5.938%

Borrowings under the Credit Facility are required to be prepaid from
Excess Cash Flow (as defined in the Credit Agreement).

The Credit Facility is secured by a first priority lien in
substantially all of the properties and assets of the Company and the guarantors
now owned or acquired later, including a pledge of all of the capital stock of
the Company owned by Holding and all of the shares held by the Company of its
existing and future subsidiaries; provided, that such pledge is limited to 65%
of the shares of any foreign subsidiary to the extent a pledge of a greater
percentage would result in adverse tax consequences to the Company. The Credit
Facility is guaranteed jointly and severally by River Holding Inc. ("Holding")
and certain of the Company's subsidiaries.

The Credit Facility contains covenants restricting the ability of
Holding, the Company and the Company's subsidiaries to, among others, (i) incur
additional debt, (ii) declare dividends or redeem or repurchase capital stock,
(iii) prepay, redeem or purchase debt, (iv) incur liens, (v) make loans and
investments, (vi) make capital expenditures, (vii) engage in mergers,
acquisitions and asset sales, and (viii) engage in transactions with affiliates.
The Company is also required to comply with financial covenants with respect to
(a) limits on annual aggregate capital expenditures (as defined), (b) a fixed
charge coverage ratio, (c) a maximum leverage ratio, (d) a minimum EBITDA test
and (e) an interest coverage ratio. The Company was not in compliance with these
covenants as of December 31, 2001. On May 14, 2002 the Company amended its
Credit Facility with its senior lenders. Under this amendment, the lenders
agreed to waive past violations of convents, amend future covenants, extend the
final maturity to June 30, 2004 and reduce scheduled amortization of the Term
Loan (see Note 12.)

Total borrowings as of December 31, 2001 were $55 million under the
Revolving Loan Facility and Acquisition Facility and $22 million under the Term
Loan Facility. As of December 31, 2001, the Company had utilized all available
credit under the Revolving Credit Facility. No additional borrowing is available
under the Term Loan Facility. As of December 31, 2001, the fair value of the
Revolving Credit Facility and Term Loan Facility approximated the face value.

Senior Subordinated Notes

The Company has $115.0 million of senior subordinated notes (the
"Notes"). The Notes are fully transferable and are general unsecured obligations
of the Company, subordinated in right of payment to all existing and future
senior debt, as defined, of the Company. The Notes bear interest at a rate equal
to 9-1/8% per annum from the date of issuance of the Notes. Interest is payable
semi-annually on April 15 and October 15 of each year, commencing October 15,
1998. The Notes mature on April 15, 2008 and will be redeemable at the option of
the Company, in whole or in part, on or after April 15, 2003 at a redemption
price of 100.0% to 104.6% of face value depending on the date of the redemption.
The Notes are guaranteed jointly and severally by Hudson Respiratory Care Inc.
and its Mexican subsidiaries.

The fair value of the Company's senior subordinated notes at December
31, 2001 was approximately $77.1 million. The fair value is estimated based on
the quoted market prices for issues listed on exchanges and is not intended to,
and does not, represent the underlying fair value of the Company.

Note Payable to Affiliate

In connection with the acquisition of Hudson RCI AB during 1999, the
Company borrowed $22.0 million under an unsecured 12% note payable to an
affiliate of the Company's existing majority stockholder. The note is due August
1, 2006. During 1999, the Company paid approximately $14.5 million in principal
on the note. In April 2001, the Company repaid an additional $6.0 million in
principal on the note. Proceeds from the repayment of this note were then
reinvested by the Company's majority shareholder in new long term notes issued
by the Company as described below.

F-15

During 2000, the Company borrowed an additional $2.0 million from the
existing majority shareholder under an unsecured 14% note payable due on demand.
In August of 2001, this note was exchanged for a new long-term note as described
below.

In August, 2001, the Company issued approximately $15.0 million of new
unsecured senior subordinated convertible notes consisting of $7.0 million in
new cash and an exchange of $8.0 million in existing short-term unsecured notes
to certain managers and shareholders. The notes bear interest at 10% and are due
in March 2005. The interest may be paid or deferred to the due date at the
option of the Company and the notes are convertible to common stock at the
demand of the holder. The notes are subordinated to borrowings under the Credit
Facility and rank pari-pasu with the Senior Subordinated Notes.

The fair value of the notes to affiliate approximates the face value.

In May of 2002, the Company issued an additional $20.0 million in
senior notes payable to affiliates (see note 12).

Bank Notes Payable

On March 21, 2001, the Company's primary European subsidiary, Hudson
RCI AB, replaced its existing lending agreement denominated in Swedish krona
with a new loan that allows for borrowings (the "Hudson AB Bank Notes") of up to
approximately $17.0 million. The principal is amortized over 18 equal quarterly
payments commencing June 30, 2001 with a final maturity of September 30, 2005.
Interest is based on the STIBOR rate plus 1.25% to 1.85%, based on the
outstanding balance of the loan. The loan is guaranteed jointly and severally by
Hudson Euro SarL, a wholly-owned subsidiary of the Company and 100% owner of
Hudson RCI AB and subsidiaries, Hudson RCI UK Ltd. and Hudson France S.A.S. The
loan contains certain affirmative and restrictive provisions including, but not
limited to, restrictions on additional indebtedness and compliance with certain
financial covenants. The loan also restricts Hudson RCI AB's ability to dividend
to its parent companies.

At December 31, 2001, borrowings under the Hudson AB Bank Notes
equaled $16.9 million.

The interest rate on the Bank Notes Payable as of December 31, 2001
was 5.74%.

At December 31, 2001, the Company was not in compliance with certain
financial covenants of the Hudson AB Bank Notes. The Company is currently in
discussions with the lender and expects the lender to agree to provide a waiver
curing all defaults as of December 31, 2001. Due to the uncertainty of obtaining
this waiver from the lenders, all amounts payable under the Hudson AB Bank Notes
have been classified as current on the accompanying consolidated balance sheet.

The following summarizes future principal amounts payable on all of
the Company's debt at December 31, 2001 (amounts in thousands):

2002.................... $ 20,680
2003.................... 24,250
2004.................... 49,000
2005.................... 14,951
2006.................... 2,266
Thereafter ............. 115,000
-----------
$ 226,147
===========

7 Commitments and Contingencies

The Company has capital and operating leases for certain facilities,
automobiles and office equipment under non-cancelable leases, with the majority
of the automobile leases having a term of one year with annual renewal
provisions. Rental expense for the year ended December 31, 2001 amounted to
$4,657,000. Generally, the facility leases include escalation clauses.

F-16

The following is a schedule, by year, of the future minimum payments
under capital and operating leases, together with the present value of the net
minimum payments as of December 31, 2001 (in thousands). Capital lease amounts
are included in the non-current liabilities line item on the accompanying
consolidated balance sheet:

Capital Operating
Leases Leases
----------- -----------

Year ending December 31,
2002 .............................................. $ 59 $ 2,188
2003 .............................................. 59 2,152
2004 .............................................. 59 2,087
2005 .............................................. 59 1,649
2006 .............................................. -- 896
Thereafter ........................................ -- 3,128
----------- -----------
Total minimum lease payments ............................ 236 $ 12,100
===========
Less amount representing interest ....................... 53
-----------
Total present value of minimum payment .................. 183
Less current portion of such obligations ................ 39
-----------
Long-term obligations with interest rate of 11.0% ....... $ 144
===========

Assets recorded under capital leases as of December 31, 2001 are as
follows (amounts in thousands):

Machinery and equipment .................................. $ 297
Less accumulated depreciation ............................ 31
-----------

Net property, plant and equipment ........................ $ 266
===========

Self-Insurance

The Company self-insures the majority of its medical benefit programs.
Reserves for medical claim losses totaling approximately $876,000 at December
31, 2001 were established based upon estimated obligations and are included in
accrued liabilities in the accompanying consolidated balance sheet. The Company
maintains excess coverage on an aggregate claim basis. Effective November 1,
2001, the Company became self-insured for workers' compensation. Reserves for
workers' compensation claim losses totaling approximately $350,000 at December
31, 2001 were established based upon estimated obligations and are included in
accrued liabilities in the accompanying consolidated balance sheet.

Legal

The Company is not a party to any material lawsuits or other
proceedings, including suits relating to product liability and patent
infringement. While the results of the Company's other existing lawsuits and
proceedings cannot be predicted with certainty, management does not expect that
the ultimate liabilities, if any, will have a material adverse effect on the
financial position or results of operations of the Company.

Other

Financial instruments that potentially subject the Company to
significant concentrations of credit risk consist principally of cash and
accounts receivable. The Company places its cash investments with high quality
financial institutions and limits the amount of credit exposure to any one
institution.

F-17

8. Income Taxes

The Company is included in the consolidated income tax returns of its
parent. The Company provides for income taxes on a stand-alone basis in
accordance with the asset and liability method pursuant to an informal
tax-sharing agreement.

The components of the deferred tax asset as of December 31, 2001 are
(amounts in thousands):

Basis differences arising from Section 338(h)(10) election .. $ 64,102
Net operating loss carryforwards ............................ 32,785
Other ....................................................... 1,285
------------
98,172
Valuation allowance ......................................... (98,172)
------------

$ --
============

As of December 31, 2001, the Company had net deferred tax assets
before any valuation allowance of $98.2 million. This asset relates primarily to
basis differences in goodwill and net operating loss carryforwards for tax
purposes. As of December 31, 2001, the Company had federal and state net
operating loss carryforwards of approximately $86.0 million and $56.0 million,
which begin to expire in 2018 and 2003, respectively.

Under SFAS No. 109, "Accounting for Income Taxes," the Company is
required to place a valuation allowance against any deferred tax assets unless
it is more likely than not that the asset will be realized. In accordance with
this standard, the Company has placed a valuation allowance against its deferred
tax assets of approximately $98.2 million as of December 31, 2001.

The reconciliation of the actual tax expense to tax computed at the
statutory federal rate for the year ended December 31, 2001 (amounts in
thousands):

Income taxes at statutory rate ...... $ (25,098)
Other. .............................. 4,298
Foreign taxes ....................... 959
Valuation allowance ................. 89,695
-------------

$ 69,854
=============

The provision for income taxes for the year ended December 31,
2001 consists of the following (amounts in thousands):

United States Foreign Total
------------- ------------ -----------

Current .......................... $ - $ 959 $ 959
Deferred ......................... 68,895 - 68,895
------------- ------------ -----------
$ 68,895 $ 959 $ 69,854
============= ============ ===========

F-18

9. Deferred Compensation and Benefit Plans

Pension and 401(k) Plans

The Company has a defined-contribution pension plan covering
substantially all its employees who are 21 years of age with two years of
service. The Company contributes an amount equal to 6% of employees' basic
compensation. Contribution expense relating to this plan totaled approximately
$943,000 for the fiscal year ended December 31, 2001.

During 2001, the Company determined that the pension plan for 1999 and
2000 was not fully funded. Accordingly, the Company recorded $350,000 in
associated penalties and fully funded the plan through 2000.

Additionally, the Company has a defined contribution 401(k) plan
covering substantially all of its employees who are 21 years of age with 30 days
of service. Participants may contribute up to 10% of base compensation to this
plan, subject to certain Internal Revenue Code (IRC) limitations, each year. The
Company makes no contributions under this plan.

Deferred Compensation

Effective December 1, 1994, the Company established a deferred
compensation plan for certain key employees. As of December 31, 2001 no material
amount of compensation has been deferred.

Management Bonus Plans

The Company offers a management bonus plan for its executives and
senior management. The plan is based solely on the financial goals of the
Company. The plan for 2001 required reaching a minimum of 95% of budgeted
EBITDA. During 2001, the Company did not meet this objective and no bonuses were
paid. The Company periodically offers additional incentive compensation to
individuals who demonstrate superior performance. This compensation was not
material in 2001.

Stock Subscription Plans

In April 1998, River adopted an Employee Stock Subscription Plan and
an Executive Stock Subscription Plan (collectively, the "Stock Subscription
Plans") pursuant to which executives of the Company purchased 800,000 shares of
common stock of River valued at $10.00 per share. The Stock Subscription Plans
provide for a repurchase option in favor of River upon termination of employment
at stated repurchase prices. In addition, the Stock Subscription Plans provide
for restrictions on the transferability of shares prior to the fifth anniversary
of the recapitalization or Hudson RCI's initial public offering. The shares are
also subject to a right of first refusal in favor of River, as well as
obligations to sell at the request of Freeman Spogli and co-sale rights if
Freeman Spogli sells its shares to a third party. No additional shares of River
common stock were sold under the Stock Subscription Plans in fiscal 2001.

Shareholder Agreement

Helen Hudson Lovaas (The "Continuing Shareholder") and River have
entered into a Shareholders' Agreement, as amended (the "Shareholders'
Agreement"). The Shareholder Agreement provides that i) River and the Continuing
Shareholder have the right to purchase their pro rata share of certain new
issuances, ii) in consideration for the contribution of consideration received
from River for certain issuances of the common stock of River, the Company will
issue an equivalent shares of Company common stock to River, iii) in the event
of a sale of Company stock by River or Freeman Spogli, the Continuing
Shareholder is obligated to sell all or part of her shares at the request of
River and the Continuing Shareholder has the right to participate in such sale
on a pro rata basis, iv) the restriction on the transferability of the shares
for a two year period following the recapitalization and provides for a right of
first offer on the Continuing Shareholder's common stock and v) in the event the
Company participates in an IPO, the Company will exchange all of the Company's
existing common stock for newly issued common stock.

In 2001, the Board of Directors of River approved adoption of a Stock
Option plan for eligible employees, officers and consultants of the Company. The
plan allows for the issuance of up to 2,000,000 of River common stock in the
form of

F-19

unqualified or incentive stock options under which shares shall have been
reserved for by River. Exercise price shall be set at fair market value as
determined by the Board of Directors. As of the date of this filing, no options
have been granted under this plan.

10. Geographic, Segment and Major Customer Information

The Company presents segment information externally based on how management
uses financial data internally to make operating decisions and assess
performance. The Company also reports information about the revenues derived
from the enterprise's products or services (or groups of similar products and
services), about the countries in which the enterprise earns revenues and holds
assets, and about major customers, regardless of whether that information is
used in making operating decisions.

The Company has two operating and reporting segments: United States, or
guarantor, and international or non-guarantor (see Note 11 for segment
disclosure). The non-guarantor subsidiaries consist principally of Hudson RCI AB
and subsidiaries (whose operations are principally international). Under SFAS
131, "Disclosures about Segments of an Enterprise and Related Information," the
Company's operating segments are the same as its reporting segments.

The Company sells respiratory care products to distributors and medical
facilities throughout the United States and internationally. During 2001, the
Company had foreign sales of approximately $40,772,000, which constituted
approximately 26.0% of total sales.

The Company's percentage of sales by geographic region for the fiscal year
ended December 31, 2001 is as follows:

Domestic ......................................................... 74.1%
Europe ........................................................... 13.9
Pacific Rim (Japan, Southeast Asia, Australia/New Zealand) ....... 7.2
Canada ........................................................... 1.6
Other international .............................................. 3.2
----------
100.0%
==========

The Company's percentage of sales by product category for the fiscal year
ended December 31, 2001 is as follows:

Oxygen therapy ................................................... 32.6%
Airway management ................................................ 29.2
Humidification and filtration .................................... 21.6
Aerosol therapy .................................................. 16.6
----------
100.0%
==========

The following summarizes the net book value of fixed assets at the
respective locations as of December 31, 2001 (amounts in thousands):

Ensenada, Mexico ................................................. $ 1,229
Stockholm, Sweden ................................................ 422
Kuala Lumpur, Malaysia ........................................... 721
United States .................................................... 43,896
----------
$ 46,268
==========

For the fiscal year ended December 31, 2001, the Company had sales to one
domestic distributor in the amount of $30,435,000, which represented
approximately 19.4% of sales. Additionally, the Company had sales to another
domestic distributor of approximately $15,656,000, that accounted for
approximately 10.0% of sales in 2001.

F-20

11. Subsidiaries Debt Guarantee and Segment Data

The Company is the 100% owner of certain subsidiaries, which do not
guarantee the Company's senior subordinated notes. The non-guarantor
subsidiaries consist principally of the assets, liabilities and operations of
Hudson RCI AB and subsidiaries. The following tables disclose the required
consolidating financial information for the guarantor, including the Company,
and non-guarantor subsidiaries (amounts in thousands):

HUDSON RESPIRATORY CARE INC. AND SUBSIDIARIES
GUARANTOR AND NON-GUARANTOR SUBSIDIARIES
CONSOLIDATING BALANCE SHEET DATA

As of December 31, 2001
-------------------------------------------------------
Non-
Guarantor Guarantor Eliminations Total
----------- ---------- ------------ -----------

ASSETS

CURRENT ASSETS:
Cash ................................................. $ 4,713 $ 2,372 $ -- $ 7,085
Accounts receivable .................................. 13,989 5,298 -- 19,287
Receivables from non-guarantor ....................... 6,515 -- (6,515) --
Inventories .......................................... 20,377 7,030 (2,189) 25,218
Other current assets ................................. 2,976 13,553 (15,046) 1,483
----------- ---------- ------------ -----------
Total current assets .............................. 48,570 28,253 (23,750) 53,073

PROPERTY, PLANT AND EQUIPMENT, net ...................... 45,125 1,143 -- 46,268

INTANGIBLE ASSETS, net ............................... -- 57,743 (29,245) 28,498
DEFERRED FINANCING COSTS, net ........................ 8,316 -- -- 8,316
INVESTMENT IN NON-GUARANTOR SUBSIDIARIES ............. 28,623 -- (28,623) --
OTHER ASSETS ......................................... 676 224 -- 900
----------- ---------- ----------- -----------
Total other assets ................................ 37,615 57,967 (57,868) 37,714
----------- ---------- ----------- -----------
$ 131,310 $ 87,363 $ (81,618) $ 137,055
=========== ========== =========== ===========

LIABILITIES, MANDATORILY-REDEEMABLE PREFERRED STOCK AND
STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES:
Accounts payable ...................................... $ 14,069 $ 1,182 $ -- $ 15,251
Accrued liabilities ................................... 14,366 15,356 (12,420) 17,302
Notes payable to banks - current portion .............. 3,750 16,930 -- 20,680
Payables to guarantor ................................. -- 6,515 (6,515) --
----------- ---------- ----------- -----------
Total current liabilities .......................... 32,185 39,983 (18,935) 53,233

NOTE PAYABLE TO AFFILIATE ................................ 14,951 2,266 -- 17,217
NOTES PAYABLE TO BANKS, net of current portion ........... 73,250 -- -- 73,250
SENIOR SUBORDINATED NOTES PAYABLE ........................ 115,000 -- -- 115,000
OTHER NON-CURRENT LIABILITIES ............................ 146 1,041 -- 1,187
----------- ---------- ----------- -----------
Total liabilities .................................. 235,532 43,290 (18,935) 259,887
----------- ---------- ----------- -----------

Mandatorily-redeemable preferred stock ................... 44,989 -- -- 44,989

STOCKHOLDERS' DEFICIT .................................... (149,211) 44,073 (62,683) (167,821)
----------- ---------- ----------- -----------
$ 131,310 $ 87,363 $ (81,618) $ 137,055
=========== ========== =========== ===========

F-21

HUDSON RESPIRATORY CARE INC. AND SUBSIDIARIES
GUARANTOR AND NON-GUARANTOR SUBSIDIARIES
CONSOLIDATING STATEMENT OF OPERATIONS

For the Year Ended December 31, 2001
-------------------------------------------------------------
Non-
Guarantor Guarantor Eliminations Total
--------- --------- ------------ ----------

NET SALES ...................................................... $ 143,555 $ 28,319 $ (14,762) $ 157,112
COST OF SALES .................................................. 105,789 15,749 (13,484) 108,054
--------- --------- --------- ---------
Gross profit ................................................... 37,766 12,570 (1,278) 49,058

OPERATING EXPENSES:
Selling ..................................................... 13,470 6,026 -- 19,496
Distribution ................................................ 9,514 1,915 -- 11,429
General and administrative .................................. 21,505 2,384 -- 23,889
Amortization of goodwill .................................... 1,561 1,929 -- 3,490
Impairment of goodwill ...................................... 26,217 6,911 -- 33,128
Impairment of fixed assets .................................. 4,469 -- -- 4,469
Research and development .................................... 1,015 1,028 -- 2,043
Provision for bad debts ..................................... 2,768 58 -- 2,826
--------- --------- --------- ---------
Total operating expenses 80,519 20,251 -- 100,770
--------- --------- --------- ---------

Income (loss) from operations .................................. (42,753) (7,681) (1,278) (51,712)

OTHER EXPENSES:
Interest expense ............................................ 18,890 1,652 -- 20,542
Other, net .................................................. 1,005 675 (117) 1,563
--------- --------- --------- ---------
Total other expense ...................................... 19,895 2,327 (117) 22,105
--------- --------- --------- ---------

Income (loss) before provision (benefit) for income taxes ...... (62,648) (10,008) (1,161) (73,817)

PROVISION (BENEFIT) FOR INCOME TAXES ........................ 69,097 757 -- 69,854
--------- --------- --------- ---------

Net income (loss) .............................................. $(131,745) $ (10,765) $ (1,161) $(143,671)
========= ========= ========= =========

HUDSON RESPIRATORY CARE INC. AND SUBSIDIARIES
GUARANTOR AND NON-GUARANTOR SUBSIDIARIES
CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

For the Year Ended December 31, 2001
-------------------------------------------
Non-
Guarantor Guarantor Total
--------- --------- ---------

Net cash provided by operating activities ................... $ 3,740 $ 1,824 $ 5,564
Net cash (used in) provided by investing activities ......... (8,366) (651) (9,017)
Net cash provided by financing activities ................... 8,902 (1,572) 7,330

Effect of exchange rate changes on cash ..................... -- (322) (322)
------------- ----------- ----------

NET INCREASE IN CASH ........................................ 4,276 (721) 3,555

CASH, beginning of year 437 3,093 3,530
------------- ----------- ----------

CASH, end of year ........................................... $ 4,713 $ 2,372 $ 7,085
============= =========== ==========

F-22

12. Subsequent Events

As of December 31, 2001, based on the Company's financial results, the
Company was not in compliance with certain financial covenants under its Credit
Facility. As a result of this non-compliance and resulting defaults, on March
30, 2002, the Company did not make a scheduled Term Loan payment to its senior
lenders as required under the Credit Facility and, as a result, the Company was
prevented from making a scheduled interest payment due its Subordinated Note
holders on April 15, 2002.

On May 14, 2002, the Company amended and restated the Credit Facility
to (i) waive all existing events of default; (ii) extend the final maturity of
the term and revolving facilities under the Credit Facility to June 30, 2004;
(iii) amend existing term and acquisition loan amortization to $3.8 million in
2002 and $9.3 million in 2003 and $37.0 million in 2004; and (iv) amend
financial covenants to include only a limitation on capital expenditures and a
minimum EBITDA test. In connection with this amendment, the Company and HRC
Holding, its wholly-owned subsidiary, issued a total of $20.0 million in senior
unsecured notes to affiliates of River's majority stockholder, of which $12.0
million was used to pay down the Term Loan of the Credit Facility. These notes
bear interest at 12%, with interest and principal due upon maturity on December
31, 2004.

F-23

Additional Unaudited Quarterly Financial Information

Summarized quarterly financial data for 2001 is as follows (amounts in
thousands):

Quarters Ended
-------------------------------------------------------

March 31 June 30 September 30 December 31
------------ ----------- ------------ -----------

Net sales ...................................... $ 37,805 $ 40,801 $ 45,095 $ 33,411
Gross profit ................................... 9,775 15,840 20,789 2,654
Net income (loss) .............................. (12,863) (5,819) 1,953 (126,942)

Fourth Quarter Adjustments

As a result of significant losses in the fourth quarter and cumulative
losses in recent years, the Company has reevaluated its ability to realize the
future benefit of its net deferred tax assets held in light of the historical
operating losses. Accordingly, the Company recorded a full valuation allowance
against its deferred tax assets of approximately $68.9 million.

As a result of significant losses in the fourth quarter, the Company
reassessed future cash flows and determined that goodwill was not recoverable.
Accordingly, the Company recorded a goodwill impairment charge of approximately
$33.1 million.

As a result of the Company's analysis of fixed assets in the fourth
quarter, it was determined that certain machinery and equipment was no longer
needed to support current business operations and had no value. Additionally,
certain software development costs incurred in 2001 related to the management
information system failed to achieve their intended results and, as a result,
were determined to have no future value. As a result, the Company recorded an
impairment charge of approximately $4.5 million.

As a result of an analysis of product lines during the fourth quarter of
2001, the Company concluded that it would no longer support a certain number of
individual products, resulting in the related inventories of those products no
longer having value. The Company recorded charges of $4.6 million related to the
destruction of obsolete inventory resulting from this strategic decision.

The Company made a decision in the fourth quarter of 2001 to not pursue
certain aged accounts receivable for collection and to allocate resources to
other customer receivables and collection activities. As a result, the Company
increased its provision for write-offs based on analysis of those aged customer
receivables.

The Company recorded a charge of approximately $0.9 million related to the
fourth quarter closure of its Atlanta distribution center. This charge primarily
consisted of future rent commitments.

During fiscal 2001, the Company made a decision to relocate from its
manufacturing operation in Argyle, New York to Tecate, Mexico. In addition, the
Company made a decision to move certain product manufacturing from Temecula,
California to Ensenada, Mexico. The Company recorded approximately $0.9 million
in severance costs related to the relocations.

F-24

Arthur Andersen LLP (Andersen) is the former auditor of the Company.
As a result of recent events at Andersen, Andersen declined the Company's
request to reissue their audit report dated July 30, 2001 for the fiscal years
ended December 31, 2000 and 1999 for inclusion in the Company's 10-K filing for
the fiscal year ended December 31, 2001. As such, pursuant to the guidance given
in the Temporary Final Rule and Final Rule: Requirements for Arthur Andersen LLP
Auditing Clients, Release Nos. 33-8070; 34-45590; 35-27503; 39-2395; IA-2018;
IC-25464; FR-62; File No. S7-03-02, the Company is filing this copy of the
latest signed and dated accountant's report issued by Andersen for such periods.

REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS

To the Board of Directors of
Hudson Respiratory Care Inc.:

We have audited the accompanying consolidated balance sheets of HUDSON
RESPIRATORY CARE INC., (a California Corporation) and subsidiaries as of
December 31, 1999 and 2000, and the related consolidated statements of
operations and comprehensive loss, stockholders' equity (deficit) and cash flows
for the years ended December 25, 1998, December 31, 1999 and 2000. These
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.

We conducted our audits in accordance with auditing standards generally
accepted in the United States. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements. An
audit also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.

In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of Hudson Respiratory Care Inc.
and subsidiaries as of December 31, 1999 and 2000, and the results of their
operations and their cash flows for the years ended December 25, 1998, December
31, 1999 and 2000 in conformity with accounting principles generally accepted in
the United States.

/s/ ARTHUR ANDERSEN LLP

Orange County, California
July 30, 2001

F-25

HUDSON RESPIRATORY CARE INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
(In thousands)

ASSETS

December 31, December 31,
1999 2000
------------ ------------

CURRENT ASSETS:
Cash ........................................................................................... $ 2,917 $ 3,530
Accounts receivable, less allowance for doubtful accounts of $973 and $3,500 at December 31,
1999 and 2000, respectively ................................................................... 30,425 28,307
Inventories .................................................................................... 24,043 44,610
Other current assets ........................................................................... 4,612 1,832
---------- ----------
Total current assets ........................................................................ 61,997 78,279
---------- ----------

PROPERTY, PLANT AND EQUIPMENT, net ............................................................... 42,476 49,425
---------- ----------

OTHER ASSETS:
Intangible assets, net ......................................................................... 66,970 67,573
Deferred financing costs, net of accumulated amortization of $2,528 and $4,306 at December
31, 1999 and December 31, 2000, respectively ................................................ 11,134 9,587
Deferred tax asset ............................................................................. 68,943 69,105
Other assets ................................................................................... 299 1,265
---------- ----------
Total other assets .......................................................................... 147,346 147,530
---------- ----------
Total assets .................................................................... $ 251,819 $ 275,234
========== ==========

LIABILITIES, MANDATORILY-REDEEMABLE PREFERRED STOCK AND
STOCKHOLDERS' EQUITY (DEFICIT)

CURRENT LIABILITIES:
Notes payable to banks ........................................................................ $ 6,673 $ 10,686
Accounts payable .............................................................................. 6,168 20,320
Accrued liabilities ........................................................................... 11,700 12,707
Notes payable to affiliates ................................................................... - 2,000
Other current liabilities ..................................................................... 1,485 3,007
---------- ----------
Total current liabilities ................................................................... 26,026 48,720

NOTE PAYABLE TO AFFILIATE, net of current portion ................................................ 7,508 8,266

NOTES PAYABLE TO BANKS, net of current portion ................................................... 82,513 85,962

SENIOR SUBORDINATED NOTES PAYABLE ................................................................ 115,000 115,000
---------- ----------

Total liabilities ........................................................................... 231,047 257,948
---------- ----------

COMMITMENTS AND CONTINGENCIES (Note 7)

MANDATORILY-REDEEMABLE PREFERRED STOCK,
$.01 par value: 1,800 shares authorized; 356 and 398 shares issued and outstanding at
December 31, 1999 and 2000, respectively; liquidation preference--$35,558 and $39,783
respectively (Note 4) ......................................................................... 34,558 39,043
Accrued preferred stock dividends, payable in kind ............................................... 863 1,018
---------- ----------
35,421 40,061
---------- ----------
STOCKHOLDERS' EQUITY (DEFICIT):
Common stock, no par value: 15,000 shares authorized; 10,044 and 10,387 shares issued and
outstanding at December 31, 1999 and 2000, respectively ...................................... 92,158 98,158
Cumulative translation adjustment ............................................................. (862) (1,151)
Accumulated deficit ........................................................................... (105,945) (119,782)
---------- ----------
Total stockholders' equity (deficit) ........................................................ (14,649) (22,775)
---------- ----------
Total liabilities, mandatorily-redeemable preferred stock and
stockholders' equity (deficit) .............................................................. $ 251,819 $ 275,234
========== ==========

The accompanying notes are an integral part of these consolidated balance
sheets.

F-26

HUDSON RESPIRATORY CARE INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands)

For the Years Ended
------------------------------------------------------

December 25, December 31, December 31,
1998 1999 2000
---------------- ---------------- ----------------

NET SALES ................................................................ $ 100,498 $ 128,803 $ 159,278
COST OF SALES ............................................................ 56,802 75,418 84,923
------------ ------------ ------------
Gross profit ........................................................ 43,696 53,385 74,355
------------ ------------ ------------

OPERATING EXPENSES:
Selling ............................................................... 10,350 13,122 18,262
Distribution .......................................................... 3,336 4,647 10,109
General and administrative ............................................ 10,125 13,269 24,023
Amortization of goodwill .............................................. 159 1,463 3,320
Research and development .............................................. 976 2,031 2,387
------------ ------------ ------------
Total operating expenses ............................................ 24,946 34,532 58,101
------------ ------------ ------------

PROVISION FOR EQUITY PARTICIPATION PLAN AND RETENTION
PAYMENTS .............................................................. (68,693) - -

(Loss) Income from operations ....................................... (49,943) 18,853 16,254

OTHER EXPENSES:
Interest expense ...................................................... (11,327) (17,263) (21,089)
Other, net ............................................................ (406) (1,232) (1,159)
------------ ------------ ------------
(11,733) (18,495) (22,248)
------------ ------------ ------------

(Loss) income before provision for income taxes and extraordinary item ... (61,676) 358 (5,994)

PROVISION FOR INCOME TAXES ............................................... 8,405 1,586 3,203
------------ ------------ ------------
Loss before extraordinary item ........................................... (70,081) (1,228) (9,197)

EXTRAORDINARY ITEM-loss on extinguishment of debt ........................ 104 - -
------------ ------------ ------------
Net loss ................................................................. (70,185) (1,228) (9,197)

OTHER COMPREHENSIVE LOSS:
Foreign currency translation loss ..................................... (119) (398) (289)
------------ ------------ ------------
Comprehensive loss ....................................................... $ (70,304) $ (1,626) $ (9,486)
============ ============ ============

The accompanying notes are an integral part of these
consolidated financial statements.

F-27

HUDSON RESPIRATORY CARE INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
(In thousands)

Cumulative Retained Earnings
Common Stock Translation (Accumulated
-----------------
Shares Amount Adjustment Deficit Total
------ ------ ----------- ----------------- -----

BALANCE, December 25, 1997 ................................... 14,469 $ 3,789 $ (345) $ 19,071 $ 22,515

Stockholder redemption ..................................... (12,969) (3,379) - (124,244) (127,623)
Foreign currency translation loss .......................... - - (119) - (119)
Recapitalization investment ............................ 6,300 63,000 - - 63,000
Issuance of common stock ................................... 13 125 - - 125
Pay-in-kind preferred stock dividends .................... - - - (2,512) (2,512)
Effect of Section 338(h)(10) election on deferred taxes .... - - - 77,064 77,064
Net loss ................................................... - - - (70,185) (70,185)
-------- --------- ----------- ---------- ----------
BALANCE, December 25, 1998 ................................... 7,813 63,535 (464) (100,806) (37,735)

Issuance of common stock to parent for cash and
contribution of Hudson RCI AB Stock (see Note 2) ........... 2,231 28,623 - - 28,623
Foreign currency translation loss .......................... - - (398) - (398)
Pay-in-kind preferred stock dividends ...................... - - - (3,911) (3,911)
Net loss ................................................... - - - (1,228) (1,228)
-------- --------- ----------- ---------- ----------
BALANCE, December 31, 1999 ................................... 10,044 92,158 (862) (105,945) (14,649)

Issuance of common stock to parent for cash ................ 343 6,000 - - 6,000
Foreign currency translation loss .......................... - - (289) - (289)
Pay-in-kind preferred stock dividends ...................... - - - (4,640) (4,640)
Net loss ................................................... - - - (9,197) (9,197)
-------- --------- ----------- ---------- ----------

BALANCE, December 31, 2000 ................................... 10,387 $ 98,158 $ (1,151) $ (119,782) $ (22,775)
======== ========= =========== ========== ==========

The accompanying notes are an integral part of these
consolidated financial statements.

F-28

HUDSON RESPIRATORY CARE INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

For the Years Ended
--------------------------------------------

December 25, December 31, December 31,
1998 1999 2000
-------- -------- --------

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss .............................................................. $ (70,185) $ (1,228) $ (9,197)
Adjustments to reconcile net loss to net cash (used in) provided by
operating activities--
Depreciation and amortization .................................... 6,101 8,315 11,719
Amortization/write-off of deferred financing costs and other ..... 1,119 1,374 991
Loss (gain) on disposal of equipment ............................. 14 (5) 9
Change in deferred tax asset ..................................... 6,735 1,385 (161)
Changes in operating assets and liabilities:
Accounts receivable .............................................. (4,547) (2,701) 2,118
Inventories ...................................................... (1,411) (2,865) (12,351)
Other current assets ............................................. 437 (1,194) 2,780
Other assets ..................................................... 247 13 (966)
Accounts payable ................................................. 2,482 (741) 14,152
Accrued liabilities .............................................. 1,687 4,277 1,008
Management bonus accrual ......................................... (20,000) - -
Other current liabilities ........................................ - 1,426 1,522
Other non-current liabilities .................................... - (959) -
Accrued equity participation plan (EPP) .......................... 83,939 - -
Payment of EPP liabilities and retention bonuses ................. (89,642) - -
---------- ---------- ----------
Net cash (used in) provided by operating activities ............ (83,024) 7,097 11,624
---------- ---------- ----------

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment ............................ (3,111) (10,973) (11,329)
Proceeds from sale of property, plant and equipment ................... 18 23 4
(Advances) collections on notes receivable and other .................. - (200) 2,384
Acquisition of certain assets of Gibeck, Inc. ......................... (3,351) - -
Acquisition of certain assets of Medimex .............................. - (2,168) -
Acquisition of certain assets of Tyco ................................. - (23,750) (18,000)
Acquisition of Louis Gibeck AB stock, net of cash acquired of
$8,208 ............................................................. - (38,750) -
---------- ---------- ----------
Net cash used in investing activities .......................... (6,444) (75,818) (26,941)
---------- ---------- ----------

CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of notes payable to bank .................................... (43,250) (17,355) -
Proceeds from bank borrowings ......................................... 67,000 59,376 7,461
Additions to deferred financing costs ................................. (12,918) - -
Redemption of stockholder interest .................................... (127,623) - -
Proceeds from senior subordinated notes payable ....................... 115,000 - -
Proceeds from note payable to affiliate ............................... - 22,000 2,758
Repayment of note payable to affiliate ................................ - (14,492) -
Net proceeds from sale of common and mandatorily-redeemable
preferred stock, net of transaction costs ........................ 91,415 22,000 6,000
---------- ---------- ----------
Net cash provided by financing activities ...................... 89,624 71,529 16,219
---------- ---------- ----------

Effect of exchange rate changes on cash .................................. (119) (398) (289)

NET INCREASE IN CASH ..................................................... 37 2,410 613

CASH, beginning of year .................................................. 470 507 2,917
---------- ---------- ----------
CASH, end of year ........................................................ $ 507 $ 2,917 $ 3,530
========== ========== ==========

The accompanying notes are an integral part of these
consolidated financial statements.

F-29

For the Years Ended
----------------------------------------------

December 25, December 31, December 31,
1999 1999 2000
-------- -------- --------

SUPPLEMENTAL DISCLOSURES OF CASH FLOW
INFORMATION:
Cash paid during the year for--
Interest .................................. $ 8,742 $ 15,333 $ 17,726
============= ============= =============

Income taxes .............................. $ 1,699 $ 27 $ 898
============= ============= =============

DETAILS OF ACQUISITIONS (Note 2):

Acquisition price .......................... $ 3,351 $ 79,499 $ 18,000
Less:
Common stock issued for acquisition ....... - (6,623) -
Cash acquired ............................. - (8,208) -
------------- -------------- -------------
Net cash paid for acquisitions ........ $ 3,351 $ 64,668 $ 18,000
============= ============= =============

NON-CASH OPERATING ACTIVITIES:

Net income includes approximately $2,825,000 and $1,199,000 of non-cash
expense related to the recognition of the portion of the purchase price
allocation related to acquired inventories in 1999 and 2000, respectively.

NON-CASH FINANCING ACTIVITIES:

The Company satisfies its preferred dividend requirements by the issuance
of additional shares of preferred stock. Such accrued dividend requirements
totaled $9,765,000 from the date of issuance of the preferred stock through
December 31, 2000; preferred stock with an approximate face value of
$1,801,000 was issued in 1998, $3,757,000 was issued in 1999, $4,207,000
was issued in 2000.

The Company issued common stock to its parent in partial consideration for
the contribution of Hudson RCI AB stock (see Note 2).

The accompanying notes are an integral part of these
consolidated financial statements.

F-30

HUDSON RESPIRATORY CARE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2000

1. Company Background

Hudson Respiratory Care Inc. ("Hudson" or the "Company"), a California
corporation founded in 1945, is a manufacturer and marketer of disposable
medical products utilized in the respiratory care and anesthesia segments of the
domestic and international health care markets. The Company is a wholly-owned
subsidiary of River Holding Corp., a Delaware corporation ("River"). River has
no operations of its own, except the Company. The Company's respiratory care and
anesthesia product lines include such products as oxygen masks, humidification
systems, nebulizers, cannulae and tubing. In the United States, the Company
markets its products to a variety of health care providers, including hospitals
and alternate site service providers such as outpatient surgery centers,
long-term care facilities, physician offices and home health care agencies.
Internationally, the Company sells its products to distributors that market to
hospitals and other health care providers. The Company's products are sold to
distributors and alternate site service providers throughout the United States
and internationally. The Company's respiratory product operations are conducted
from its primary facility in Temecula, California, facilities in Arlington
Heights and Elk Grove, Illinois, and a facility in Ensenada, Mexico. The
Company's anesthesia product operations are conducted from facilities located
principally in Sweden and Malaysia, which were acquired in July 1999 (see Note
2).

Recapitalization

In April 1998, the Company consummated a plan pursuant to which a
majority interest in the Company was sold in accordance with an agreement and
plan of merger (the "Recapitalization").

Key components of the Recapitalization included:

(1) Common and preferred equity investments in consideration for an
80.8% ownership in the Company's common stock and preferred
stock with an initial liquidation preference of $30.0 million
(2) Issuance of 9-1/8% senior subordinated notes with a par value of
$115.0 million, maturing in 2008 (see Note 5)
(3) Execution of a new term loan facility and revolving loan facility
(see Note 5)
(4) Repayment of existing indebtedness
(5) Payment of amounts due under the Equity Participation Plan (see
Note 10)
(6) Payment for common shares acquired from the existing shareholder;
this shareholder retained a 19.2% interest in the common shares
outstanding
(7) Potential contingent payments based on 1998 performance, payable
to the continuing shareholder and former participants in the
Equity Participation Plan; however, as a result of the
Company's 1998 performance, no additional amounts were due.

The Company has terminated the Equity Participation Plan and has
adopted an executive stock purchase plan. Additionally, Hudson's sole
shareholder prior to the Recapitalization, who owned the remaining 21.0% of
Industrias Hudson ("Industrias"), a subsidiary of the Company, transferred this
interest to the Company in consideration of one dollar. Because of the
commonality of ownership, the 21.0% minority interest has been included in the
financial statements for all periods presented.

The Company effected a 245:1 stock split concurrent with the
Recapitalization. The stock split has been reflected in the stock amounts shown
herein for all periods presented.

F-31

The Recapitalization resulted in no change to the carrying amounts of
the Company's existing assets and liabilities. The Company recorded a deferred
tax asset due to the conversion from S to C corporation status and a tax
election to revalue the basis of assets and liabilities for tax purposes.

2. Acquisitions

Gibeck, Inc.

During 1998, the Company acquired certain assets of Gibeck Inc.
("Gibeck"), a subsidiary of Louis Gibeck AB, for a cash purchase price of $3.4
million. Gibeck engages primarily in the business of manufacturing, marketing,
and selling custom anesthesia circuits. The acquisition was accounted for as a
purchase and the purchase price was allocated as follows (amounts in thousands):

Goodwill ................................. $ 1,817
Inventory ................................ 871
Machinery and equipment .................. 663
----------
$ 3,351
==========

Hudson RCI AB

On July 22, 1999, the Company acquired substantially all of the
outstanding capital stock of Hudson RCI AB (formerly Louis Gibeck AB or "LGAB")
and subsidiaries, a Swedish company engaged primarily in the business of
manufacturing, marketing and selling respiratory and anesthesia equipment. The
purchase price was approximately $53.6 million, which included cash
consideration of approximately $45.5 million (including approximately $8.2
million of cash acquired), a non-cash contribution of shares of common stock of
River of $6.6 million and transaction expenses of approximately $1.5 million.

The acquisition was funded with (i) a $22.0 million common stock sale
to the Company's existing majority shareholder, (ii) a $22.0 million, 12.0% per
annum unsecured note payable to an affiliate of the Company's existing majority
shareholder due August 1, 2006 and (iii) a $5.9 million unsecured bank loan
bearing interest at the bank's reference rate plus 1/4% per annum due July 30,
2006.

The acquisition of Hudson RCI AB was accounted for as a purchase and
the purchase price was allocated based upon management's estimate of the assets
acquired and liabilities assumed as follows (amounts in thousands):

Cash ....................................... $ 8,208
Accounts receivable ........................ 1,823
Inventories ................................ 5,161
Fixed assets ............................... 1,206
Other assets ............................... 2,939
Current liabilities ........................ (4,856)
Non-current liabilities .................... (4,123)
Goodwill ................................... 43,223
----------
$ 53,581
==========
F-32

Had this acquisition and the acquisition of certain assets of Gibeck,
Inc. occurred at the beginning of 1998 and 1999, the unaudited pro forma net
sales, net loss before extraordinary item and net loss would be as follows
(amounts in thousands):

Year Ended
--------------------------------
December 25, December 31,
1998 1999
---- ----

Net sales .................................. $ 122,819 $ 139,494
Net loss before extraordinary .............. (66,344) (1,949)
Net loss ................................... (66,448) (1,949)

Goodwill related to the Hudson RCI AB acquisition is being
amortized over a period of 20 years.

Acquisition of Product Lines

On November 8, 1999, the Company acquired certain assets of Tyco
Healthcare Group LP ("Tyco"), including Tyco's incentive breathing exerciser and
pulmonary function monitor product lines, for a cash purchase price of
approximately $23.8 million.

On October 28, 2000, the Company acquired certain assets of Tyco,
including Tyco's Sheridan(R) endotracheal tube for a cash purchase price of
approximately $18.0 million.

3. Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying consolidated financial statements include the
accounts of Hudson and its wholly-owned subsidiaries. All significant
intercompany account balances and transactions have been eliminated in
consolidation. Hudson and its wholly-owned subsidiaries are collectively
referred to herein as the Company.

Use of Estimates

The preparation of financial statements in conformity with accounting
principles generally accepted in the United States requires management to make
certain estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities as of the date
of the consolidated financial statements and the reported amounts of revenues
and expenses during the reporting period. Actual results could differ from those
estimates.

Inventories

Inventories are stated at the lower of cost (first-in, first-out
(FIFO) method) or market. At December 31, 1999 and December 31, 2000,
inventories consisted of the following (amounts in thousands):

1999 2000
---- ----

$ 5,901 $ 8,134
5,682 6,591
Raw materials .......................... 12,460 29,885
Work-in-process ........................ -------- --------
Finished goods ......................... $ 24,043 $ 44,610
======== ========

F-33

Raw materials principally consist of bulk resins. Work-in-process and
finished goods include raw materials, labor and overhead costs. Certain finished
goods are purchased for resale and are not manufactured.

Foreign Currency Translation

The Company uses the local currency as the functional currency of its
operating subsidiaries. Accordingly, all assets and liabilities outside the
United States are translated into U.S. dollars at the rate of exchange in effect
at the balance sheet date. Income and expense items are translated at the
weighted-average exchange rate prevailing during the period.

Beginning in the second quarter of 1998, the Company commenced using
the U.S. dollar as the functional currency of its Mexican operations since
Mexico was considered a highly inflationary economy. Management believes that
the effect of not using the U.S. dollar as the functional currency from January
1, 1997 was not material to the financial statements. Beginning in January 1999,
Mexico was no longer considered a highly inflationary economy and, accordingly,
the Company resumed using the Mexican Peso as the functional currency.

Revenue Recognition

The Company recognizes revenue when product is shipped. The Company
establishes reserves for sales returns and other allowances based on historical
experience. The Company's policy is to provide a reserve for estimated
uncollectable trade accounts receivable. During 2000, the Company provided
approximately $3.5 million for such accounts.

Income Taxes

The Company applies the asset and liability method in recording income
taxes, under which deferred income tax assets and liabilities are determined,
based on the differences between the financial reporting and tax bases of assets
and liabilities and are measured using currently enacted tax rates and laws.
Additionally, deferred tax assets are evaluated and a valuation allowance is
established if it is more likely than not that all or a portion of the deferred
tax asset will not be realized.

Fiscal Year-End

The Company reported its operations on a 52-53 week fiscal year ending
on the Friday closest to December 31 for the fiscal years ended December 25,
1998 and December 31, 1999. Beginning in 2000, the Company adopted calendar year
reporting, with the year ending on December 31, 2000.

New Accounting Pronouncements

In June 1998, the Financial Accounting Standards Board issued SFAS No.
133, "Accounting for Derivative Instruments and Hedging Activities," as amended
by SFAS No. 137 and SFAS No. 138, effective for fiscal years beginning after
June 15, 2000. SFAS No. 133 establishes accounting and reporting standards for
derivative instruments. The statement requires that every derivative instrument
be recorded in the balance sheet as either an asset or liability measured at its
fair value, and that changes in the derivative's fair value be recognized
currently in earnings unless specific hedge accounting criteria are met. The
impact of adoption was not material to the financial statements.

During the second quarter of fiscal year 2000, Emerging Issues Task
Force (EITF) No. 00-10 "Accounting for Shipping and Handling Fees and Costs" was
issued. EITF No. 00-10 clarifies the accounting treatment and classification of
the Company's delivery revenues and expenses. The adoption of this EITF only
affects the classification of certain revenues and costs related to delivery
services and does not affect the Company's net loss. Delivery costs include
direct and incremental costs incurred to warehouse and move product to the
Company's customers. Since the Company records freight costs associated with
delivery of product to customers as a component of cost of sales and warehousing
costs as distribution expenses management believes the Company is in compliance
with this pronouncement.

F-34

During December 1999, the Securities and Exchange Commission issued
Staff Accounting Bulletin No. 101, "Revenue Recognition in Financial
Statements." SAB No. 101 summarizes certain of the SEC's views in applying
generally accepted accounting principles to revenue recognition in financial
statements. Management believes the Company is in compliance with this
pronouncement.

In June 2001, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standards No. 141, "Business Combinations"
("SFAS 141"). This Statement addresses financial accounting and reporting for
business combinations and supersedes APB Opinion No. 16, "Business
Combinations," and FASB Statement No. 38, "Accounting for Preacquisition
Contingencies of Purchased Enterprises." All business combinations in the scope
of this Statement are to be accounted for using one method, the purchase method.
The Company will adopt SFAS 141 for all business combinations initiated after
June 30, 2001.

Also in June 2001, the FASB issued Statement of Financial Accounting
Standards No. 142, "Goodwill and Other Intangible Assets" ("SFAS 142"). SFAS 142
addresses financial accounting and reporting for acquired goodwill and other
intangible assets and supersedes APB Opinion No. 17, "Intangible Assets." This
pronouncement addresses, among other things, how goodwill and other intangible
assets should be accounted for after they have been initially recognized in the
financial statements. Goodwill would no longer be amortized but would be
assessed at least annually for impairment using a fair value methodology. The
Company will adopt this statement for all goodwill and other intangible assets
acquired after June 30, 2001 and for all existing goodwill and other intangible
assets beginning January 1, 2002. Upon adoption of this standard on January 1,
2002 The Company will cease recording amortization of goodwill which would
increase net income in 2002 by approximately $2.8 million, net of income taxes.
Other than ceasing the amortization of goodwill, The Company does not anticipate
that the adoption of SFAS 142 will have a significant effect on our financial
position or the results of our operations as The Company does not currently
anticipate any impairment charges for existing goodwill.

Reclassifications

Certain reclassifications have been made in the 1998 and 1999
statements to conform to the 2000 presentation.

4. Preferred Stock

In connection with the Recapitalization, the Company issued 300,000
shares of mandatorily-redeemable 11-1/2% senior exchangeable pay-in-kind ("PIK")
preferred stock due 2010. Net proceeds from the original issuance were $29.0
million. Dividends are payable semi-annually in arrears on April 15 and October
15 each year. Dividends will be payable in cash, except on dividend payment
dates occurring on or prior to April 15, 2003, for which the Company has the
option to issue additional shares of preferred stock (including fractional
shares) having an aggregate liquidation preference equal to the amount of such
dividends. The preferred stock will rank junior in right of payment to all
obligations of the Company and its subsidiaries.

The Company issued PIK preferred stock with a liquidation preference
of approximately $3,757,000 and $4,207,000 to satisfy the dividend requirements
in 1999 and 2000, respectively. As of December 31, 1999 and December 31, 2000
the Company accrued for PIK preferred stock dividends in the amount of $863,000
and $1,018,000, respectively.

5. Long-Term Debt Obligations

Summary of Amounts Outstanding

F-35

The Company's long-term debt obligations as of December 31, 1999 and
December 31, 2000 consist of the following (amounts in thousands):

1999 2000
---- ----

Borrowings under revolving credit facility ......... $ 36,600 $ 53,000
Term loan payable to domestic banks ................ 35,000 29,500
Term and revolving loan payable to Swedish bank .... 17,586 14,148
Senior subordinated notes .......................... 115,000 115,000
Note payable to affiliate .......................... 7,508 10,266
--------- ----------
211,694 221,914
Less--current portion .............................. (6,673) (12,686)
--------- ----------
Long-term debt ..................................... $ 205,021 $ 209,228
========= ==========

Credit Facility

In connection with the Recapitalization, the Company entered into a
new credit agreement (the Credit Facility) with a bank group, which provides for
borrowings of up to $100.0 million. This agreement consists of two separate
facilities as follows:

1.) Revolving credit--maximum borrowings of $60.0 million with a
letter of credit sub-limit of $7.5 million.
This facility must be prepaid upon payment in
full of the Term Loan facility.
2.) Term loan--maximum borrowings of $40.0 million with quarterly
installments to be made through maturity.

Interest on the Credit Facility is based, at the option of the
Company, upon either a eurodollar rate (as defined) plus 2.25%, or a base rate
(as defined) plus 1.25% per annum. A commitment fee of 0.50% per annum is
charged on the unused portion of the Credit Facility.

The following summarizes interest rate data on the Credit Facility as
of December 31, 1999 and 2000:

1999 2000
---- ----

Revolving credit facility rate ....... 8.5625% to 9.563%
10.0%

Term loan facility rate .............. 8.75% 9.250%

Total borrowings as of December 31, 2000 were $53.0 million and $29.5
million under the Revolving Credit Facility and Term Loan Facility,
respectively. The Credit Facility will mature on April 7, 2004.

The agreement provides the bank a first security interest in
substantially all of the properties and assets of the Company and a pledge of
65.0% of the stock of Industrias, a wholly-owned subsidiary of the Company. The
agreement also requires the Company to maintain certain financial ratios and
financial covenants, as defined in the agreement, the most restrictive of which
and among other restrictions, prohibit additional indebtedness and limit
dividend payments to the Company's stockholders. The Credit Facility is
guaranteed by the Company's parent.

As of December 31, 2000, the Company had available credit under the
Revolving Loan Facility in the amount of $7.0 million ($5.0 million of which is
restricted for use on future acquisitions). No additional borrowing is available
under the Term Loan Facility.

The Company is required under restrictive covenants of the Credit
Facility Agreement to maintain certain financial ratios, and meet certain
operating cash flow tests for which the Company was not in compliance as of
December 31, 2000 (see Note 15).

F-36

Senior Subordinated Notes

Also related to the Recapitalization, the Company issued under an
Indenture $115.0 million of senior subordinated notes (the "Notes"). The Notes
are fully transferable and are general unsecured obligations of the Company,
subordinated in right of payment to all existing and future senior debt, as
defined, of the Company.

The Notes bear interest at a rate equal to 9-1/8% per annum from the
date of issuance of the Notes. Interest is payable semi-annually on April 15 and
October 15 of each year, commencing October 15, 1998. The Notes will mature on
April 15, 2008 and will be redeemable at the option of the Company, in whole or
in part, on or after April 15, 2003. The Notes are guaranteed by Industrias.

The fair value of the Company's senior subordinated notes at December
31, 2000 was approximately $69.0 million. The fair value is estimated based on
the quoted market prices for issues listed on exchanges and is not intended to,
and does not, represent the underlying fair value of the Company. Subsequent to
December 31, 2000, the Company was in default of certain financial reporting
requirements to the noteholders. Management believes that it has cured this
default.

Note Payable to Affiliate

In connection with the acquisition of Hudson RCI AB during 1999, the
Company borrowed $22.0 million under an unsecured 12% note payable to an
affiliate of the Company's existing majority stockholder. The note is due August
1, 2006. During 1999, the Company paid approximately $14.5 million in principal
on the note. During 2000, the Company Borrowed an additional $2 million from the
existing majority shareholder under an unsecured 14% note payable due on demand.

Bank Notes Payable

The Company has bank borrowings of $14.1 million outstanding at
December 31, 2000, which are denominated in Swedish Krona. The borrowings bear
interest at the 3-month STIBOR plus 0.75% to 1.75% (4.884% to 5.884% at December
31, 2000), are due December 21, 2003 and are secured by the common stock of
Hudson RCI AB.

Future Debt Principal Payments

As of December 31, 2000, future debt principal payments on the
aforementioned debt are as follows (amounts in thousands):

Fiscal Year Ending:
-------------------

2001 ....................... $ 10,686
2002 ....................... 11,444
2003 ....................... 13,444
2004 ....................... 55,944
2005 ....................... 5,130
Thereafter 125,266
--------
$221,914
========

F-37

6. Detail of Selected Balance Sheet Accounts

Property, Plant and Equipment

The following is a summary as of December 31, 1999 and December 31,
2000 (amounts in thousands):

1999 2000
---- ----

Land .............................................. $ 2,044 $ 2,044
Buildings.......................................... 15,078 15,875
Leasehold improvements............................. 1,322 1,322
Machinery, equipment and purchased software........ 65,667 90,789
Furniture and fixtures............................. 4,227 2,883
--------- --------
88,338 112,913
Less-- Accumulated depreciation and amortization... (57,740) (64,556)
---------- --------
30,598 48,357
Equipment installation in progress................. 8,481 268
ERP software installation in progress.............. 3,397 800
--------- --------
Property and equipment, net........................ $ 42,476 $ 49,425
========= ========

Depreciation of property, plant and equipment is provided using the
straight-line method over the following estimated useful lives:

Buildings ................................... 31.5 years
Leasehold improvements ...................... Lesser of the useful
life or lease term
Machinery, equipment and purchased software.. 5 to 7 years
Furniture and fixtures ...................... 3 to 7 years

Upon retirement or disposal of depreciable assets, the cost and
related accumulated depreciation are removed and the resulting gain or loss is
reflected in income from operations. Major renewals and betterments are
capitalized while maintenance costs and repairs are expensed in the year
incurred. ERP software installation costs are capitalized in accordance with
Statement of Position ("SOP") 98-1, "Accounting for the Costs of Computer
Software Developed or Obtained for Internal Use." The Company implemented the
new ERP system on April 1, 2000.

Total depreciation expense related to property, plant and equipment
and amortization expense related to intangible and other assets was $6,101,000,
$8,315,000 and $11,719,000 for the years ended December 25, 1998, December 31,
1999 and December 31, 2000, respectively.

Intangible Assets and Deferred Financing Costs, net

Amortization of intangible assets is provided using the straight-line
method over the applicable amortization period. During 1999, the Company
wrote-off certain fully-amortized patents. The following is a summary of the
components of intangible assets as of December 31, 1999 and December 31, 2000
(amounts in thousands):

Useful lives 1999 2000
------------ ---- ----

Covenant not-to-compete ................. 5 to 7 years $ 3,500 $ 3,500
Patents ................................. 15 years 472 68
Goodwill ................................ 15 to 20 years 67,834 69,927
Other ................................... 5 to 20 years 133 133
---------- ----------
71,939 73,628
Less-- Accumulated amortization ......... (4,969) (6,055)
---------- ----------
$ 66,970 $ 67,573
========== ==========

Deferred financing costs are amortized using the straight-line method
over the period of the related debt.

F-38

Management reviews Goodwill on a regular basis for possible
impairment. Management knows of no factors at December 31, 2000 which may affect
the impairment recorded of long-lived assets.

Accrued Liabilities and Accounts Payable

Accrued liabilities consisted of the following as of December 31, 1999
and December 31, 2000 (amounts in thousands):

1999 2000
---- ----

Interest................................. $ 4,162 $ 3,605
Payroll and related...................... 4,095 4,224
Vacation................................. 1,509 1,824
Pension.................................. 1,353 1,767
Medical self-insurance................... 577 569
Other.................................... 4 718
--------- ----------
$ 11,700 $ 12,707
========= ==========

Accounts payable includes a book overdraft of approximately $0.9
million and $1.2 million at December 31, 1999 and 2000.

7. Commitments and Contingencies

The Company leases certain facilities, automobiles and office
equipment under noncancellable leases, with the majority of the automobile
leases having a term of one year with annual renewal provisions. All of these
leases have been classified as operating leases.

As of December 31, 2000, the Company had future obligations under
operating leases as follows (amounts in thousands):

Fiscal Year Ending:
-------------------

2001....................... $ 2,534
2002....................... 2,290
2003....................... 2,099
2004....................... 1,914
2005....................... 1,378
Thereafter ................ 4,023
----------
$ 14,238
==========

Rental expense was approximately $1,506,000, $2,052,000 and $3,115,000
in fiscal 1998, 1999 and 2000, respectively.

The Company self-insures the majority of its medical benefit programs.
Reserves for losses totaling approximately $577,000 and $569,000 at December 31,
1999 and December 31, 2000, respectively, were established based upon estimated
obligations and are included in accrued liabilities in the accompanying balance
sheets. The Company maintains excess coverage on an aggregate claim basis.

The Company is party to lawsuits and other proceedings, including suits
relating to product liability and patent infringement. While the results of such
lawsuits and other proceedings cannot be predicted with certainty, management
does not expect that the ultimate liabilities, if any, will have a material
adverse effect on the financial position or results of operations of the
Company.

F-39

8. Income Taxes

Effective November 1, 1987, the stockholder of Hudson elected S
corporation status under the Internal Revenue Code, such that income of the
Company is taxed directly to the stockholder for both federal and state income
tax purposes. Hudson's provision for income taxes and income taxes payable was
limited to the California S corporation tax of 1.5%.

The Company became a C corporation upon consummation of the
transaction discussed in Note 1. Accordingly, the Company has presented pro
forma net income (loss) amounts to reflect a provision for income taxes at a
combined effective rate of approximately 39% in 1998, after consideration of
permanent differences between financial reporting and income tax amounts. The
pro forma amounts presented do not include the one-time effect of the conversion
to C corporation status reflected in the 1998 financial statements. During 1999,
the Company revised its estimate of the combined effective income tax rate to
approximately 40%.

The actual provision for income taxes for 1998 reflects that the
Company was a C corporation for a portion of the period presented. The
conversion from S to C corporation status and the related Section 338(h)(10)
election to increase the tax bases of assets in connection with the
Recapitalization resulted in a one-time net benefit of $77,064,000 in the second
quarter of 1998 which was recorded directly to retained earnings.

From the date of the Recapitalization, the Company is included in the
consolidated income tax returns of its parent. The Company provides for income
taxes on a stand-alone basis in accordance with the asset and liability method
pursuant to an informal tax-sharing agreement.

During the fourth quarter of 1998, management evaluated the Company's
subsequent actual performance relative to certain budget projections which were
originally used to evaluate the realizability of the deferred tax asset
established at the time of the Recapitalization. Based upon this assessment,
management provided a valuation allowance of $8,477,000 in the fourth quarter to
reduce the deferred tax asset to an amount that management believes are more
likely than not to be realizable. This change in estimate was included in the
deferred tax provision for the year ended December 25, 1998.

The effective tax rate for 1998, 1999 and 2000 consists of the
following (amounts in thousands):

1998 1999 2000
---- ---- ----

Income taxes at combined statutory rate of approximately 40% ........ $ (24,094) $ 143 $ (2,398)
Domestic losses not benefited. ...................................... 24,022 - 2,730
Foreign taxes ....................................................... - 1,443 2,871
Valuation allowance ................................................. 8,477 - -
------------- ------------- -------------
$ 8,405 $ 1,586 $ 3,203
============= ============= =============

F-40

The provision (benefit) for income taxes consists of the following
(amounts in thousands):

United States Foreign Total
------------- ------- -----
2000

Current ............................ $ - $ 3,203 $ 3,203
Deferred ........................... - - -
----------- ----------- -----------
$ - $ 3,203 $ 3,203
=========== =========== ===========

1999

Current ............................ $ - $ 340 $ 340
Deferred ........................... 1,724 (478) 1,246
----------- ----------- -----------
$ 1,724 $ (138) $ 1,586
=========== =========== ===========

1998

Current ............................ $ - $ - $ -
Deferred ........................... 8,405 - 8,405
----------- ----------- -----------
$ 8,405 $ - $ 8,405
=========== =========== ===========

The 1998 tax provision results primarily from the valuation allowance
discussed previously. As of December 31, 2000, the Company has recorded a net
deferred tax asset of approximately $69.0 million primarily related to basis
differences between financial reporting and tax purposes arising from the
Section 338(h)(10) election to increase the tax bases of assets in connection
with the Recapitalization (see Note 1), which in management's opinion is more
likely than not to be realized. As of December 31, 2000, the Company had a
United States net operating loss carryforward of approximately $34.0 million.

The components of the deferred tax asset as of December 31, 1999 and
December 31, 2000 are (amounts in thousands):

1999 2000
---- ----
Basis differences arising from Section 338(h)(10)
election ........................................... $ 68,873 $ 66,933
Net operating loss carryforwards ................... 10,640 11,927
Other .............................................. (2,093) (1,278)
----------- -----------
77,420 77,582
Valuation allowance ................................ (8,477) (8,477)
----------- -----------
$ 68,943 $ 69,105
=========== ===========
9. Related-Party Transactions

Amounts included in the consolidated financial statements with respect
to transactions with companies controlled by officers, the stockholders or
members of their immediate families are as follows (amounts in thousands):

December 25, December 31, December 31,
1998 1999 2000
---- ----- ----

Purchases .......................................... $ 128 $ - $ -
=========== ============ ==============

Notes and advances receivable ...................... $ 91 $ 7,608 $ 10,366
=========== ============ ==============

10. Deferred Compensation and Benefit Plans

Pension Plan

The Company has a defined-contribution pension plan covering
substantially all its employees. Amounts charged to expense relating to this
plan totaled approximately $810,000, $972,000 and $914,000 for the fiscal years
ended 1998, 1999 and 2000, respectively.

F-41

Deferred Compensation

Effective December 1, 1994, the Company established a deferred
compensation plan for certain key employees. As of December 31, 2000 no material
amount of compensation has been deferred.

Equity Participation Plan

Effective January 1, 1994, the Company's Board of Directors adopted
the Equity Participation Plan, as amended (the "Plan"). This Plan provided
certain key employees and independent contractors deferred compensation based
upon the Company's value, as defined in the agreement. Benefits earned by
participants were based upon a formula with a specified minimum benefit accruing
each year for each participant, and benefits were accrued and charged to
compensation in the year earned. As of the fiscal year ended 1998, the Company
recorded $68,693,000 related to amounts earned by the Plan participants.

In fiscal 1998, the Company declared bonuses totaling $20.0 million
that resulted in a corresponding decrease in amounts payable under the Plan. The
effect of the bonuses was to accelerate the timing of payments to the
participants.

Effective with the Recapitalization, all amounts owed to participants
were paid out and the plan was terminated. Total amounts paid in 1998 were
$89,642,000.

11. Extraordinary Item

In accordance with the Recapitalization, the Company recorded an
extraordinary loss on the extinguishment of the existing debt related to the
write-off of unamortized deferred finance fees of $104,000 in 1998.

12. Geographic, Segment and Major Customer Information

The Company presents segment information externally the same way
management uses financial data internally to make operating decisions and assess
performance. The Company also reports information about the revenues derived
from the enterprise's products or services (or groups of similar products and
services), about the countries in which the enterprise earns revenues and holds
assets and about major customers regardless of whether that information is used
in making operating decisions.

As discussed in Note 14, the non-guarantor subsidiaries consist
principally of Hudson RCI AB and subsidiaries (whose operations are principally
international). The Company operates in two segments: United States operations
and international operations. The financial data of these two segments closely
approximates the guarantor/non-guarantor information set forth in Note 14 and,
accordingly, no additional segment data has been provided.

The Company sells respiratory care products to distributors and
medical facilities throughout the United States and internationally. During
1998, 1999 and 2000, the Company had foreign sales of approximately $20,148,000,
$28,497,000 and $31,383,000 respectively, which constituted approximately 20.0%,
22.1% and 19.7% of total sales, respectively.

The Company's percentage of sales by geographic region for the fiscal years
ended 1998, 1999 and 2000 are as follows:

1998 1999 2000
---- ---- ----

Domestic ...................................................... 79.9% 77.9% 80.3%
Europe ........................................................ 7.8 10.1 9.0
Pacific Rim (Japan, Southeast Asia, Australia/New Zealand) .... 6.2 6.1 5.8
Canada ........................................................ 2.0 1.9 1.6
Other international ........................................... 4.1 4.0 3.3
---------- ---------- ----------
100.0% 100.0% 100.0%
========== ========== ==========

F-42

The following summarizes the net book value of fixed assets at the
respective locations as of December 31, 1999 and December 31, 2000 (amounts in
thousands):

December 31, December 31,
1999 2000
------------ ------------

Ensenada, Mexico ................. $ 1,134 $ 1,137
Stockholm, Sweden ................ 342 291
Kuala Lumpur, Malaysia ........... 741 672
United States .................... 40,259 47,325
------------ ------------
$ 42,476 $ 49,425
============ ============

For the fiscal years ended 1998, 1999 and 2000, the Company had sales
to one domestic distributor in the amount of $24,940,000, $24,491,000 and
$32,184,000 which represented approximately 24.8%, 19.0% and 20.2% of sales,
respectively. Additionally, the Company had sales to another domestic
distributor of $14,775,000 and $16,936,000, that accounted for approximately
11.5% and 10.6% of sales in 1999 and 2000, respectively.

13. Unaudited Consolidated Quarterly Data

1998 Quarters Ended
------------------------------------------------------------

March 27 June 26 September 25 December 25
----------- ------- ------------ -----------

Net sales ................................... $ 24,265 $ 22,432 $ 22,130 $ 31,671
Gross profit ................................ 10,431 9,600 9,843 13,822
Income (loss) before extraordinary item ..... 1,498 (66,623) (243) (4,713)
Net income (loss) ........................... 1,498 (66,727) (243) (4,713)

1999 Quarters Ended
------------------------------------------------------------

March 26 June 25 September 24 December 31
----------- ------- ------------ -----------

Net sales ................................... $ 27,169 $ 27,274 $ 30,827 $ 43,533
Gross profit ................................ 11,389 11,414 12,185 18,397
Income (loss) before extraordinary item ..... 281 327 (1,554) (282)
Net income (loss) ........................... 281 327 (1,554) (282)

2000 Quarters Ended
------------------------------------------------------------
March 31 June 30 September 30 December 31
----------- ------- ------------ -----------

Net sales ................................... $ 40,807 $ 31,811 $ 41,111 $ 45,549
Gross profit ................................ 18,304 16,986 21,524 17,541
Income (loss) before extraordinary item ..... 1,599 (385) 1,662 (12,073)
Net income (loss) ........................... 1,599 (385) 1,662 (12,073)

14. Subsidiaries Debt Guarantee and Segment Data

The Company is the 100% owner of certain subsidiaries, which do not
guarantee the Company's senior subordinated notes. The non-guarantor
subsidiaries consist principally of the assets, liabilities and operations of
Hudson RCI AB and subsidiaries. The following tables disclose the required
consolidating financial information for the guarantor, including the Company,
and non-guarantor subsidiaries (amounts in thousands):

F-43

HUDSON RESPIRATORY CARE INC. AND SUBSIDIARIES
GUARANTOR AND NON-GUARANTOR SUBSIDIARIES
CONSOLIDATING BALANCE SHEET

As of December 31, 1999
--------------------------------------------------------
Non-
Guarantor Guarantor Adjustments Total
--------- --------- ----------- -----

ASSETS

CURRENT ASSETS:
Cash .......................................... $ 184 $ 2,733 $ - $ 2,917
Accounts receivable ........................... 28,329 2,096 - 30,425
Inventories ................................... 21,124 4,065 (1,146) 24,043
Other current assets .......................... 4,578 16,673 (16,639) 4,612
----------- ----------- ------------ -----------
Total current assets ....................... 54,215 25,567 (17,785) 61,997

PROPERTY, PLANT AND EQUIPMENT, net ............... 41,335 1,141 - 42,476

OTHER ASSETS:
Intangible assets, net ........................ 22,770 44,200 - 66,970
Deferred financing costs, net ................. 10,749 385 - 11,134
Deferred tax asset ............................ 68,600 223 120 68,943
Investment in non-guarantor subsidiaries ...... 29,245 - (29,245) -
Other assets .................................. 833 162 (696) 299
----------- ----------- ------------ -----------
Total other assets ......................... 132,197 44,970 (29,821) 147,346
----------- ----------- ------------ -----------
$ 227,747 $ 71,678 $ (47,606) $ 251,819
=========== =========== ============ ===========

LIABILITIES, MANDATORILY-REDEEMABLE PREFERRED STOCK AND
STOCKHOLDERS' EQUITY (DEFICIT)

CURRENT LIABILITIES:
Notes payable to banks ........................ $ 5,500 $ 1,173 $ - $ 6,673
Accounts payable .............................. 6,625 1,559 (2,016) 6,168
Accrued liabilities ........................... 8,344 3,356 - 11,700
Other current liabilities ..................... 458 10,876 (9,849) 1,485
----------- ----------- ------------ -----------
Total current liabilities .................... 20,927 16,964 (11,865) 26,026

NOTE PAYABLE TO AFFILIATE ........................ - 13,906 (6,398) 7,508
NOTES PAYABLE TO BANKS, net of current portion ... 66,100 16,413 - 82,513
SENIOR SUBORDINATED NOTES PAYABLE ................ 115,000 - - 115,000
----------- ----------- ------------ -----------
Total liabilities .......................... 202,027 47,283 (18,263) 231,047
----------- ----------- ------------ -----------

Mandatorily-redeemable preferred stock ........... 35,421 - - 35,421

STOCKHOLDERS' EQUITY (DEFICIT) ................... (9,701) 24,395 (29,343) (14,649)
----------- ----------- ------------ -----------
$ 227,747 $ 71,678 $ (47,606) $ 251,819
=========== =========== ============ ===========

F-44

HUDSON RESPIRATORY CARE INC. AND SUBSIDIARIES
GUARANTOR AND NON-GUARANTOR SUBSIDIARIES
CONSOLIDATING BALANCE SHEET

As of December 31, 2000
--------------------------------------------------------
Non-
Guarantor Guarantor Adjustments Total
--------- --------- ----------- -----

ASSETS
CURRENT ASSETS:
Cash ........................................... $ 437 $ 3,093 $ - $ 3,530
Accounts receivable ............................ 32,665 4,395 (8,753) 28,307
Inventories .................................... 38,703 7,973 (2,066) 44,610
Other current assets ........................... 6,350 52,467 (56,985) 1,832
----------- ----------- ----------- -----------
Total current assets ........................ 78,155 67,928 (67,804) 78,279

PROPERTY, PLANT AND EQUIPMENT, net ................ 48,260 1,165 - 49,425

OTHER ASSETS:
Intangible assets, net ......................... 27,719 39,854 - 67,573
Deferred financing costs, net .................. 9,587 - - 9,587
Deferred tax asset ............................. 68,881 224 - 69,105
Investment in non-guarantor subsidiaries ....... 29,245 - (29,245) -
Other assets ................................... 294 971 - 1,265
----------- ----------- ----------- -----------
Total other assets .......................... 135,726 41,049 (29,245) 147,530
----------- ----------- ----------- -----------
$ 262,141 $ 110,142 $ (97,049) $ 275,234
=========== =========== =========== ===========

LIABILITIES, MANDATORILY-REDEEMABLE PREFERRED STOCK AND
STOCKHOLDERS' EQUITY (DEFICIT)

CURRENT LIABILITIES:
Notes payable to banks ......................... $ 7,500 $ 3,186 $ - $ 10,686
Accounts payable ............................... 24,758 4,711 (9,149) 20,320
Accrued liabilities ............................ 9,420 3,287 - 12,707
Other current liabilitiesv ..................... 1,242 22,764 (20,999) 3,007
----------- ----------- ----------- -----------
Total current liabilities ................... 42,920 33,948 (30,148) 46,720
----------- ----------- ----------- -----------

NOTES PAYABLE TO AFFILIATE ........................ 2,000 8,266 - 10,266
NOTES PAYABLE TO BANKS, net of current portion .... 75,000 10,962 - 85,962
SENIOR SUBORDINATED NOTES PAYABLE ................. 115,000 - - 115,000
OTHER NON-CURRENT LIABILTIES ...................... - 1,095 (1,095) -
----------- ----------- ----------- ----------
Total liabilities ........................... 234,920 54,271 (31,243) 257,948
----------- ----------- ----------- ----------

MANDATORILY-REDEEMABLE PREFERRED STOCK ............ 40,061 - - 40,061

STOCKHOLDERS' EQUITY (DEFICIT) .................... (12,840) 55,871 (65,806) (22,775)
----------- ----------- ----------- -----------
$ 262,141 $ 110,142 $ (97,049) $ 275,234
=========== =========== =========== ===========

F-45

HUDSON RESPIRATORY CARE INC. AND SUBSIDIARIES
GUARANTOR AND NON-GUARANTOR SUBSIDIARIES
CONSOLIDATING STATEMENT OF OPERATIONS

For the Year Ended December 31, 1999
----------------------------------------------------
Non-
Guarantor Guarantor Adjustments Total
--------- --------- ----------- -----

NET SALES ........................................................ $ 121,796 $ 9,500 $ (2,493) $ 128,803
COST OF SALES .................................................... 71,146 6,465 (2,193) 75,418
----------- ----------- ----------- -----------
Gross profit ..................................................... 50,650 3,035 (300) 53,385
----------- ----------- ----------- -----------

OPERATING EXPENSES:
Selling ....................................................... 10,649 2,473 - 13,122
Distribution .................................................. 4,647 - - 4,647
General and administrative .................................... 11,815 1,454 - 13,269
Amortization of goodwill ...................................... 416 1,047 - 1,463
Research and development ...................................... 1,362 669 - 2,031
----------- ----------- ----------- -----------
Total operating expenses ................................... 28,889 5,643 - 34,532
----------- ----------- ----------- -----------

Income (loss) from operations .................................... 21,761 (2,608) (300) 18,853

OTHER EXPENSES:
Interest expense .............................................. (16,023) (1,240) - (17,263)
Other, net .................................................... (633) (599) - (1,232)
----------- ----------- ----------- -----------
Total other expense ........................................ (16,656) (1,839) - (18,495)
----------- ----------- ----------- -----------

Income (loss) before provision (benefit) for income taxes ........ 5,105 (4,447) (300) 358
PROVISION (BENEFIT) FOR INCOME TAXES .......................... 2,183 (477) (120) 1,586
----------- ------------ ----------- -----------
Net income (loss) ................................................ $ 2,922 $ (3,970) $ (180) $ (1,228)
=========== =========== =========== ===========
Depreciation and amortization (a) ................................ $ 6,531 $ 4,609 $ - $ 11,140
=========== =========== =========== ===========
Adjusted EBITDA (b) .............................................. $ 28,292 $ 2,001 $ (300) $ 29,993
=========== =========== =========== ===========

___________________________________

(a) Includes approximately $2,825,000 of non-cash expense related to the
recognition of the portion of purchase price allocation related to acquired
inventories.

(b) Adjusted EBITDA represents income before depreciation and amortization,
interest expense, income tax expense and recognition of the portion of
purchase price allocation related to acquired inventories. Adjusted EBITDA
is not a measure of performance under accounting principles generally
accepted in the United States, and should not be considered as a substitute
for net income, cash flows from operating activities and other income or
cash flow statement data prepared in accordance with accounting principles
generally accepted in the United States, or as a measure of profitability
or liquidity.

F-46

HUDSON RESPIRATORY CARE INC. AND SUBSIDIARIES
GUARANTOR AND NON-GUARANTOR SUBSIDIARIES
CONSOLIDATING STATEMENT OF OPERATIONS

For the Year Ended December 31, 2000
---------------------------------------------------
Non-
Guarantor Guarantor Adjustments Total
--------- --------- ----------- -----

NET SALES ..................................................... $ 145,786 $ 33,536 $ (20,044) $ 159,278
COST OF SALES ................................................. 87,092 16,875 (19,044) 84,923
----------- ------------ ----------- ----------
Gross profit .................................................. 58,694 16,661 (1,000) 74,355

OPERATING EXPENSES:
Selling .................................................... 12,434 5,828 - 18,262
Distribution ............................................... 9,566 543 - 10,109
General & Administrative ................................... 20,659 3,364 - 24,023
Amortization of goodwill ................................... 1,281 2,039 - 3,320
Research and development ................................... 1,072 1,315 - 2,387
----------- ------------ ----------- ----------
Total operating expenses ................................ 45,012 13,089 - 58,101
----------- ------------ ----------- ----------

Income (loss) from operations ................................. 13,682 3,572 (1,000) 16,254

OTHER INCOME AND (EXPENSES):
Interest expense ........................................... (18,506) (2,583) - (21,089)
Other, net ................................................. (205) (556) (398) (1,159)
----------- ------------ ----------- ----------
Total other income (expense) ............................ (18,711) (3,139) (398) (22,248)
----------- ------------ ----------- ----------

Income (loss) before provision (benefit) for income taxes ..... (5,029) 433 (1,398) (5,994)
PROVISION (BENEFIT) FOR INCOME TAXES ....................... - 3,203 - 3,203
----------- ------------ ----------- ----------
Net income (loss) ............................................. $ (5,029) $ (2,770) $ (1,398) $ (9,197)
=========== ============ =========== ==========
Depreciation and amortization (c) ............................ $ 10,450 $ 2,468 $ - $ 12,918
=========== ============ =========== ==========
Adjusted EBITDA (d) ........................................... $ 24,132 $ 6,040 $ (1,000) $ 29,172
=========== ============ =========== ==========

_____________________

(c) Includes approximately $1,199,000 of non-cash expense related to the
recognition of the portion of purchase price allocation related to acquired
inventories.

(d) Adjusted EBITDA represents income before depreciation and amortization,
interest expense, income tax expense and recognition of the portion of
purchase price allocation related to acquired inventories. Adjusted EBITDA
is not a measure of performance under accounting principles generally
accepted in the United States, and should not be considered as a substitute
for net income, cash flows from operating activities and other income or
cash flow statement data prepared in accordance with accounting principles
generally accepted in the United States, or as a measure of profitability
or liquidity.

F-47

HUDSON RESPIRATORY CARE INC. AND SUBSIDIARIES
GUARANTOR AND NON-GUARANTOR SUBSIDIARIES
CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

For the Year Ended December 31, 1999
--------------------------------------
Non-
Guarantor Guarantor Total
--------- --------- -----

Net cash provided by operating activities ................. $ 6,108 $ 989 $ 7,097
Net cash used in investing activities ..................... (34,928) (40,890) (75,818)
Net cash provided by financing activities ................. 28,197 43,332 71,529

Effect of exchange rate changes on cash ................... -- (398) (398)
--------- --------- ---------

NET INCREASE IN CASH ...................................... (623) 3,033 2,410

CASH, beginning of year ................................... 507 -- 507
--------- --------- ---------

CASH, end of year ......................................... $ (116) $ 3,033 $ 2,917
========= ========= =========

For the Year Ended December 31, 2000
--------------------------------------
Non-
Guarantor Guarantor Total
--------- --------- -----

Net cash provided by operating activities ................. $ 11,804 $ (180) $ 11,624
Net cash used in investing activities ..................... (29,329) 2,388 (26,941)
Net cash provided by financing activities ................. 17,778 (1,559) 16,219

Effect of exchange rate changes on cash ................... -- (289) (289)
--------- --------- ---------

NET INCREASE IN CASH ...................................... 253 360 613

CASH, beginning of year ................................... 184 2,733 2,917
--------- --------- ---------

CASH, end of year ......................................... $ 437 $ 3,093 $ 3,530
========= ========= =========

15. Subsequent Events

On March 21, 2001, the Company replaced its existing lending agreement
denominated in Swedish Krona with a new loan that allows for borrowings up to
approximately $19,100,000. The principal is amortized over 18 equal quarterly
payments commencing June 30, 2001. Interest is based on the STIBOR rate + 0% to
1.65%, based on the outstanding balance of the loan. The loan is secured by a
pledge of Hudson Euro SarL stock, a wholly-owned subsidiary of the Company and
100% owner of Hudson RCI AB, Hudson RCI UK Ltd. and Hudson RCI France S.A.S.

In April and May of 2001, the company issued for cash unsecured senior
subordinated convertible notes to certain managers and shareholders in the
amount of $9,451,250 and will issues an additional $3,500,000 in August of 2001.
The notes bear interest at 10% and are due in 2005. The interest may be paid or
deferred to the due date at the option of the Company and are convertible to
common stock at the demand of the note holder. Additionally, in August of 2001
the Company will issue for $3,000,000 cash an additional 30,000 shares of
mandatorily-redeemable preferred stock.

As discussed in Note 5, the Company was not in compliance with certain
restrictive covenants of the Credit Facility at December 31, 2000. On July 30,
2001, the Company amended its Credit Facility covenants so that under the
amended terms, the Company was in compliance as of December 31, 2000 and expects
to remain in compliance until December 31, 2001. As part of this amendment (1)
the Company's shareholders agreed to invest an additional $3 million in senior
subordinated convertible notes of the Company (2) certain maturities were
extended and (3) interest rate margins increased.

F-48

HUDSON RESPIRATORY CARE INC.

SCHEDULE II -- VALUATION AND QUALIFYING ACCOUNTS

(Amounts in thousands)

Balance at Balance at
Beginning of Charges to End of
Period Expenses Write-offs Period
-------------- -------------- --------------- --------------

Description
- -----------
For the Year Ended December 31, 2001:
Allowance for doubtful accounts
receivable ............................. $ (3,500) $ (2,826) $ 4,525 $ (1,801)
============== ============== =============== ==============

II-1

Arthur Andersen LLP ("Andersen") is the former auditor of the Company. As a
result of recent events at Andersen, Andersen declined the Company's request to
reissue their audit report dated July 30, 2001 for the fiscal years ended
December 31, 2000 and 1999 for inclusion in the Company's 10-K filing for the
fiscal year ended December 31, 2001. As such, pursuant to the guidance given in
the Temporary Final Rule and Final Rule: Requirements for Arthur Andersen LLP
Auditing Clients, Release Nos. 33-8070; 34-45590; 35-27503; 39-2395; IA-2018;
IC-25464; FR-62; File No. S7-03-02, the Company is filing this copy of the
latest signed and dated accountant's report issued by Andersen for such periods.

REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS

To the Board of Directors of
Hudson Respiratory Care Inc.:

We have audited in accordance with auditing standards generally accepted in
the United States, the financial statements of HUDSON RESPIRATORY CARE INC. (a
California corporation) and subsidiaries included in this Form 10-K and have
issued our report thereon dated July 30, 2001. Our audit was made for the
purpose of forming an opinion on the basic financial statements taken as a
whole. The accompanying Schedule II -- Valuation and Qualifying Accounts listed
in the index above is the responsibility of the company's management and is
presented for purposes of complying with the Securities and Exchange
Commission's rules and is not part of the basic financial statements. This
schedule has been subjected to the auditing procedures applied in the audit of
those financial statements and in our opinion, fairly states in all material
respects the financial data required to be set forth therein in relation to the
basic financial statements taken as a whole.

/s/ ARTHUR ANDERSEN LLP

Orange County, California
July 30, 2001

HUDSON RESPIRATORY CARE INC.

SCHEDULE II -- VALUATION AND QUALIFYING ACCOUNTS

(Amounts in thousands)

Balance at Balance at
Beginning of Charges to End of
Period Expenses Write-offs Period
------ -------- ---------- ------

For the Year Ended December 31, 2000:
Allowance for doubtful accounts
receivable.............................. $ (973) $ (3,106) $ 579 $ (3,500)
========== ========== ========= ==========

For the Year Ended December 31, 1999:
Allowance for doubtful accounts
receivable............................... $ (794) $ (440) $ 261 $ (973)
========== ========== ========= ==========

II-2

EXHIBIT 12.1

Ratio Support

Ratio Of Earnings To Fixed Charges

Hudson RCI
----------------------------------------------------
1997 1998 1999 2000 2001
-------- -------- -------- -------- --------

Earnings:
Pre-tax income (loss) ................ $ 11,443 $(61,676) $ 358 $ (5,994) $(73,817)

Fixed charges ........................
Interest expense ..................... 1,834 11,327 17,263 21,089 20,542
Amortization of debt expense ......... 62 -- -- -- --
Interest factor of rent expense ...... 374 497 677 1,038 1,537
-------- -------- -------- -------- --------

Total fixed charges .................. 2,270 11,824 17,940 22,127 22,079
-------- -------- -------- -------- --------

Total earnings (loss) before fixed
charges .................... 13,713 (49,852) 18,298 16,133 (51,738)
-------- -------- -------- -------- --------

Ratio of earnings (loss) to fixed
charges .................... 6.0 -- 1.0 -- --
Deficiency of earnings to cover
fixed charges ...................... -- (61,676) -- (5,994) (73,817)

II-3

Ratio of Earnings to Fixed Charges and Preferred Dividends

Hudson RCI
-------------------------------------------------------
1997 1998 1999 2000 2001
--------- --------- ---------- ------- ---------

Earnings:
Pre-tax income (loss) ................... $ 11,443 $ (61,676) $ 358 $(5,994) $ (73,817)

Fixed charges
Interest expense ........................ 1,834 11,327 17,263 21,089 20,542
Amortization of debt expense ............ 62 -- -- -- --
Interest factor of rent expense ......... 374 497 677 1,028 1,537
Preferred stock dividend
expense .............................. -- 4,187 6,518 7,733 8,213
--------- --------- ---------- ------- ---------

Total fixed charges ..................... 2,270 16,011 24,458 29,850 30,292
--------- --------- ---------- ------- ---------

Total earnings (loss) before
fixed charges ....................... 13,713 (45,665) 24,816 23,856 (43,525)
--------- ---------- ---------- ------- ---------

Ratio of earnings (loss) to
fixed charges ....................... 6.0 -- 1.0 -- --
Deficiency of earnings to
cover fixed charges ................. -- (61,676) -- (5,994) (73,817)

Computation of Interest Factor of Rental

Hudson RCI
-------------------------------------------------------
1997 1998 1999 2000 2001
--------- --------- ---------- ------- ---------

Operating rental expense $ 1,132 $ 1,506 $ 2,052 $ 3,115 $ 4,657

Interest factor 33% 33% 33% 33% 33%
--------- --------- ---------- ------- ---------

Total $ 374 $ 497 $ 677 $ 1,028 $ 1,537
========= ========= ========== ======= =========

II-4

Computation of Preferred Stock Expense

Hudson RCI
-------------------------------------------------------
1997 1998 1999 2000 2001
--------- --------- ---------- -------- ---------

Preferred stock dividend expense $ -- $ 2,512 $ 3,911 $ 4,640 $ 4,928

Tax effect (1.0-.40) 60% 60% 60% 60% 60%
--------- -------- ---------- -------- ---------

Total $ -- $ 4,187 $ 6,518 $ 7,733 $ 8,213
========= ======== ========== ======== =========

II-5